Atezolizumab Clinical Trials (2026): 746 Studies for Hepatocellular Carcinoma & Non-Small Cell Lung Cancer

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

746 Atezolizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 339 indications (including Hepatocellular Carcinoma & Non-Small Cell Lung Cancer) and 150,522 total planned enrollment. 106 Phase 3 Atezolizumab trials and 323 Phase 2, 7 Phase 4 are listed. 180 Atezolizumab clinical trials are actively recruiting at 1,934 U.S. sites across 51 states. Most recent activity: NCT04817956 (Apr 2045).

Where to Participate: All Atezolizumab Trial Sites in the U.S. (1,934 sites across 51 states)

Every actively recruiting Atezolizumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
ALThe Kirklin Clinic of University of Alabama Birmingham HospitalBirmingham35233NCT05440708Map
ALUniversity of Alabama -BirminghamBirmingham35233NCT06362252Map
ALUniversity of Alabama at BirminghamBirmingham35294NCT06294548Map
ALUniversity of Alabama at Birmingham (UAB)Birmingham35233NCT06031441Map
ALUniversity of Alabama at Birmingham Comprehensive Cancer CenterBirmingham35294NCT02693535Map
ALSouthern Cancer Center, PCDaphne36526NCT06646276Map
AKKatmai Oncology GroupAnchorage99508NCT04402788Map
AZPioneer Research Center, LLCBullhead City86442NCT06463665Map
AZCancer Center at Saint Joseph'sPhoenix85004NCT04402788Map
AZCancer Center at Saint Joseph'sPhoenix85004NCT05058651Map
AZCancer Center at Saint Joseph'sPhoenix85004NCT06632327Map
AZCancer Treatment Centers of America-PhoenixPhoenix85338NCT02693535Map
AZMayo Clinic ArizonaPhoenix85054NCT06362252Map
AZMayo Clinic Hospital in ArizonaPhoenix85054NCT06632327Map
AZResearch SitePhoenix85054NCT06921785Map
AZMayo Clinic in ArizonaScottsdale85259NCT05168163Map
AZACRC Arizona Clinical Research CenterTucson85715NCT06712355Map
AZBanner University Medical Center - TucsonTucson85719NCT01810913Map
AZUniversity of Arizona Cancer CenterTucson85724NCT06096779Map
AZUniversity of Arizona Cancer Center-North CampusTucson85719NCT01810913Map
ARHighlands Oncology GroupFayetteville72703NCT07226999Map
ARMercy Hospital Fort SmithFort Smith72903NCT06632327Map
ARNEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboro72401NCT04402788Map
ARNEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboro72401NCT06632327Map
ARCARTI Cancer CenterLittle Rock72205NCT06632327Map
ARHighlands Oncology GroupRogers72758NCT07226999Map
ARHighlands Oncology GroupSpringdale72762NCT07226999Map
CAKaiser Permanente-AnaheimAnaheim92806NCT05058651Map
CAMission Hope Medical Oncology - Arroyo GrandeArroyo Grande93420NCT06632327Map
CASutter AuburnAuburn95602NCT02693535Map
CASutter Auburn Faith HospitalAuburn95602NCT05058651Map
CASutter Cancer Centers Radiation Oncology Services-AuburnAuburn95603NCT01810913Map
CASutter Cancer Centers Radiation Oncology Services-AuburnAuburn95603NCT05058651Map
CAKaiser Permanente-Baldwin ParkBaldwin Park91706NCT05058651Map
CAKaiser Permanente-BellflowerBellflower90706NCT05058651Map
CAAlta Bates Summit Medical Center-Herrick CampusBerkeley94704NCT05058651Map
CAAlta Bates Summit Medical Center-Herrick CampusBerkeley94704NCT07166406Map
CASutter Alta BatesBerkeley94705NCT02693535Map
CABeverly Hills Cancer CenterBeverly Hills90211NCT05733598Map
CAProvidence Saint Joseph Medical Center/Disney Family Cancer CenterBurbank91505NCT01810913Map
CASutter Cancer Centers Radiation Oncology Services-Cameron ParkCameron Park95682NCT01810913Map
CASutter Cancer Centers Radiation Oncology Services-Cameron ParkCameron Park95682NCT05058651Map
CASutter Cancer Centers Radiation Oncology Services-Cameron ParkCameron Park95682NCT07166406Map
CAMercy Cancer Center - CarmichaelCarmichael95608NCT05058651Map
CAMercy Cancer Center - CarmichaelCarmichael95608NCT06632327Map
CAMercy San Juan Medical CenterCarmichael95608NCT01810913Map
CAMercy San Juan Medical CenterCarmichael95608NCT05058651Map
CAMercy San Juan Medical CenterCarmichael95608NCT06632327Map
CAEnloe Medical CenterChico95926NCT06632327Map
CAUC Irvine Medical CenterCosta Mesa92627NCT04524871Map
CACity of HopeDuarte91010NCT04802759Map
CACity of HopeDuarte91010NCT04524871Map
CACity of Hope (City of Hope National Medical Center, City of Hope Medical Center)Duarte91010NCT05652686Map
CACity of Hope /ID# 261468Duarte91010NCT06109272Map
CACity of Hope Comprehensive Cancer CenterDuarte91010NCT06287775Map
CACity of Hope Medical CenterDuarte91010NCT05085496Map
CAZai Lab Site 2005Duarte91010NCT06179069Map
CAMercy Cancer Center - Elk GroveElk Grove95758NCT05058651Map
CAMercy Cancer Center - Elk GroveElk Grove95758NCT06632327Map
CAMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #002Fair Oaks95628NCT05434234Map
CAKaiser Permanente-FontanaFontana92335NCT05058651Map
CAPalo Alto Medical Foundation-FremontFremont94538NCT05058651Map
CAPalo Alto Medical Foundation-FremontFremont94538NCT07166406Map
CAClinRé 001-022 (Premier Cancer Care and Infusion Center)Fresno93710NCT07195695Map
CAOPN Healthcare, Inc.Glendale91203NCT07195695Map
CAKaiser Permanente South BayHarbor City90710NCT05058651Map
CACity of Hope - Orange County Lennar Foundation Cancer CenterIrvine92618-2377NCT04802759Map
CACity of Hope at Irvine LennarIrvine92618NCT06287775Map
CACity of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669Irvine92618NCT06109272Map
CAKaiser Permanente-IrvineIrvine92618NCT05058651Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT04402788Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT07166406Map
CAMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #001La Jolla92093-0698NCT05434234Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT04981509Map
CAUC San Diego Moores Cancer CenterLa Jolla92037NCT05733598Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT06096779Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT06287775Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT06632327Map
CACedars-Sinai Medical CenterLos Angeles90048NCT01810913Map
CAKaiser Permanente Los Angeles Medical CenterLos Angeles90027NCT05058651Map
CAKaiser Permanente West Los AngelesLos Angeles90034NCT05058651Map
CAKeck Medicine of USC KoreatownLos Angeles90020NCT05333458Map
CALos Angeles General Medical CenterLos Angeles90033NCT05333458Map
CANorris Comprehensive Cancer CenterLos Angeles90033NCT05440708Map
CAThe Angeles Clinic and Research Institute, A Cedars-Sinai AffiliateLos Angeles90025NCT02693535Map
CAUCLALos Angeles90095NCT04929223Map
CAUniversity of California Los Angeles - Jonsson Comprehensive Cancer CenterLos Angeles90095NCT04302025Map
CAUniversity of Southern California-Keck School of Medicine -1975 Zonal AveLos Angeles90089-5601NCT06096779Map
CAUSC / Norris Comprehensive Cancer CenterLos Angeles90033NCT05333458Map
CAUSC Norris Comprehensive Cancer CenterLos Angeles90033NCT05968326Map
CAUSC/Norris Comprehensive Cancer CenterLos Angeles90033NCT06444815Map
CAFremont - Rideout Cancer CenterMarysville95901NCT06632327Map
CAMercy Cancer CenterMerced95340NCT06632327Map
CAMemorial Medical CenterModesto95355NCT01810913Map
CAMemorial Medical CenterModesto95355NCT05058651Map
CAPalo Alto Medical Foundation-Camino DivisionMountain View94040NCT05058651Map
CAPalo Alto Medical Foundation-Camino DivisionMountain View94040NCT07166406Map
CAHoag Memorial Hospital PresbyterianNewport Beach92663NCT06362252Map
CAUniversity of Southern CaliforniaNewport Beach92663NCT06096779Map
CAUSC Norris Cancer CenterNewport Beach92663NCT05968326Map
CAKaiser Permanente - Oakland Medical CenterOakland94611NCT02693535Map
CAKaiser Permanente-OntarioOntario91761NCT05058651Map
CAThe Center for Cancer Prevention and Treatment at St.Joseph Hospital of OrangeOrange92868NCT04302025Map
CAUC Irvine /ID# 255673Orange92868NCT06109272Map
CAUC Irvine HealthOrange92868NCT06444815Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT07166406Map
CAUC Irvine Medical CenterOrange92868NCT04524871Map
CAUniversity of California Irvine Medical CenterOrange92868NCT05440708Map
CAPalo Alto Medical Foundation Health CarePalo Alto94301NCT07166406Map
CAResearch SitePalo Alto94304NCT06921785Map
CAStanford Cancer Institute Palo AltoPalo Alto94304NCT01810913Map
CASutter Palo Alto Medical Foundation: Palo AltoPalo Alto94301NCT02693535Map
CAKaiser Permanente - Panorama CityPanorama City91402NCT05058651Map
CACalifornia Liver Research InstitutePasadena91105-2561NCT06096779Map
CAKaiser Permanente-RiversideRiverside92505NCT05058651Map
CAMercy Cancer Center - RocklinRocklin95765NCT05058651Map
CAMercy Cancer Center - RocklinRocklin95765NCT06632327Map
CAKaiser Permanente - Roseville Medical CenterRoseville95661NCT02693535Map
CASutter Cancer Centers Radiation Oncology Services-RosevilleRoseville95661NCT01810913Map
CASutter Cancer Centers Radiation Oncology Services-RosevilleRoseville95661NCT05058651Map
CASutter Cancer Centers Radiation Oncology Services-RosevilleRoseville95661NCT07166406Map
CASutter RosevilleRoseville95661NCT02693535Map
CASutter Roseville Medical CenterRoseville95661NCT05058651Map
CASutter Roseville Medical CenterRoseville95661NCT07166406Map
CAKaiser Permanente - Sacramento Medical CenterSacramento95814NCT02693535Map
CAMercy Cancer Center - SacramentoSacramento95816NCT05058651Map
CAMercy Cancer Center - SacramentoSacramento95816NCT06632327Map
CASutter Medical Center SacramentoSacramento95816NCT01810913Map
CASutter Medical Center SacramentoSacramento95816NCT05058651Map
CASutter Medical Center SacramentoSacramento95816NCT07166406Map
CASutter SacramentoSacramento95816NCT02693535Map
CAUC Davis Comprehensive Cancer CenterSacramento95817NCT04302025Map
CAUniversity of California DavisSacramento95817NCT04812366Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT06287775Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT06632327Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT07166406Map
CAKaiser Permanente-San Diego ZionSan Diego92120NCT05058651Map
CAUniversity of California San Diego Medical CenterSan Diego92103NCT04524871Map
CACalifornia Pacific Medical Center Research InstituteSan Francisco94115NCT02693535Map
CACalifornia Pacific Medical Center-Pacific CampusSan Francisco94115NCT05058651Map
CACalifornia Pacific Medical Center-Pacific CampusSan Francisco94115NCT07166406Map
CAKaiser Permanente - San Francisco Medical CenterSan Francisco94115NCT02693535Map
CAKaiser Permanente - South San Francisco Medical CenterSan Francisco94080NCT02693535Map
CAStanford UniversitySan Francisco94305NCT05581004Map
CASutter Cancer Research ConsortiumSan Francisco94115NCT02693535Map
CAUniversity of California San FranciscoSan Francisco94115NCT04434040Map
CAUniversity of California San Francisco Cancer CenterSan Francisco94115NCT04524871Map
CAUniversity of California, San FranciscoSan Francisco94143NCT03821246Map
CAUniversity of California, San FranciscoSan Francisco94143NCT06069726Map
CAUniversity of California, San Francisco (UCSF)San Francisco94143NCT04802759Map
CAUniversity of California, San Francisco (UCSF)San Francisco94158-2350NCT05968326Map
CAUniversity of San Francisco, CaliforniaSan Francisco94143NCT03708224Map
CAKaiser Permanente - San Jose Medical CenterSan Jose95119NCT02693535Map
CAKaiser Permanente - San Leandro Medical CenterSan Leandro94577NCT02693535Map
CAPacific Central Coast Health Center-San Luis ObispoSan Luis Obispo93401NCT06632327Map
CAKaiser Permanente-San MarcosSan Marcos92078NCT05058651Map
CAMills Health CenterSan Mateo94401NCT01810913Map
CASutter Sansum ClinicSanta Barbara93105NCT02693535Map
CAKaiser Permanente - Santa Clara Medical CenterSanta Clara95051NCT02693535Map
CAPalo Alto Medical Foundation-Santa CruzSanta Cruz95065NCT05058651Map
CASutter Palo Alto Medical Foundation: FremontSanta Cruz994538NCT02693535Map
CASutter Palo Alto Medical Foundation: Santa CruzSanta Cruz95065NCT02693535Map
CAMission Hope Medical Oncology - Santa MariaSanta Maria93444NCT06632327Map
CALundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterSanta Monica90404NCT04802759Map
CAUCLA Center for EastSanta Monica90404NCT04524871Map
CAUniversity of California Los AngelesSanta Monica90404NCT05968326Map
CAUniversity of California Los AngelesSanta Monica90404NCT07195695Map
CAProvidence Medical Foundation ( Site 0124)Santa Rosa95403NCT07227597Map
CASutter Pacific Medical FoundationSanta Rosa95403NCT05058651Map
CASutter Pacific Medical FoundationSanta Rosa95403NCT07166406Map
CAGSK Investigational SiteStanford94063NCT06551142Map
CAStanford Cancer Institute (SCI)Stanford94305NCT04802759Map
CAStanford Health CareStanford94305NCT06096779Map
CASaint Joseph's Medical CenterStockton95204NCT06632327Map
CAPalo Alto Medical Foundation-SunnyvaleSunnyvale94086NCT05058651Map
CAPalo Alto Medical Foundation-SunnyvaleSunnyvale94086NCT07166406Map
CASutter Palo Alto Medical Foundation: SunnyvaleSunnyvale94086NCT02693535Map
CAHarbor UCLA Medical CenterTorrance90502-2006NCT06096779Map
CAKaiser Permanente - Vallejo Medical CenterVallejo94589NCT02693535Map
CASutter Solano Medical Center/Cancer CenterVallejo94589NCT05058651Map
CAKaiser Permanente - Walnut Creek Medical CenterWalnut Creek94596NCT02693535Map
CACedars Sinai Comprehensive Transplant CenterWest Hollywood90048-2422NCT06096779Map
CAWoodland Memorial HospitalWoodland95695NCT05058651Map
CAWoodland Memorial HospitalWoodland95695NCT06632327Map
CAKaiser Permanente-Woodland HillsWoodland Hills91367NCT05058651Map
COCherry Creek Medical CenterAurora80045NCT04524871Map
COUniversity Of ColoradoAurora80045NCT05581004Map
COUniversity of Colorado Hospital - Anschutz Cancer PavilionAurora80045NCT04524871Map
COUniversity of Colorado Hospital - Anschutz Medical CampusAurora80045NCT05440708Map
COUniversity of Colorado Hospital- Anschutz Cancer Center Pavillion (ACP)Aurora80045NCT07235293Map
COPenrose-Saint Francis HealthcareColorado Springs80907NCT01810913Map
COPenrose-Saint Francis HealthcareColorado Springs80907NCT06632327Map
CORocky Mountain Cancer Centers-PenroseColorado Springs80907NCT06632327Map
COSaint Francis Cancer CenterColorado Springs80923NCT06632327Map
COAdventHealth PorterDenver80210NCT01810913Map
COAdventHealth PorterDenver80210NCT05058651Map
COGSK Investigational SiteDenver80218NCT06551142Map
CORocky Mountain Cancer Centers (Williams) - USORDenver80218-1237NCT06096779Map
COSarah Cannon Research Institute at HealthONEDenver80218NCT05652686Map
COCommonSpirit Cancer Center MercyDurango81301NCT06632327Map
COMercy Medical CenterDurango81301NCT06632327Map
COShaw Cancer CenterEdwards81632NCT01810913Map
COCancer Care and Hematology-Fort CollinsFort Collins80528NCT07166406Map
COPoudre Valley HospitalFort Collins80524NCT07166406Map
COSaint Mary's Hospital and Regional Medical CenterGrand Junction81501NCT07166406Map
COUCHealth Greeley HospitalGreeley80631NCT07166406Map
COUCHealth Cancer Center Pharmacy - Highlands Ranch HospitalHighlands Ranch80129-6694NCT04524871Map
COUniversity of Colorado Cancer Center - Highlands Ranch HospitalHighlands Ranch80129NCT07235293Map
COCommonSpirit Saint Anthony Hospital Cancer CenterLakewood80228NCT06632327Map
COAdventHealth LittletonLittleton80122NCT05058651Map
COMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #003Lone Tree80124NCT05434234Map
CORocky Mountain Cancer Centers, LLPLone Tree80124NCT04929223Map
CORocky Mountain Cancer Centers, LLPLone Tree80124NCT05703971Map
COLongmont United HospitalLongmont80501NCT01810913Map
COLongmont United HospitalLongmont80501NCT06632327Map
COMedical Center of the RockiesLoveland80538NCT07166406Map
COAdventHealth ParkerParker80138NCT01810913Map
COAdventHealth ParkerParker80138NCT05058651Map
COSaint Mary Corwin Medical CenterPueblo81004NCT06632327Map
COSaint Anthony North HospitalWestminster80023NCT06632327Map
CTSaint Vincent's Medical Center (SVMC)Bridgeport06606NCT02693535Map
CTSmilow Cancer Hospital-Derby Care CenterDerby06418NCT05058651Map
CTSmilow Cancer Hospital-Derby Care CenterDerby06418NCT07166406Map
CTSmilow Cancer Hospital Care Center-FairfieldFairfield06824NCT04402788Map
CTSmilow Cancer Hospital Care Center-FairfieldFairfield06824NCT05058651Map
CTSmilow Cancer Hospital Care Center-FairfieldFairfield06824NCT07166406Map
CTSmilow Cancer Hospital Care Center at GlastonburyGlastonbury06033NCT05058651Map
CTSmilow Cancer Hospital Care Center at GlastonburyGlastonbury06033NCT07166406Map
CTSmilow Cancer Hospital Care Center at GreenwichGreenwich06830NCT04402788Map
CTSmilow Cancer Hospital Care Center at GreenwichGreenwich06830NCT05058651Map
CTSmilow Cancer Hospital Care Center at GreenwichGreenwich06830NCT07166406Map
CTSmilow Cancer Hospital Care Center - GuilfordGuilford06437NCT04402788Map
CTSmilow Cancer Hospital Care Center - GuilfordGuilford06437NCT05058651Map
CTSmilow Cancer Hospital Care Center - GuilfordGuilford06437NCT07166406Map
CTSmilow Cancer Hospital-Hamden Care CenterHamden06518NCT04402788Map
CTSmilow Cancer Hospital-Hamden Care CenterHamden06518NCT07166406Map
CTHartford Healthcare Cancer Institute at Hartford HospitalHartford06106NCT06096779Map
CTHartford HospitalHartford06102NCT02693535Map
CTSmilow Cancer Hospital Care Center at Saint FrancisHartford06105NCT05333458Map
CTSmilow Cancer Hospital Care Center at Saint FrancisHartford06105NCT05058651Map
CTSmilow Cancer Hospital Care Center at Saint FrancisHartford06105NCT07166406Map
CTSt. Francis Hospital and Medical CenterHartford06105NCT05968326Map
CTMidstate Medical Center (MSMC)Meriden06451NCT02693535Map
CTThe Hospital of Central Connecticut (HOCC) Cancer CenterNew Britain06053NCT02693535Map
CTGSK Investigational SiteNew Haven06511NCT06551142Map
CTResearch SiteNew Haven06520NCT06921785Map
CTSmilow Cancer Center/Yale-New Haven HospitalNew Haven06510NCT07166406Map
CTSmilow Cancer Hospital at Yale New HavenNew Haven06510NCT04524871Map
CTYale Cancer CenterNew Haven06520NCT04929223Map
CTYale Cancer CenterNew Haven06511NCT04302025Map
CTYale Cancer CenterNew Haven06520NCT05968326Map
CTYale Cancer CenterNew Haven06520NCT06031441Map
CTYale UniversityNew Haven06520NCT05333458Map
CTYale UniversityNew Haven06520NCT04402788Map
CTYale UniversityNew Haven06520NCT01810913Map
CTYale UniversityNew Haven06520NCT05058651Map
CTYale UniversityNew Haven06520NCT06287775Map
CTYale UniversityNew Haven06510NCT07113691Map
CTYale UniversityNew Haven06520NCT07166406Map
CTYale University School of Medicine /ID# 278181New Haven06510NCT07155174Map
CTZai Lab Site 2030New Haven06519NCT06179069Map
CTYale-New Haven Hospital North Haven Medical CenterNorth Haven06473NCT04402788Map
CTYale-New Haven Hospital North Haven Medical CenterNorth Haven06473NCT05058651Map
CTYale-New Haven Hospital North Haven Medical CenterNorth Haven06473NCT06287775Map
CTYale-New Haven Hospital North Haven Medical CenterNorth Haven06473NCT07166406Map
CTWilliam W. Backus HospitalNorwich06360NCT02693535Map
CTSmilow Cancer Hospital Care Center at Long RidgeStamford06902NCT04402788Map
CTSmilow Cancer Hospital Care Center at Long RidgeStamford06902NCT05058651Map
CTSmilow Cancer Hospital Care Center at Long RidgeStamford06902NCT07166406Map
CTCharlotte HungerfordTorrington06790NCT02693535Map
CTSmilow Cancer Hospital-Torrington Care CenterTorrington06790NCT04402788Map
CTSmilow Cancer Hospital-Torrington Care CenterTorrington06790NCT05058651Map
CTSmilow Cancer Hospital-Torrington Care CenterTorrington06790NCT07166406Map
CTSmilow Cancer Hospital Care Center at TrumbullTrumbull06611NCT05968326Map
CTSmilow Cancer Hospital Care Center-TrumbullTrumbull06611NCT05333458Map
CTSmilow Cancer Hospital Care Center-TrumbullTrumbull06611NCT04402788Map
CTSmilow Cancer Hospital Care Center-TrumbullTrumbull06611NCT05058651Map
CTSmilow Cancer Hospital Care Center-TrumbullTrumbull06611NCT06287775Map
CTSmilow Cancer Hospital Care Center-TrumbullTrumbull06611NCT07166406Map
CTSmilow Cancer Hospital-Waterbury Care CenterWaterbury06708NCT04402788Map
CTSmilow Cancer Hospital-Waterbury Care CenterWaterbury06708NCT05058651Map
CTSmilow Cancer Hospital-Waterbury Care CenterWaterbury06708NCT07166406Map
CTSmilow Cancer Hospital Care Center - WaterfordWaterford06385NCT04402788Map
CTSmilow Cancer Hospital Care Center - WaterfordWaterford06385NCT01810913Map
CTSmilow Cancer Hospital Care Center - WaterfordWaterford06385NCT05058651Map
CTSmilow Cancer Hospital Care Center - WaterfordWaterford06385NCT07166406Map
CTWindham Hospital (WH)Willimantic06226NCT02693535Map
DEBeebe Medical CenterLewes19958NCT06632327Map
DEBeebe South Coastal Health CampusMillville19967NCT04402788Map
DEBeebe South Coastal Health CampusMillville19967NCT06632327Map
DEChristiana Care Health System-Christiana HospitalNewark19718NCT06632327Map
DEHelen F Graham Cancer CenterNewark19713NCT04402788Map
DEHelen F Graham Cancer CenterNewark19713NCT06632327Map
DEMedical Oncology Hematology Consultants PANewark19713NCT04402788Map
DEMedical Oncology Hematology Consultants PANewark19713NCT06632327Map
DEResearch SiteNewark19713NCT06921785Map
DEBeebe Health CampusRehoboth Beach19971NCT04402788Map
DEBeebe Health CampusRehoboth Beach19971NCT06632327Map
DEChristiana Care Health System-Wilmington HospitalWilmington19801NCT06632327Map
DCMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #004Washington D.C.20007NCT05434234Map
DCGeorge Washington University Medical CenterWashington D.C.20037NCT01810913Map
DCGeorgetown Lombardi Comprehensive Cancer CenterWashington D.C.20007NCT05482516Map
DCGeorgetown University Medical CenterWashington D.C.20007NCT04524871Map
DCJohns Hopkins University: Sibley Memorial HospitalWashington D.C.20016NCT05312671Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT05333458Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT06287775Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT06632327Map
DCMedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)Washington D.C.20007NCT04302025Map
DCMedstar Washington Hospital CenterWashington D.C.20010NCT05482516Map
DCMedStar Washington Hospital CenterWashington D.C.20010NCT06632327Map
DCWashington DC VA Medical CenterWashington D.C.20422-0001NCT06096779Map
FLUniversity of Miami/Sylvester Cancer Institute - AventuraAventura33180NCT02693535Map
FLClermont Oncology CenterClermont34711NCT06463665Map
FLUM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables33146NCT04402788Map
FLUniversity of Miami/Sylvester Cancer Institute - LennarCoral Gables33146NCT02693535Map
FLBRCR Coral SpringsCoral Springs33065NCT07226999Map
FLOncology & Hematology Associates of West BrowardCoral Springs33065NCT06463665Map
FLUM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT04402788Map
FLUniversity of Miami/Sylvester Cancer Institute - Deerfield BeachDeerfield Beach33442NCT02693535Map
FLMayo ClinicFlorida City32224NCT07235293Map
FLHelios Clinical ResearchFort Lauderdale33316NCT06463665Map
FLHoly Cross HospitalFort Lauderdale33308NCT02693535Map
FLHoly Cross HospitalFort Lauderdale33308NCT01810913Map
FLHoly Cross HospitalFort Lauderdale33308NCT05058651Map
FLFlorida Cancer Specialists - SouthFort Myers33901NCT06646276Map
FLUF Health Cancer Institute - GainesvilleGainesville32610NCT06287775Map
FLUniversity of FloridaGainesville32608NCT05000294Map
FLUniversity of Florida HealthGainesville32610NCT02693535Map
FLBioresearch PartnerHialeah33013NCT06463665Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT05058651Map
FLMayo Clinic-JacksonvilleJacksonville32224NCT06362252Map
FLResearch SiteJacksonville32224NCT06921785Map
FLOrlando Health Cancer Institute - Lake MaryLake Mary32746NCT06632327Map
FLBioresearch PartnerMiami33155NCT06463665Map
FLMiami Cancer Institute at Baptist HealthMiami33176NCT05317858Map
FLSylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics)Miami33136NCT05733598Map
FLUniversity of MiamiMiami33136NCT06444815Map
FLUniversity of Miami - Sylvester Comprehensive Cancer CenterMiami33136NCT06463665Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT04402788Map
FLUniversity of Miami Sylvester Comprehensive Cancer CenterMiami33136NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - Alex's PlaceMiami33136NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - Griffin Cancer Research BuildingMiami33136NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - KendallMiami33176NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - Sole MiaMiami33181NCT02693535Map
FLOcala Oncology Center /ID# 278269Ocala34474NCT07155174Map
FLHealth CentralOcoee34761NCT06632327Map
FLMid Florida Hematology and Oncology CenterOrange City32763NCT06463665Map
FLMid Florida Hematology and Oncology CenterOrange City32763NCT06646276Map
FLMid Florida Hematology and Oncology CenterOrange City32763NCT07195695Map
FLMid Florida Hematology and Oncology CenterOrange City32763NCT07226999Map
FLAdvent Health OrlandoOrlando32804NCT06362252Map
FLOrlando Health Cancer InstituteOrlando32806NCT01810913Map
FLOrlando Health Cancer InstituteOrlando32806NCT06632327Map
FLOrlando Health Cancer Institute ( Site 0108)Orlando32806NCT07227597Map
FLOrlando Health Inc.Orlando32806NCT06096779Map
FLCancer Care Centers of Brevard, IncPalm Bay32901NCT06712355Map
FLBRCR Medical Center, Inc.Plantation33322NCT06463665Map
FLUniversity of Miami/Sylvester Cancer Institute - PlantationPlantation33324NCT02693535Map
FLMoffitt Cancer Center at SouthShoreRuskin33570NCT01810913Map
FLFlorida Cancer Specialists - SarasotaSarasota34232NCT05581004Map
FLZai Lab Site 2026Sarasota34232NCT06179069Map
FLFlorida Cancer Specialists - NorthSt. Petersburg33705NCT06646276Map
FLBRCR Global - TamaracTamarac33321NCT07226999Map
FLMoffitt Cancer CenterTampa33612NCT05317858Map
FLMoffitt Cancer CenterTampa33612NCT05440708Map
FLMoffitt Cancer CenterTampa33612NCT04302025Map
FLMoffitt Cancer CenterTampa33612NCT05733598Map
FLMoffitt Cancer CenterTampa33612NCT01810913Map
FLMoffitt Cancer CenterTampa33612NCT05058651Map
FLMoffitt Cancer CenterTampa33612NCT06362252Map
FLMoffitt Cancer Center /ID# 277573Tampa33612NCT07155174Map
FLMoffitt Cancer Center-International PlazaTampa33607NCT01810913Map
GACancer Treatment Centers of America - AtlantaAtlanta30265NCT02693535Map
GAChilldren's Healthcare of AtlantaAtlanta30322NCT06492954Map
GAEmory Proton Therapy CenterAtlanta30308NCT07166406Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT04981509Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT04402788Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT06287775Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT07166406Map
GAEmory University Hospital MidtownAtlanta30308NCT04981509Map
GAEmory University Hospital MidtownAtlanta30308NCT04402788Map
GAEmory University Hospital MidtownAtlanta30308NCT01810913Map
GAEmory University Hospital MidtownAtlanta30308NCT06287775Map
GAEmory University Hospital MidtownAtlanta30308NCT06731270Map
GAEmory University Hospital MidtownAtlanta30308NCT07166406Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT04981509Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT04402788Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT01810913Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT06287775Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT06731270Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT07166406Map
GAEmory University Winship Cancer InstituteAtlanta30322NCT02693535Map
GAGrady Health SystemAtlanta30303NCT04402788Map
GAGrady Health SystemAtlanta30303NCT07166406Map
GAPiedmont Cancer InstituteAtlanta30318NCT07195695Map
GAResearch SiteAtlanta30318NCT06921785Map
GAWinship Cancer Institute at Emory UniversityAtlanta30322NCT06043674Map
GAAugusta University Medical CenterAugusta30912NCT01810913Map
GANorthwest Georgia Oncology CentersMarietta30060NCT07195695Map
GANorthwest Georgia Oncology Centers, a Service of Wellstar Cobb HospitalMarietta30060NCT06646276Map
GACTCA at Southeastern Regional Medical CenterNewnan30265NCT04402788Map
GACTCA at Southeastern Regional Medical CenterNewnan30265NCT06632327Map
GAGynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research PavilionSavannah31405NCT02693535Map
GALewis Cancer & Research PavilionSavannah31405NCT02693535Map
GALewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma InstituteSavannah31405NCT02693535Map
GAMemorial Health University Medical CenterSavannah31404NCT01810913Map
GASummit Cancer CareSavannah31405NCT02693535Map
HIHawaii Cancer Care - Westridge‘Aiea96701NCT05058651Map
HIThe Queen's Medical Center - West Oahu‘Ewa Beach96706NCT02693535Map
HIThe Queen's Medical Center - West Oahu‘Ewa Beach96706NCT05058651Map
HIHawaii Cancer Care Inc - Waterfront PlazaHonolulu96813NCT05058651Map
HIQueen's Cancer Cenrer - POB IHonolulu96813NCT05058651Map
HIQueen's Cancer Center - KuakiniHonolulu96817NCT05058651Map
HIQueen's Medical CenterHonolulu96813NCT05058651Map
HIStraub Clinic and HospitalHonolulu96813NCT05058651Map
HIThe Queen's Medical Center - KuakiniHonolulu96817NCT02693535Map
HIThe Queen's Medical Center - POB IHonolulu96813NCT02693535Map
HIThe Queen's Medical Center - PunchbowlHonolulu96813NCT02693535Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT04402788Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT04402788Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT06632327Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT04402788Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT01810913Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT05058651Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT06632327Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT06632327Map
ILOSF Saint Anthony's Health CenterAlton62002NCT06632327Map
ILIllinois Cancer SpecialistsArlington Heights60005NCT04929223Map
ILRush-Copley Medical CenterAurora60504NCT05058651Map
ILRush-Copley Medical CenterAurora60504NCT06632327Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT06632327Map
ILIllinois CancerCare-CantonCanton61520NCT06632327Map
ILMemorial Hospital of CarbondaleCarbondale62902NCT06632327Map
ILSIH Cancer InstituteCarterville62918NCT06632327Map
ILIllinois CancerCare-CarthageCarthage62321NCT06632327Map
ILCentralia Oncology ClinicCentralia62801NCT05058651Map
ILCentralia Oncology ClinicCentralia62801NCT06632327Map
ILAlliance for Clinical Trials in OncologyChicago60606NCT05001880Map
ILAnn & Robert H. Lurie Children's Hospital of ChicagoChicago60611NCT04796012Map
ILCancer Treatment Centers of America-ChicagoChicago60099NCT02693535Map
ILJohn H Stroger Jr Hospital of Cook CountyChicago60612NCT01810913Map
ILJohn H Stroger Jr Hospital of Cook CountyChicago60612NCT06632327Map
ILNorthwestern Memorial HospitalChicago60611NCT05968326Map
ILNorthwestern UniversityChicago60611NCT04981509Map
ILNorthwestern UniversityChicago60611NCT04302025Map
ILNorthwestern UniversityChicago60611NCT05620771Map
ILNorthwestern UniversityChicago60611NCT05058651Map
ILNorthwestern UniversityChicago60611-2908NCT06096779Map
ILNorthwestern UniversityChicago60611NCT06632327Map
ILRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityChicago60611NCT06362252Map
ILThe Duchossois Center for Advanced MedicineChicago60637-1426NCT06096779Map
ILThe University of Chicago Medical Center /ID# 255674Chicago60637-1443NCT06109272Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05001880Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05058651Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT06287775Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT07166406Map
ILUniversity of IllinoisChicago60612NCT04402788Map
ILUniversity of IllinoisChicago60612NCT06632327Map
ILUniversity of Illinois Cancer CenterChicago60612NCT04919382Map
ILUniversity of Illinois Health Outpatient Care CenterChicago60612-4795NCT06096779Map
ILUniversity of Illinois Hospital and Health Sciences SystemChicago60612NCT07195695Map
ILCarle at The RiverfrontDanville61832NCT05001880Map
ILCarle at The RiverfrontDanville61832NCT04402788Map
ILCarle at The RiverfrontDanville61832NCT06632327Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT05058651Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT06632327Map
ILDecatur Memorial HospitalDecatur62526NCT04402788Map
ILDecatur Memorial HospitalDecatur62526NCT01810913Map
ILDecatur Memorial HospitalDecatur62526NCT05058651Map
ILDecatur Memorial HospitalDecatur62526NCT06632327Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT04302025Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT05058651Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT06632327Map
ILNorthwestern Medicine Kishwaukee HospitalDeKalb60115NCT05620771Map
ILIllinois CancerCare-DixonDixon61021NCT06632327Map
ILCarle Physician Group-EffinghamEffingham62401NCT05001880Map
ILCarle Physician Group-EffinghamEffingham62401NCT04402788Map
ILCarle Physician Group-EffinghamEffingham62401NCT06632327Map
ILCrossroads Cancer CenterEffingham62401NCT04402788Map
ILCrossroads Cancer CenterEffingham62401NCT01810913Map
ILCrossroads Cancer CenterEffingham62401NCT05058651Map
ILCrossroads Cancer CenterEffingham62401NCT06632327Map
ILElmhurst Memorial HospitalElmhurst60126NCT04402788Map
ILIllinois CancerCare-EurekaEureka61530NCT06632327Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT01810913Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT06632327Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT04302025Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT05058651Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT06632327Map
ILNorthwestern Medicine Delnor HospitalGeneva60134NCT05620771Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT01810913Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT05058651Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT06632327Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT05620771Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT05058651Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT06632327Map
ILIngalls Memorial HospitalHarvey60426NCT05058651Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT01810913Map
ILEdward Hines Jr VA HospitalHines60141NCT06632327Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT06632327Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT05620771Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT05058651Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT06632327Map
ILIllinois CancerCare-MacombMacomb61455NCT06632327Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05001880Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT04402788Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT06632327Map
ILSSM Health Good SamaritanMount Vernon62864NCT06632327Map
ILEdward Hospital/Cancer CenterNaperville60540NCT04402788Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT05058651Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT06287775Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT07166406Map
ILIllinois Cancer SpecialistsNiles60714NCT06712355Map
ILCarle BroMenn Medical CenterNormal61761NCT05058651Map
ILCarle Cancer Institute NormalNormal61761NCT05058651Map
ILCancer Care Center of O'FallonO'Fallon62269NCT05058651Map
ILCancer Care Center of O'FallonO'Fallon62269NCT06632327Map
ILHSHS Saint Elizabeth's HospitalO'Fallon62269NCT04402788Map
ILHSHS Saint Elizabeth's HospitalO'Fallon62269NCT01810913Map
ILHSHS Saint Elizabeth's HospitalO'Fallon62269NCT06632327Map
ILNorthwestern Medicine Oak BrookOak Brook60523NCT06632327Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT05620771Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT05058651Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT06632327Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT05058651Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT06287775Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT07166406Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT06632327Map
ILIllinois CancerCare-PekinPekin61554NCT06632327Map
ILIllinois Cancer CarePeoria61615NCT06646276Map
ILIllinois CancerCare-PeoriaPeoria61615NCT06632327Map
ILMethodist Medical Center of IllinoisPeoria61636NCT06632327Map
ILOSF Saint Francis Medical CenterPeoria61637NCT01810913Map
ILOSF Saint Francis Radiation Oncology at Peoria Cancer CenterPeoria61615NCT01810913Map
ILIllinois CancerCare-PeruPeru61354NCT06632327Map
ILValley Radiation OncologyPeru61354NCT06632327Map
ILEdward Hospital/Cancer Center?PlainfieldPlainfield60585NCT04402788Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT06632327Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT04402788Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT01810913Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT05058651Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT06632327Map
ILMemorial Hospital EastShiloh62269NCT06632327Map
ILMemorial Hospital EastShiloh62269NCT07166406Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT05058651Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT06632327Map
ILSpringfield ClinicSpringfield62702NCT05058651Map
ILSpringfield ClinicSpringfield62702NCT06632327Map
ILSpringfield Memorial HospitalSpringfield62781NCT04402788Map
ILSpringfield Memorial HospitalSpringfield62781NCT01810913Map
ILSpringfield Memorial HospitalSpringfield62781NCT05058651Map
ILSpringfield Memorial HospitalSpringfield62781NCT06632327Map
ILCarle Cancer CenterUrbana61801NCT05001880Map
ILCarle Cancer CenterUrbana61801NCT04402788Map
ILCarle Cancer CenterUrbana61801NCT01810913Map
ILCarle Cancer CenterUrbana61801NCT06632327Map
ILCarle Cancer Center NCI Community Oncology Research ProgramUrbana61801NCT05168163Map
ILThe Carle Foundation HospitalUrbana61801NCT05001880Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT04302025Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT05058651Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT06632327Map
ILNorthwestern Medicine WarrenvilleWarrenville60555NCT05620771Map
ILIllinois CancerCare - WashingtonWashington61571NCT06632327Map
ILRush-Copley Healthcare CenterYorkville60560NCT05058651Map
ILRush-Copley Healthcare CenterYorkville60560NCT06632327Map
ILMidwestern Regional Medical CenterZion60099NCT06632327Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT05058651Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT06287775Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT07166406Map
INFort Wayne Medical Oncology And Hematology /ID# 277336Fort Wayne46804NCT07155174Map
INFort Wayne Medical Oncology and Hematology, IncFort Wayne46804NCT06712355Map
INGSK Investigational SiteFort Wayne46804NCT06551142Map
INGoshen Center for Cancer CareGoshen46526NCT06632327Map
INNorthwest Cancer Center - HobartHobart46342NCT04402788Map
INCommunity Health NetworkIndianapolis46250NCT06444815Map
INCommunity Health Network (The University of Texas MD Anderson Cancer Center)Indianapolis46250NCT02693535Map
INIndiana University Health Melvin & Bren Simon Cancer CenterIndianapolis46202NCT05968326Map
INIndiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis46202NCT04919382Map
INBaptist Health FloydNew Albany47150NCT04402788Map
IAMary Greeley Medical CenterAmes50010NCT05058651Map
IAMcFarland ClinicAmes50010NCT06712355Map
IAMcFarland Clinic - AmesAmes50010NCT05058651Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT04402788Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT05058651Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT07166406Map
IASaint Anthony Regional HospitalCarroll51401NCT05058651Map
IAHelen G. Nassif Community Cancer CenterCedar Rapids52403NCT06712355Map
IAMercy HospitalCedar Rapids52403NCT06632327Map
IAOncology Associates at Mercy Medical CenterCedar Rapids52403NCT06632327Map
IAPhysicians' Clinic of Iowa PCCedar Rapids52402NCT04402788Map
IAMercy Cancer Center-West LakesClive50325NCT04402788Map
IAMercy Cancer Center-West LakesClive50325NCT05058651Map
IAMercy Cancer Center-West LakesClive50325NCT07166406Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT04402788Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT05058651Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT07166406Map
IAHeartland Oncology and Hematology LLPCouncil Bluffs51503NCT04402788Map
IAGreater Regional Medical CenterCreston50801NCT04402788Map
IAGreater Regional Medical CenterCreston50801NCT05058651Map
IAGreater Regional Medical CenterCreston50801NCT07166406Map
IABroadlawns Medical CenterDes Moines50314NCT04402788Map
IABroadlawns Medical CenterDes Moines50314NCT05058651Map
IAIowa Methodist Medical CenterDes Moines50309NCT04402788Map
IAIowa Methodist Medical CenterDes Moines50309NCT05058651Map
IAIowa Methodist Medical CenterDes Moines50309NCT07166406Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT04402788Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT05058651Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT07166406Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT04402788Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT05058651Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT07166406Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT04402788Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT05058651Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT07166406Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT05058651Map
IAUniversity of Iowa Hospitals and ClinicsIowa City52242NCT04919382Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT05058651Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT04402788Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT05058651Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT07166406Map
IAMercy Medical Center-West LakesWest Des Moines50266NCT04402788Map
IAMercy Medical Center-West LakesWest Des Moines50266NCT05058651Map
IAMercy Medical Center-West LakesWest Des Moines50266NCT07166406Map
IAThe Iowa Clinic PCWest Des Moines50266NCT07166406Map
KSUniversity of Kansas Clinical Research CenterFairway66205NCT06287775Map
KSCentral Care Cancer Center - Garden CityGarden City67846NCT06632327Map
KSCentral Care Cancer Center - Great BendGreat Bend67530NCT06632327Map
KSHaysMedHays67601NCT06632327Map
KSThe University of Kansas Cancer Center, Westwood CampusKansas City66205NCT04467723Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT01810913Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT06287775Map
KSLawrence Memorial HospitalLawrence66044NCT01810913Map
KSLawrence Memorial HospitalLawrence66044NCT06632327Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT01810913Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT06632327Map
KSUniversity of Kansas Cancer Center-Overland ParkOverland Park66210NCT01810913Map
KSUniversity of Kansas Hospital-Indian Creek CampusOverland Park66211NCT06287775Map
KSMercy Hospital PittsburgPittsburg66762NCT06632327Map
KSSalina Regional Health CenterSalina67401NCT01810913Map
KSSalina Regional Health CenterSalina67401NCT06632327Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT06632327Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT06287775Map
KSAscension Via Christi Hospitals WichitaWichita67214NCT04402788Map
KYKing's Daughter's Medical CenterAshland41101NCT06632327Map
KYFlaget Memorial HospitalBardstown40004NCT06632327Map
KYCommonwealth Cancer Center-CorbinCorbin40701NCT06632327Map
KYSaint Elizabeth Medical Center Edgewood ( Site 0112)Edgewood41017NCT07227597Map
KYBaptist Health Hardin Cancer CenterElizabethtown42701NCT06712355Map
KYBaptist Health Lexington /ID# 277729Lexington40503NCT07155174Map
KYSaint Joseph HospitalLexington40504NCT06632327Map
KYSaint Joseph Hospital EastLexington40509NCT04402788Map
KYSaint Joseph Hospital EastLexington40509NCT06632327Map
KYSaint Joseph Radiation Oncology Resource CenterLexington40504NCT06632327Map
KYUniversity of Kentucky - Markey Cancer CenterLexington40536-7001NCT04524871Map
KYUniversity of Kentucky - Markey Cancer CenterLexington40536-7001NCT06096779Map
KYUniversity of Kentucky Medical CenterLexington40536NCT05968326Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT06287775Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT07166406Map
KYSaint Joseph LondonLondon40741NCT06632327Map
KYBaptist Health LouisvilleLouisville40207NCT04402788Map
KYNorton Cancer Institute /ID# 260775Louisville40217-1395NCT06109272Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT04402788Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT01810913Map
KYUofL Health Medical Center NortheastLouisville40245NCT04402788Map
KYUofL Health Medical Center NortheastLouisville40245NCT01810913Map
KYSaint Joseph Mount SterlingMount Sterling40353NCT06632327Map
KYOwensboro Health Mitchell Memorial Cancer CenterOwensboro42303NCT06632327Map
LALSU Health Baton RougeBaton Rouge70805NCT06096779Map
LALSU Health Baton Rouge-North ClinicBaton Rouge70805NCT01810913Map
LALSU Health Baton Rouge-North ClinicBaton Rouge70805NCT05058651Map
LAMary Bird Perkins Cancer CtrBaton Rouge70809NCT04929223Map
LAOur Lady of the Lake Cancer InstituteBaton Rouge70808-4300NCT06096779Map
LAOur Lady of the Lake Physician GroupBaton Rouge70808NCT01810913Map
LAOur Lady of the Lake Physician GroupBaton Rouge70808NCT05058651Map
LAEast Jefferson General HospitalMetairie70006NCT05058651Map
LALSU Healthcare Network / Metairie Multi-Specialty ClinicMetairie70006NCT05058651Map
LATouro InfirmaryNew Orleans70115NCT01810913Map
LATulane University School of MedicineNew Orleans70112NCT06632327Map
LAUniversity Medical Center New OrleansNew Orleans70112NCT01810913Map
LAUniversity Medical Center New OrleansNew Orleans70112NCT05058651Map
LAUniversity Medical Center New OrleansNew Orleans70112NCT05168163Map
LAUniversity Medical Center New OrleansNew Orleans70112NCT06632327Map
MEHarold Alfond Center for Cancer CareAugusta04330NCT02693535Map
MEJackson Laboratory - Maine Cancer Genomics InitiativeAugusta04330NCT02693535Map
MEEastern Maine Medical CenterBangor04401NCT06632327Map
MEMaineHealth Coastal Cancer Treatment CenterBath04530NCT04402788Map
MEWaldo County General HospitalBelfast04915NCT02693535Map
MESMHC Cancer Care and Blood Disorders -BiddefordBiddeford04005NCT02693535Map
MELafayette Family Cancer Center-EMMCBrewer04412NCT06632327Map
MENorthern Light Cancer CareBrewer04412NCT02693535Map
MERaish Peavey Haskell Children's Cancer and Treatment CenterBrewer04412NCT02693535Map
MEMaineHealth Cancer Care -BrunswickBrunswick04011NCT02693535Map
MENew England Cancer SpecialistKennebunk04043NCT02693535Map
MEYork Hopsital Oncology & Infusion Care in KitteryKittery03904NCT02693535Map
MEStephens Memorial HospitalNorway04268NCT02693535Map
MEMaineHealth Maine Medical Center - PortlandPortland04102NCT04402788Map
MEPenobscot Bay Medical CenterRockport04856NCT02693535Map
MEMaineHealth Cancer Care Center of York CountySanford04073NCT04402788Map
MESMHC Cancer Care and Blood Disorders -SandfordSanford04073NCT02693535Map
MEMaine Children's Cancer ProgramScarborough04074NCT02693535Map
MEMaine Medical Partner's Women's HealthScarborough04074NCT02693535Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT04402788Map
MENew England Cancer SpecialistScarborough04074NCT02693535Map
MEMaineHealth Cancer Care -South PortlandSouth Portland04106NCT02693535Map
MEMaineHealth Cancer Care and IV Therapy - South PortlandSouth Portland04106NCT04402788Map
MENew England Cancer SpecialistTopsham04086NCT02693535Map
MEYork Hospital Oncology & Infusion Care in WellsWells04090NCT02693535Map
MEYork Hospital Oncology & Infusion Care in YorkYork Village03909NCT02693535Map
MDGreater Baltimore Medical CenterBaltimore21204NCT01810913Map
MDJohns Hopkins University: Sidney Kimmel Comprehensive Cancer CenterBaltimore21287NCT05312671Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT01810913Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT06287775Map
MDMedStar Franklin Square Medical Center/Weinberg Cancer InstituteBaltimore21237NCT06632327Map
MDMedStar Good Samaritan HospitalBaltimore21239NCT06632327Map
MDSidney Kimmel Comprehensive Cancer Center at John HopkinsBaltimore21287NCT05652686Map
MDThe Sidney Kimmel Comprehensive Cancer CenterBaltimore21231NCT05440708Map
MDUniversity of MarylandBaltimore21201NCT05317858Map
MDUniversity of Maryland Medical CenterBaltimore21201NCT05733598Map
MDUniversity of Maryland/Greenebaum Cancer CenterBaltimore21201NCT01810913Map
MDUniversity of Maryland/Greenebaum Cancer CenterBaltimore21201NCT06287775Map
MDUM Upper Chesapeake Medical CenterBel Air21014NCT01810913Map
MDNational Cancer Institute Developmental Therapeutics ClinicBethesda20892NCT05333458Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT06066138Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT06161532Map
MDNCI - Center for Cancer ResearchBethesda20892NCT04981509Map
MDCentral Maryland Radiation Oncology in Howard CountyColumbia21044NCT01810913Map
MDChristiana Care - Union HospitalElkton21921NCT06632327Map
MDFrederick Health Hospital- James M Stockman Cancer InstituteFrederick21704NCT06712355Map
MDUM Baltimore Washington Medical Center/Tate Cancer CenterGlen Burnie21061NCT01810913Map
MABeverly HospitalBeverly01915NCT06632327Map
MAMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #005Boston02114NCT05434234Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06096779Map
MABoston Children's HospitalBoston02115NCT04796012Map
MABoston Medical CenterBoston02118NCT04402788Map
MABoston Medical CenterBoston02118NCT01810913Map
MABoston Medical Center (BMC) - Cancer Care CenterBoston02118NCT05968326Map
MABrigham & Women's HospitalBoston02115NCT04812366Map
MABrigham and Women's HospitalBoston02215NCT06043674Map
MADana Farber Cancer InstituteBoston02215NCT05581004Map
MADana Farber Cancer InstituteBoston02215NCT06043674Map
MADana-Farber Cancer InstituteBoston02215NCT04302025Map
MADana-Farber Cancer InstituteBoston02215NCT04434040Map
MADana-Farber Cancer InstituteBoston02215NCT05652686Map
MADana-Farber Cancer InstituteBoston02215NCT05019703Map
MADana-Farber Cancer InstituteBoston02215NCT05096715Map
MADana-Farber Cancer InstituteBoston02215NCT07195695Map
MADana-Farber Cancer Institute /ID# 277732Boston02215NCT07155174Map
MAGSK Investigational SiteBoston02114NCT06551142Map
MAHarvard Medical School - Massachusetts General Hospital (MGH) - Cancer CenterBoston02114-2621NCT05968326Map
MAMassachusetts General HospitalBoston02114NCT04802759Map
MAMassachusetts General HospitalBoston02114NCT05652686Map
MAMassachusetts General Hospital Cancer CenterBoston02114NCT05096715Map
MATufts Medical CenterBoston02111NCT06096779Map
MATufts Medical CenterBoston02111NCT06632327Map
MABeth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical CenterBurlington01805NCT06712355Map
MALahey Hospital and Medical CenterBurlington01805NCT05058651Map
MALahey Hospital and Medical CenterBurlington01805NCT06632327Map
MAAddison Gilbert HospitalGloucester01930NCT06632327Map
MALowell General HospitalLowell01854NCT04402788Map
MALahey Medical Center-PeabodyPeabody01960NCT05058651Map
MALahey Medical Center-PeabodyPeabody01960NCT06632327Map
MATufts Medical Center Cancer Center StonehamStoneham02180NCT06632327Map
MAUMass Memorial Medical Center - University CampusWorcester01655NCT04402788Map
MIMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #006Ann Arbor48109NCT05434234Map
MIMichigan Cancer Research Consortium NCORPAnn Arbor48106NCT05168163Map
MITrinity Health Ann Arbor HospitalAnn Arbor48106NCT02693535Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT01810913Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT05058651Map
MIUniversity of MichiganAnn Arbor48109NCT04302025Map
MIUniversity of Michigan HealthAnn Arbor48109-5946NCT04812366Map
MIUniversity of Michigan Rogel Cancer CenterAnn Arbor48109NCT05440708Map
MIUniversity of Michigan Rogel Cancer CenterAnn Arbor48109NCT05058651Map
MIVeterans Affairs Ann Arbor Healthcare SystemAnn Arbor48105NCT06096779Map
MIBronson Battle CreekBattle Creek49017NCT05058651Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT04402788Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT05058651Map
MITrinity Health Medical Center - BrightonBrighton48114NCT04402788Map
MITrinity Health Medical Center - BrightonBrighton48114NCT01810913Map
MITrinity Health Medical Center - BrightonBrighton48114NCT05058651Map
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT01810913
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT05058651
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT07166406
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT04402788Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT05058651Map
MITrinity Health Medical Center - CantonCanton48188NCT04402788Map
MITrinity Health Medical Center - CantonCanton48188NCT05058651Map
MIChelsea HospitalChelsea48118NCT04402788Map
MIChelsea HospitalChelsea48118NCT05058651Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT04402788Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT05058651Map
MIMcLaren Cancer Institute-ClarkstonClarkston48346NCT04402788Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT01810913Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT05058651Map
MICorewell Health Dearborn HospitalDearborn48124NCT05058651Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT01810913Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT05058651Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT07166406Map
MIMichigan Hematology and Oncology ConsultantsDearborn48126NCT06463665Map
MIMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #007Detroit48292NCT05434234Map
MIBarbara Ann Karmanos Cancer InstituteDetroit48201NCT05440708Map
MIBarbara Ann Karmanos Cancer InstituteDetroit48201NCT06096779Map
MIGSK Investigational SiteDetroit48201NCT06551142Map
MIHenry Ford Cancer- DetroitDetroit48202NCT07339059Map
MIHenry Ford Health Saint John HospitalDetroit48236NCT02693535Map
MIHenry Ford Health Saint John HospitalDetroit48236NCT05058651Map
MIHenry Ford Health SystemDetroit48202-2610NCT05968326Map
MIHenry Ford Health SystemDetroit48202NCT06096779Map
MIHenry Ford HospitalDetroit48202NCT05581004Map
MIHenry Ford HospitalDetroit48202NCT01810913Map
MIHenry Ford HospitalDetroit48202NCT05058651Map
MIHenry Ford HospitalDetroit48202NCT07166406Map
MIHenry Ford Hospital /ID# 255803Detroit48202NCT06109272Map
MIWayne State University/Karmanos Cancer InstituteDetroit48201NCT04402788Map
MIZai Lab Site 2013Detroit48201NCT06179069Map
MIOSF Saint Francis Hospital and Medical GroupEscanaba49829NCT06632327Map
MICorewell Health Farmington Hills HospitalFarmington Hills48336NCT05058651Map
MIOakland Medical GroupFarmington Hills48336NCT06463665Map
MIWeisberg Cancer Treatment CenterFarmington Hills48334NCT04402788Map
MICancer Hematology Centers - FlintFlint48503NCT05058651Map
MIGenesys Hurley Cancer InstituteFlint48503NCT02693535Map
MIGenesys Hurley Cancer InstituteFlint48503NCT04402788Map
MIGenesys Hurley Cancer InstituteFlint48503NCT05058651Map
MIHurley Medical CenterFlint48503NCT04402788Map
MIHurley Medical CenterFlint48503NCT05058651Map
MIMcLaren Cancer Institute-FlintFlint48532NCT04402788Map
MICancer Research Consortium of West MichiganGrand Rapids49503NCT02693535Map
MICorewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids49503NCT01810913Map
MICorewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids49503NCT05058651Map
MIResearch SiteGrand Rapids49503NCT06921785Map
MITrinity Health Grand Rapids HospitalGrand Rapids49503NCT05058651Map
MIHenry Ford Saint John Hospital - BreastGrosse Pointe Woods48236NCT05058651Map
MIAllegiance HealthJackson49201NCT01810913Map
MIAllegiance HealthJackson49201NCT05058651Map
MIAllegiance HealthJackson49201NCT07166406Map
MIBronson Methodist HospitalKalamazoo49007NCT04402788Map
MIBronson Methodist HospitalKalamazoo49007NCT05058651Map
MIWest Michigan Cancer CenterKalamazoo49007NCT04402788Map
MIWest Michigan Cancer CenterKalamazoo49007NCT01810913Map
MIWest Michigan Cancer CenterKalamazoo49007NCT05058651Map
MIKarmanos Cancer Institute at McLaren Greater LansingLansing48910NCT04402788Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT02693535Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT04402788Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT01810913Map
MIMcLaren Cancer Institute-Lapeer RegionLapeer48446NCT04402788Map
MITrinity Health Livonia HospitalLivonia48154NCT02693535Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT04402788Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT01810913Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT05058651Map
MIHenry Ford Saint John Hospital - Macomb MedicalMacomb48044NCT05058651Map
MIMcLaren Cancer Institute-MacombMount Clemens48043NCT04402788Map
MITrinity Health Muskegon HospitalMuskegon49444NCT05058651Map
MICorewell Health Lakeland Hospitals - Niles HospitalNiles49120NCT05058651Map
MICancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores49444NCT05058651Map
MIHenry Ford Health Providence Novi HospitalNovi48374NCT04402788Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT01810913Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT05058651Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT07166406Map
MIMcLaren Cancer Institute-Northern MichiganPetoskey49770NCT04402788Map
MITrinity Health Oakland HospitalPontiac48341NCT02693535Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT05058651Map
MIMcLaren-Port HuronPort Huron48060NCT04402788Map
MICorewell Health Reed City HospitalReed City49677NCT05058651Map
MICorewell Health William Beaumont University HospitalRoyal Oak48073NCT04402788Map
MICorewell Health William Beaumont University HospitalRoyal Oak48073NCT05058651Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT02693535Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT04402788Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT01810913Map
MICorewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph49085NCT05058651Map
MICorewell Health Lakeland Hospitals - Saint Joseph HospitalSaint Joseph49085NCT05058651Map
MIHenry Ford Health Providence Southfield HospitalSouthfield48075NCT04402788Map
MIMyMichigan Medical Center TawasTawas City48764NCT04402788Map
MIMichigan Cancer Research ConsortiumTraverse City48341NCT02693535Map
MIMunson Medical CenterTraverse City49684NCT05058651Map
MICorewell Health Beaumont Troy HospitalTroy48085NCT04402788Map
MICorewell Health Beaumont Troy HospitalTroy48085NCT05058651Map
MIHenry Ford Health Warren HospitalWarren48093NCT02693535Map
MIHenry Ford Health Warren HospitalWarren48093NCT05058651Map
MIHenry Ford Warren Hospital - GLCMSWarren48093NCT05058651Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT01810913Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT05058651Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT07166406Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT01810913Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT05058651Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT07166406Map
MIUniversity of Michigan Health - WestWyoming49519NCT01810913Map
MIUniversity of Michigan Health - WestWyoming49519NCT05058651Map
MIHuron Gastroenterology PCYpsilanti48106NCT05058651Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT05058651Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT05001880Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT04402788Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT01810913Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT06632327Map
MNEssentia Health Saint Joseph's Medical CenterBrainerd56401NCT07166406Map
MNMinnesota Oncology - BurnsvilleBurnsville55337NCT01810913Map
MNMinnesota Oncology - BurnsvilleBurnsville55337NCT05058651Map
MNMinnesota Oncology - BurnsvilleBurnsville55337NCT06632327Map
MNCambridge Medical CenterCambridge55008NCT06632327Map
MNMinnesota Oncology Hematology PA-ChaskaChaska55318NCT06632327Map
MNMercy HospitalCoon Rapids55433NCT05001880Map
MNMercy HospitalCoon Rapids55433NCT04402788Map
MNMercy HospitalCoon Rapids55433NCT06632327Map
MNMinnesota Oncology - Coon RapidsCoon Rapids55433NCT06632327Map
MNEssentia Health - Deer River ClinicDeer River56636NCT07166406Map
MNEssentia Health Cancer CenterDuluth55805NCT07166406Map
MNEssentia Health Saint Mary's Medical CenterDuluth55805NCT07166406Map
MNMiller-Dwan HospitalDuluth55805NCT01810913Map
MNMiller-Dwan HospitalDuluth55805NCT07166406Map
MNFairview Southdale HospitalEdina55435NCT05001880Map
MNFairview Southdale HospitalEdina55435NCT05058651Map
MNFairview Southdale HospitalEdina55435NCT06632327Map
MNMinnesota Oncology - EdinaEdina55435NCT06632327Map
MNEssentia Health Hibbing ClinicHibbing55746NCT07166406Map
MNFairview Clinics and Surgery Center Maple GroveMaple Grove55369NCT06632327Map
MNMinnesota Oncology - Maple GroveMaple Grove55369NCT06632327Map
MNMinnesota Oncology Hematology PA-MaplewoodMaplewood55109NCT06632327Map
MNSaint John's Hospital - HealtheastMaplewood55109NCT04402788Map
MNSaint John's Hospital - HealtheastMaplewood55109NCT06632327Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05001880Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT04402788Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05058651Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT06632327Map
MNHealth Partners IncMinneapolis55454NCT06632327Map
MNHennepin County Medical CenterMinneapolis55415NCT01810913Map
MNHennepin County Medical CenterMinneapolis55415NCT05058651Map
MNHennepin County Medical CenterMinneapolis55415NCT06632327Map
MNRegents of the University of MinnesotaMinneapolis55455NCT06362252Map
MNMonticello Cancer CenterMonticello55362NCT06632327Map
MNNew Ulm Medical CenterNew Ulm56073NCT06632327Map
MNFairview Northland Medical CenterPrinceton55371NCT06632327Map
MNNorth Memorial Medical Health CenterRobbinsdale55422NCT01810913Map
MNNorth Memorial Medical Health CenterRobbinsdale55422NCT06632327Map
MNMayo ClinicRochester55905NCT04302025Map
MNMayo ClinicRochester55905NCT06362252Map
MNMayo Clinic in RochesterRochester55905NCT05001880Map
MNMayo Clinic in RochesterRochester55905NCT03942328Map
MNMayo Clinic in RochesterRochester55905NCT01810913Map
MNMayo Clinic in RochesterRochester55905NCT05058651Map
MNMayo Clinic in RochesterRochester55905NCT05168163Map
MNMayo Clinic in RochesterRochester55905NCT06632327Map
MNMayo Clinic RochesterRochester55902NCT04929223Map
MNResearch SiteRochester55905NCT06921785Map
MNCoborn Cancer Center at Saint Cloud HospitalSaint Cloud56303NCT04402788Map
MNCoborn Cancer Center at Saint Cloud HospitalSaint Cloud56303NCT01810913Map
MNCoborn Cancer Center at Saint Cloud HospitalSaint Cloud56303NCT06632327Map
MNMetro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041Saint Louis Park55416NCT06109272Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05001880Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT04402788Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05058651Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT06632327Map
MNRegions HospitalSaint Paul55101NCT05001880Map
MNRegions HospitalSaint Paul55101NCT04402788Map
MNRegions HospitalSaint Paul55101NCT05058651Map
MNRegions HospitalSaint Paul55101NCT06632327Map
MNUnited HospitalSaint Paul55102NCT05001880Map
MNUnited HospitalSaint Paul55102NCT05058651Map
MNUnited HospitalSaint Paul55102NCT06632327Map
MNEssentia Health SandstoneSandstone55072NCT07166406Map
MNSaint Francis Regional Medical CenterShakopee55379NCT05058651Map
MNSaint Francis Regional Medical CenterShakopee55379NCT06632327Map
MNLakeview HospitalStillwater55082NCT06632327Map
MNSanford Thief River Falls Medical CenterThief River Falls56701NCT06632327Map
MNEssentia Health Virginia ClinicVirginia55792NCT07166406Map
MNRidgeview Medical CenterWaconia55387NCT06632327Map
MNRice Memorial HospitalWillmar56201NCT05001880Map
MNRice Memorial HospitalWillmar56201NCT06632327Map
MNMinnesota Oncology Hematology PA-WoodburyWoodbury55125NCT06632327Map
MNSanford Cancer Center WorthingtonWorthington56187NCT05001880Map
MNSanford Cancer Center WorthingtonWorthington56187NCT06632327Map
MNFairview Lakes Medical CenterWyoming55092NCT06632327Map
MSBaptist Memorial Hospital and Cancer Center-Golden TriangleColumbus39705NCT06632327Map
MSBaptist Cancer Center-GrenadaGrenada38901NCT06632327Map
MSBaptist Memorial Hospital and Cancer Center-Union CountyNew Albany38652NCT06632327Map
MSBaptist Memorial Hospital and Cancer Center-OxfordOxford38655NCT06632327Map
MSBaptist Cancer CenterSouthaven38671NCT06712355Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT04402788Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT06632327Map
MOMercy Oncology and Hematology - Clayton-ClarksonBallwin63011NCT06632327Map
MOCentral Care Cancer Center - BolivarBolivar65613NCT06632327Map
MOCox Cancer Center BransonBranson65616NCT06632327Map
MOMercy Cancer Center - Cape GirardeauCape Girardeau63703NCT06632327Map
MOSaint Francis Medical CenterCape Girardeau63703NCT04402788Map
MOSaint Francis Medical CenterCape Girardeau63703NCT01810913Map
MOSaint Francis Medical CenterCape Girardeau63703NCT05058651Map
MOSaint Francis Medical CenterCape Girardeau63703NCT06632327Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT01810913Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT06632327Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT07166406Map
MOEllis Fischel Cancer CenterColumbia65201NCT04302025Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT01810913Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT06632327Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT07166406Map
MOParkland Health Center - FarmingtonFarmington63640NCT04402788Map
MOParkland Health Center - FarmingtonFarmington63640NCT06632327Map
MOFreeman Health SystemJoplin64804NCT06632327Map
MOMercy Hospital JoplinJoplin64804NCT05058651Map
MOMercy Hospital JoplinJoplin64804NCT06632327Map
MOSaint Luke?s Hospital of Kansas CityKansas City64111NCT06096779Map
MOUniversity Health Truman Medical CenterKansas City64108NCT06632327Map
MOUniversity of Kansas Cancer Center - NorthKansas City64154NCT01810913Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT01810913Map
MOLake Regional HospitalOsage Beach65065NCT06632327Map
MOMercy Clinic-Rolla-Cancer and HematologyRolla65401NCT06632327Map
MOPhelps Health Delbert Day Cancer InstituteRolla65401NCT01810913Map
MOPhelps Health Delbert Day Cancer InstituteRolla65401NCT06632327Map
MOHeartland Regional Medical CenterSaint Joseph64506NCT06632327Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT04402788Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT06632327Map
MOCoxHealth South HospitalSpringfield65807NCT01810913Map
MOCoxHealth South HospitalSpringfield65807NCT05058651Map
MOCoxHealth South HospitalSpringfield65807NCT06632327Map
MOMercy Hospital SpringfieldSpringfield65804NCT01810913Map
MOMercy Hospital SpringfieldSpringfield65804NCT05058651Map
MOMercy Hospital SpringfieldSpringfield65804NCT06632327Map
MOMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #008St Louis63110NCT05434234Map
MOAlvin J. Siteman Cancer Center at Washington UniversitySt Louis63110NCT03821246Map
MOMercy Hospital Saint LouisSt Louis63141NCT04402788Map
MOMercy Hospital Saint LouisSt Louis63141NCT01810913Map
MOMercy Hospital Saint LouisSt Louis63141NCT06632327Map
MOMercy Hospital SouthSt Louis63128NCT05058651Map
MOMercy Hospital SouthSt Louis63128NCT06632327Map
MOMercy Infusion Center - ChippewaSt Louis63109NCT06632327Map
MOMissouri Baptist Medical CenterSt Louis63131NCT04402788Map
MOMissouri Baptist Medical CenterSt Louis63131NCT01810913Map
MOMissouri Baptist Medical CenterSt Louis63131NCT06632327Map
MOSiteman Cancer Center - Washington University Medical CampusSt Louis63108NCT04302025Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT06632327Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT07166406Map
MOSiteman Cancer Center-South CountySt Louis63129NCT06632327Map
MOSiteman Cancer Center-South CountySt Louis63129NCT07166406Map
MOVeteran's Affairs Medical Center - Saint LouisSt Louis63125NCT06632327Map
MOWashington University in St. LouisSt Louis63129NCT05440708Map
MOWashington University School of MedicineSt Louis63110NCT01810913Map
MOWashington University School of MedicineSt Louis63110NCT06632327Map
MOWashington University School of MedicineSt Louis63110NCT06712355Map
MOWashington University School of MedicineSt Louis63110NCT07166406Map
MOWashington University School of Medicine - Siteman Cancer CenterSt Louis63110NCT05703971Map
MOWashington University School of Medicine ( Site 0134)St Louis63110NCT07227597Map
MOWashington University School of Medicine (Siteman Cancer Center)St Louis63108NCT05652686Map
MOWashington University-School of Medicine /ID# 255720St Louis63110NCT06109272Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT04402788Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT06632327Map
MOBJC Outpatient Center at Sunset HillsSunset Hills63127NCT04402788Map
MOBJC Outpatient Center at Sunset HillsSunset Hills63127NCT06632327Map
MOMercy Hospital WashingtonWashington63090NCT06632327Map
MTCommunity Hospital of AnacondaAnaconda59711NCT06632327Map
MTBillings Clinic Cancer CenterBillings59101NCT06632327Map
MTSaint Vincent Frontier Cancer CenterBillings59102NCT05058651Map
MTBozeman Health Deaconess HospitalBozeman59715NCT04402788Map
MTBozeman Health Deaconess HospitalBozeman59715NCT06632327Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT04402788Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT06632327Map
MTGreat Falls ClinicGreat Falls59405NCT06632327Map
MTHi-Line Sletten Cancer CenterHavre59501NCT06632327Map
MTBenefis Helena Specialty CenterHelena59601NCT06632327Map
MTLogan Health Medical CenterKalispell59901NCT06632327Map
MTCommunity Medical CenterMissoula59804NCT06632327Map
NECHI Health Saint FrancisGrand Island68803NCT06632327Map
NECHI Health Good SamaritanKearney68847NCT01810913Map
NECHI Health Good SamaritanKearney68847NCT06632327Map
NENebraska Hematology-Oncology (NHO)Lincoln68506NCT06712355Map
NEAlegent Health Bergan Mercy Medical CenterOmaha68124NCT01810913Map
NEAlegent Health Bergan Mercy Medical CenterOmaha68124NCT06632327Map
NEAlegent Health Immanuel Medical CenterOmaha68122NCT06632327Map
NEAlegent Health Lakeside HospitalOmaha68130NCT06632327Map
NECreighton University Medical CenterOmaha68131NCT06632327Map
NENebraska Methodist HospitalOmaha68114NCT04402788Map
NEUniversity of NebraskaOmaha68198-5300NCT05968326Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT02693535Map
NVCancer Care SpecialistsReno89511NCT07195695Map
NVRenown Regional Medical CenterReno89502NCT04402788Map
NHNH Oncology - Hematology, PAConcord03103NCT02693535Map
NHDartmouth Hitchcock Medical CenterLebanon03756NCT04302025Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT04402788Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT01810913Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT05058651Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT06632327Map
NHDartmouth-Hitchcock Medical CenterLebanon03766NCT06362252Map
NHDartmouth Cancer Center - Manchester/ DCC ManchesterManchester03104NCT06632327Map
NHSolinsky Center for Cancer CareManchester03103NCT02693535Map
NHDartmouth Cancer Center - NashuaNashua03063NCT06632327Map
NHNew England Cancer SpecialistPortsmouth03801NCT02693535Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT01810913Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT06287775Map
NJMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge07920NCT06807632Map
NJMemorial Sloan Kettering Cancer Center Basking RidgeBasking Ridge07920NCT05968326Map
NJCooper Hospital University Medical CenterCamden08103NCT06632327Map
NJAstera Cancer CareEast Brunswick08816NCT06362252Map
NJEnglewood Hospital and Medical CenterEnglewood07631NCT04402788Map
NJJohn Theurer Cancer Center At Hackensack UmcHackensack07601NCT06362252Map
NJJohn Theurer Cancer Center at Hackensack University Medical CenterHackensack07601NCT05482516Map
NJJohn Theurer Cancer Center at Hackensack University Medical CenterHackensack07601-2191NCT07291076Map
NJJohn Theurer Cancer Center at Hackensack University Medical Center ( Site 0101)Hackensack07601NCT07227597Map
NJZai Lab Site 2001Hackensack07601NCT06179069Map
NJThe Cancer Institute of New Jersey HamiltonHamilton08690NCT01810913Map
NJSaint Barnabas Medical CenterLivingston07039NCT01810913Map
NJMonmouth Medical CenterLong Branch07740NCT01810913Map
NJMemorial Sloan Kettering Cancer CenterMiddletown07748NCT05968326Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT01810913Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT06287775Map
NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown07748NCT06807632Map
NJMemorial Sloan Kettering BergenMontvale07645NCT01810913Map
NJMemorial Sloan Kettering BergenMontvale07645NCT06287775Map
NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale07645NCT06807632Map
NJMemorial Sloan Kettering Cancer Center at BergenMontvale07645NCT05968326Map
NJMorristownMedicalCenterMorristown07962NCT06096779Map
NJCooper CyberKnife CenterMount Laurel08054NCT06632327Map
NJInspira Medical Center Mullica HillMullica Hill08062NCT06463665Map
NJJersey Shore Medical CenterNeptune City07753NCT06632327Map
NJGSK Investigational SiteNew Brunswick08903NCT06551142Map
NJResearch SiteNew Brunswick08901NCT06921785Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08901NCT05581004Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT04981509Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT01810913Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08901NCT06096779Map
NJRutgers Cancer Institute of New Jersey at University HospitalNewark07103NCT06096779Map
NJRutgers New Jersey Medical SchoolNewark07101NCT01810913Map
NJThe Valley Hospital - Luckow PavilionParamus07652NCT06632327Map
NJCapital Health Medical Center-HopewellPennington08534NCT04402788Map
NJValley Health System Ridgewood CampusRidgewood07450NCT06632327Map
NJRobert Wood Johnson University Hospital SomersetSomerville08876NCT01810913Map
NJCommunity Medical CenterToms River08755NCT01810913Map
NJMD Anderson Cancer Center at Cooper-VoorheesVoorhees Township08043NCT06632327Map
NMLovelace Medical Center - Saint Joseph SquareAlbuquerque87102NCT02693535Map
NMNew Mexico Oncology Hematology ConsultantsAlbuquerque87109NCT01810913Map
NMPresbyterian Kaseman HospitalAlbuquerque87110NCT02693535Map
NMThe University of New Mexico Comprehensive Cancer CenterAlbuquerque87131NCT02693535Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT01810913Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT06632327Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT07166406Map
NMUniversity of New Mexico Comprehensive Cancer CenterAlbuquerque87106NCT06646276Map
NMMemorial Medical CenterLas Cruces88011NCT02693535Map
NMMemorial Medical Center-Las CrucesLas Cruces88011NCT06632327Map
NMPresbyterian Rust Medical CenterRio Rancho87124NCT02693535Map
NMMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #009Santa Fe87505-699NCT05434234Map
NYRoswell Park Cancer InstituteBuffalo14263NCT04696575Map
NYRoswell Park Cancer InstituteBuffalo14263NCT05168163Map
NYRoswell Park Comprehensive Cancer CenterBuffalo14236NCT05733598Map
NYZai Lab Site 2002Buffalo14263NCT06179069Map
NYHematology Oncology Associates of CNY at CamillusCamillus13031NCT04402788Map
NYSands Cancer CenterCanandaigua14424NCT01810913Map
NYMemorial Sloan Kettering Cancer Center - CommackCommack11725NCT05968326Map
NYMemorial Sloan Kettering CommackCommack11725NCT01810913Map
NYMemorial Sloan Kettering CommackCommack11725NCT06287775Map
NYMemorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack11725NCT06807632Map
NYHematology Oncology Associates of Central New York-East SyracuseEast Syracuse13057NCT04402788Map
NYGlens Falls HospitalGlens Falls12801NCT06632327Map
NYMemorial Sloan Kettering Cancer Center at WestchesterHarrison10604NCT05968326Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT01810913Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT06287775Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT06807632Map
NYNorthwell HealthLake Success11042NCT05968326Map
NYNorthwell Health Monter Cancer CenterLake Success11042NCT02693535Map
NYNew York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu LangoneMineola11501NCT06362252Map
NYNYU Langone Hospital - Long IslandMineola11501NCT01810913Map
NYNYU Langone Hospital - Long IslandMineola11501-4064NCT06096779Map
NYNYU Langone Hospital - Long IslandMineola11501NCT06362252Map
NYNorthern Westchester HospitalMount Kisco10549NCT02693535Map
NYCohen Children's Medical CenterNew Hyde Park11040NCT02693535Map
NYNew York Cancer & Blood Specialists - New Hyde ParkNew Hyde Park11042-1116NCT04929223Map
NYMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #010New York10029NCT05434234Map
NYColumbia University Hervert Irving Comprehensive Cancer CenterNew York10032NCT06362252Map
NYColumbia University Medical CenterNew York10032NCT04302025Map
NYColumbia University Medical CenterNew York10032NCT05968326Map
NYCornell University - NewYork-Presbyterian/Weill Cornell Medical CenterNew York10065NCT06712355Map
NYIcahn School of Medicine at Mount SinaiNew York10029NCT06096779Map
NYIcahn School of Medicine at Mount SinaiNew York10029NCT07059494Map
NYIcahn School of Medicine at Mount Sinai (ISMMS)New York10029NCT06031441Map
NYLaura & Isaac Perlmutter Cancer Center at NYU Langone HealthNew York10016NCT07195695Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT01810913Map
NYLaura and ISAAC Perlmutter Cancer Center at NYU Langone.New York10016NCT04302025Map
NYManhattan Eye, Ear, and Throat HospitalNew York10065NCT02693535Map
NYMEETH-LHH Northwell Health Cancer Clinical Trials Office at MEETH-LHHNew York10065-7471NCT05968326Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT04302025Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05968326Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT01810913Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06287775Map
NYMemorial Sloan Kettering Cancer CenterNew York10021NCT06362252Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06807632Map
NYMemorial Sloan Kettering Cancer Center - New YorkNew York10065NCT05440708Map
NYMemorial Sloan-Kettering Cancer CenterNew York10065NCT07195695Map
NYMontefiore Medical CenterNew York10461NCT06362252Map
NYMount Sinai HospitalNew York10029NCT04402788Map
NYMount Sinai HospitalNew York10029NCT07166406Map
NYMount SInai Medical CenterNew York10029NCT05968326Map
NYMount Sinai Union SquareNew York10003NCT01810913Map
NYNew York Cancer and Blood Specialists-Central Park Hematology & OncologyNew York10028NCT04929223Map
NYNYU Langone Medical CenterNew York10016-9451NCT06096779Map
NYResearch SiteNew York10029NCT06921785Map
NYStaten Island University HospitalNew York10305NCT02693535Map
NYNew York Cancer & Blood SpecialistsPort Jefferson Station11776NCT04929223Map
NYQueens Cancer CenterRego Park11374NCT02693535Map
NYHighland HospitalRochester14620NCT01810913Map
NYUniversity of RochesterRochester14642NCT01810913Map
NYUniversity of RochesterRochester14642NCT06632327Map
NYWilmot Cancer Institute Radiation Oncology at GreeceRochester14606NCT01810913Map
NYPhelps HospitalSleepy Hollow10591NCT02693535Map
NYStony Brook University HospitalStony Brook11794NCT05423210Map
NYStony Brook University Medical CenterStony Brook11794NCT04402788Map
NYState University of New York Upstate Medical UniversitySyracuse13210NCT04402788Map
NYState University of New York Upstate Medical UniversitySyracuse13210NCT01810913Map
NYJames J Peters VA Medical CenterThe Bronx10468NCT06632327Map
NYJames J Peters Veterans Administration Medical Center - NAVREFThe Bronx10468-3904NCT06096779Map
NYMontefiore Medical CenterThe Bronx10467NCT06096779Map
NYMontefiore Medical Center - Moses CampusThe Bronx10467NCT01810913Map
NYMontefiore Medical Center - Moses CampusThe Bronx10467NCT07166406Map
NYMontefiore Medical Center-Einstein CampusThe Bronx10461NCT01810913Map
NYMontefiore Medical Center-Einstein CampusThe Bronx10461NCT07166406Map
NYMontefiore Medical CenterMontefiore Medical ParkThe Bronx10461NCT05733598Map
NYNew York Cancer & Blood Specialists - BronxThe Bronx10469-5930NCT04929223Map
NYMemorial Sloan Kettering Cancer Center at NassauUniondale11553NCT05968326Map
NYMemorial Sloan Kettering NassauUniondale11553NCT01810913Map
NYMemorial Sloan Kettering NassauUniondale11553NCT06287775Map
NYMemorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale11553NCT06807632Map
NYWestchester Medical CenterValhalla10595NCT04402788Map
NYWilmot Cancer Institute at WebsterWebster14580NCT06632327Map
NYWhite Plains HospitalWhite Plains10601NCT06712355Map
NCAtrium Health Stanly/LCI-AlbemarleAlbemarle28002NCT04402788Map
NCAtrium Health Stanly/LCI-AlbemarleAlbemarle28002NCT01810913Map
NCMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #011Chapel Hill27514NCT05434234Map
NCLineberger Comprehensive Cancer CenterChapel Hill27599NCT02693535Map
NCLineberger Comprehensive Cancer CenterChapel Hill27599NCT05542407Map
NCThe University of North Carolina at Chapel HillChapel Hill27599NCT06043674Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT01810913Map
NCUniversity of North Carolina at Chapel HillChapel Hill27599NCT05652686Map
NCAtrium Health Pineville/LCI-PinevilleCharlotte28210NCT04402788Map
NCAtrium Health Pineville/LCI-PinevilleCharlotte28210NCT01810913Map
NCAtrium Health Pineville/LCI-PinevilleCharlotte28210NCT05058651Map
NCAtrium Health University City/LCI-UniversityCharlotte28262NCT04402788Map
NCAtrium Health University City/LCI-UniversityCharlotte28262NCT01810913Map
NCAtrium Health University City/LCI-UniversityCharlotte28262NCT05058651Map
NCAtrium Health's Levine Cancer InstituteCharlotte28277NCT02693535Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT04402788Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT01810913Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT05058651Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT06287775Map
NCLevine Cancer InstituteCharlotte28204NCT04802759Map
NCLevine Cancer InstituteCharlotte28204NCT06096779Map
NCLevine Cancer Institute-BallantyneCharlotte28277NCT04402788Map
NCLevine Cancer Institute-BallantyneCharlotte28277NCT05058651Map
NCLevine Cancer Institute-SouthParkCharlotte28211NCT04402788Map
NCLevine Cancer Institute-SouthParkCharlotte28211NCT05058651Map
NCSoutheastern Medical Oncology Center-ClintonClinton28328NCT05058651Map
NCAtrium Health Cabarrus/LCI-ConcordConcord28025NCT04402788Map
NCAtrium Health Cabarrus/LCI-ConcordConcord28025NCT01810913Map
NCAtrium Health Cabarrus/LCI-ConcordConcord28025NCT05058651Map
NCAtrium Health Cabarrus/LCI-ConcordConcord28025NCT06287775Map
NCDuke Cancer InstituteDurham27710-4000NCT05968326Map
NCDuke Cancer InstituteDurham27710NCT06646276Map
NCDuke UniversityDurham27705NCT06069726Map
NCDuke University Medical Center - Duke Cancer CenterDurham27710NCT07235293Map
NCZai Lab Site 2018Durham27710NCT06179069Map
NCLevine Cancer Institute - RutherfordForest City28043NCT04402788Map
NCLevine Cancer Institute-GastonGastonia28054NCT04402788Map
NCLevine Cancer Institute-GastonGastonia28054NCT05058651Map
NCSoutheastern Medical Oncology Center-GoldsboroGoldsboro27534NCT05058651Map
NCMargaret R Pardee Memorial HospitalHendersonville28791NCT04402788Map
NCSoutheastern Medical Oncology Center-JacksonvilleJacksonville28546NCT05058651Map
NCECU Health Oncology KinstonKinston28501NCT01810913Map
NCAtrium Health Lincoln/LCI-LincolntonLincolnton28092NCT04402788Map
NCLevine Cancer Institute - Union WestMatthews28104NCT04402788Map
NCAtrium Health Union/LCI-UnionMonroe28112NCT04402788Map
NCAtrium Health Union/LCI-UnionMonroe28112NCT01810913Map
NCFirstHealth of the Carolinas-Moore Regional HospitalPinehurst28374NCT05058651Map
NCAtrium Health Cleveland/LCI-ClevelandShelby28150NCT04402788Map
NCAtrium Health Cleveland/LCI-ClevelandShelby28150NCT05058651Map
NCAtrium Health Wake Forest BaptistWinston-Salem27103NCT05317858Map
NCWake Forest University Health SciencesWinston-Salem27157NCT06287775Map
NDSanford Bismarck Medical CenterBismarck58501NCT05001880Map
NDSanford Bismarck Medical CenterBismarck58501NCT04402788Map
NDSanford Bismarck Medical CenterBismarck58501NCT01810913Map
NDSanford Bismarck Medical CenterBismarck58501NCT06632327Map
NDSanford Health- BismarckBismarck58501NCT02693535Map
NDSanford Medical CenterBismarck58501NCT06646276Map
NDSanford Broadway Medical CenterFargo58122NCT05001880Map
NDSanford Broadway Medical CenterFargo58122NCT04402788Map
NDSanford Broadway Medical CenterFargo58122NCT06632327Map
NDSanford Fargo Medical CenterFargo58102NCT06646276Map
NDSanford Health- FargoFargo58122NCT02693535Map
NDSanford Medical Center FargoFargo58104NCT06632327Map
NDSanford Roger Maris Cancer CenterFargo58122NCT05001880Map
NDSanford Roger Maris Cancer CenterFargo58122NCT04402788Map
NDSanford Roger Maris Cancer CenterFargo58122NCT01810913Map
NDSanford Roger Maris Cancer CenterFargo58122NCT06632327Map
NDSanford South University Medical CenterFargo58103NCT06632327Map
NDSouthpointe-Sanford Medical Center FargoFargo58103NCT06632327Map
OHCleveland Clinic - Akron General Hematology & OncologyAkron44302NCT06712355Map
OHUH Seidman Cancer Center at UH Avon Health CenterAvon44011NCT01810913Map
OHUHHS-Chagrin Highlands Medical CenterBeachwood44122NCT01810913Map
OHAultman Health FoundationCanton44710NCT04402788Map
OHCleveland Clinic Mercy Hospital Cancer CenterCanton44708NCT06712355Map
OHGabrail Cancer and Research CenterCanton44718NCT06463665Map
OHGabrail Cancer Center ResearchCanton44718NCT05703971Map
OHMiami Valley Hospital SouthCenterville45459NCT04402788Map
OHGeauga HospitalChardon44024NCT01810913Map
OHAdena Regional Medical CenterChillicothe45601NCT01810913Map
OHBethesda North HospitalCincinnati45242NCT06632327Map
OHCincinnati Children's HospitalCincinnati45229NCT04796012Map
OHGood Samaritan Hospital - CincinnatiCincinnati45220NCT06632327Map
OHOncology Hematology CareCincinnati45242NCT06646276Map
OHOncology_Hematology Care Clinical Trials, LLCCincinnati45211NCT05703971Map
OHOncology_Hematology Care Clinical Trials, LLCCincinnati45236NCT05703971Map
OHOncology_Hematology Care Clinical Trials, LLCCincinnati45242NCT05703971Map
OHOncology_Hematology Care Clinical Trials, LLCCincinnati45245NCT05703971Map
OHThe Christ Hospital Cancer CenterCincinnati45219NCT06712355Map
OHTriHealth Cancer Institute-AndersonCincinnati45255NCT06632327Map
OHTriHealth Cancer Institute-WestsideCincinnati45247NCT06632327Map
OHUniversity of Cincinnati Cancer Center-UC Medical CenterCincinnati45219NCT04402788Map
OHUniversity of Cincinnati Cancer InstituteCincinnati45219NCT05968326Map
OHUniversity of Cincinnati Medical CenterCincinnati45219NCT02693535Map
OHCase Western Reserve UniversityCleveland44106NCT01810913Map
OHCase Western Reserve UniversityCleveland44106NCT06287775Map
OHCleveland Clinic Cancer Center/Fairview HospitalCleveland44111NCT04402788Map
OHCleveland Clinic FoundationCleveland44195NCT04402788Map
OHCleveland Clinic FoundationCleveland44195NCT01810913Map
OHCleveland Clinic FoundationCleveland44195-0001NCT06712355Map
OHCleveland Clinic Lerner College of MedicineCleveland44195NCT05440708Map
OHMetroHealth Medical CenterCleveland44109NCT04402788Map
OHThe Cleveland Clinic Cancer Center at Fairview Hospital, Moll PavilionCleveland44111NCT06712355Map
OHUniversity Hospitals Cleveland Medical CenterCleveland44106NCT06712355Map
OHUniversity Hospitals Cleveland Medical Center /ID# 277556Cleveland44106NCT07155174Map
OHZai Lab Site 2024Cleveland44106NCT06179069Map
OHMount Carmel East HospitalColumbus43213NCT04402788Map
OHMount Carmel Health Center WestColumbus43222NCT04402788Map
OHOhio State UniversityColumbus43210NCT04302025Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05333458Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT04919382Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT04981509Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05001880Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT04402788Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT01810913Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05058651Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT06287775Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT06616623Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT07166406Map
OHThe Mark H Zangmeister CenterColumbus43219NCT04402788Map
OHThe Ohio State UniversityColumbus43221-3502NCT06031441Map
OHThe Ohio State University Comprehensive Cancer CenterColumbus43210NCT06043674Map
OHDayton VA Medical Center - NAVREF - PPDSDayton45428-9000NCT06096779Map
OHMiami Valley HospitalDayton45409NCT04402788Map
OHMiami Valley Hospital NorthDayton45415NCT04402788Map
OHPremier Blood and Cancer CenterDayton45409NCT04402788Map
OHOncology_Hematology Care Clinical Trials, LLCFairfield45014NCT05703971Map
OHAtrium Medical Center-Middletown Regional HospitalFranklin45005-1066NCT04402788Map
OHMiami Valley Cancer Care and InfusionGreenville45331NCT04402788Map
OHCleveland Clinic Cancer Center IndependenceIndependence44131NCT04402788Map
OHKettering HealthKettering45429NCT02693535Map
OHKettering Medical CenterKettering45429NCT06712355Map
OHCleveland Clinic Cancer Center MansfieldMansfield44906NCT04402788Map
OHCleveland Clinic - Hillcrest HospitalMayfield Heights44124NCT06712355Map
OHHillcrest Hospital Cancer CenterMayfield Heights44124NCT04402788Map
OHUH Seidman Cancer Center at Lake Health Mentor CampusMentor44060NCT01810913Map
OHUH Seidman Cancer Center at Southwest General HospitalMiddleburg Heights44130NCT01810913Map
OHUniversity Hospitals Parma Medical CenterParma44129NCT01810913Map
OHSouthern Ohio Medical CenterPortsmouth45662NCT01810913Map
OHUniversity Hospitals Portage Medical CenterRavenna44266NCT01810913Map
OHNorth Coast Cancer CareSandusky44870NCT04402788Map
OHUH Seidman Cancer Center at Firelands Regional Medical CenterSandusky44870NCT01810913Map
OHCleveland Clinic Cancer Center StrongsvilleStrongsville44136NCT04402788Map
OHCleveland Clinic Cancer Center StrongsvilleStrongsville44136NCT01810913Map
OHUpper Valley Medical CenterTroy45373NCT04402788Map
OHUniversity of Cincinnati Cancer Center-West ChesterWest Chester45069NCT04402788Map
OHWest Chester HospitalWest Chester45069NCT02693535Map
OHSaint Ann's HospitalWesterville43081NCT04402788Map
OHUHHS-Westlake Medical CenterWestlake44145NCT01810913Map
OHCleveland Clinic Wooster Family Health and Surgery CenterWooster44691NCT04402788Map
OHCleveland Clinic Wooster Family Health and Surgery CenterWooster44691NCT01810913Map
OHGenesis Healthcare System Cancer Care CenterZanesville43701NCT04402788Map
OKCancer Centers of Southwest Oklahoma ResearchLawton73505NCT04402788Map
OKCancer Centers of Southwest Oklahoma ResearchLawton73505NCT05058651Map
OKCancer Centers of Southwest Oklahoma ResearchLawton73505NCT06632327Map
OKMercy Hospital Oklahoma CityOklahoma City73120NCT04402788Map
OKMercy Hospital Oklahoma CityOklahoma City73120NCT05058651Map
OKMercy Hospital Oklahoma CityOklahoma City73120NCT06632327Map
OKSarah Cannon Research Institute University of OklahomaOklahoma City73104NCT05652686Map
OKThe University of Oklahoma Health Sciences CenterOklahoma City73104-5020NCT06096779Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05333458Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05440708Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05001880Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT04402788Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT01810913Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05058651Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT06632327Map
OKUniversity of Oklahoma Health Stephenson Cancer CenterOklahoma City73104NCT04486352Map
ORSaint Charles Health SystemBend97701NCT05058651Map
ORClackamas Radiation Oncology CenterClackamas97015NCT01810913Map
ORClackamas Radiation Oncology CenterClackamas97015NCT07166406Map
ORWillamette Valley Cancer Institute (Oregon)Eugene97401NCT05703971Map
ORLegacy Mount Hood Medical CenterGresham97030NCT04402788Map
ORLegacy Mount Hood Medical CenterGresham97030NCT06632327Map
ORKaiser Permanente Westside Medical CenterHillsboro97124-5806NCT06096779Map
ORProvidence Newberg Medical CenterNewberg97132NCT04402788Map
ORProvidence Newberg Medical CenterNewberg97132NCT05058651Map
ORProvidence Newberg Medical CenterNewberg97132NCT07166406Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT05058651Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT07166406Map
ORLegacy Good Samaritan Hospital and Medical CenterPortland97210NCT04402788Map
ORLegacy Good Samaritan Hospital and Medical CenterPortland97210NCT06632327Map
ORNorthwest Cancer Specialists, P.C.Portland97213-2982NCT05703971Map
ORNorthwest Cancer Specialists, P.C.Portland97227NCT05703971Map
OROHSU Knight Cancer Institute Hematology OncologyPortland97239-3011NCT06096779Map
OROregon Health & Science UniversityPortland97239NCT05317858Map
OROregon Health & Science UniversityPortland97239NCT04524871Map
ORProvidence Cancer InstitutePortland97213NCT05703971Map
ORProvidence Cancer InstitutePortland97213NCT07195695Map
ORProvidence Cancer Institute, Franz Clinic - Eastside ( Site 0107)Portland97213NCT07227597Map
ORProvidence Health & ServicesPortland97213NCT02693535Map
ORProvidence Portland Medical CenterPortland97213NCT04402788Map
ORProvidence Portland Medical CenterPortland97213NCT05652686Map
ORProvidence Portland Medical CenterPortland97213NCT01810913Map
ORProvidence Portland Medical CenterPortland97213NCT05058651Map
ORProvidence Portland Medical CenterPortland97213NCT07166406Map
ORProvidence Portland Medical CenterPortland97213NCT07291076Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT04402788Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT01810913Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05058651Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT07166406Map
ORProvidence St. Vincent Medical CenterPortland97225NCT07291076Map
ORSalem HospitalSalem97301NCT06632327Map
ORNorthwest Cancer Specialists, P.C.Tigard97223NCT05703971Map
ORLegacy Meridian Park HospitalTualatin97062NCT04402788Map
ORLegacy Meridian Park HospitalTualatin97062NCT06632327Map
PALehigh Valley Hospital - Cedar CrestAllentown18103NCT02693535Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT04402788Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT01810913Map
PASaint Luke's Cancer Center - AllentownAllentown18104NCT01810913Map
PAUPMC AltoonaAltoona16601NCT01810913Map
PAUPMC-Heritage Valley Health System BeaverBeaver15009NCT04402788Map
PAUPMC-Heritage Valley Health System BeaverBeaver15009NCT01810913Map
PALehigh Valley Hospital - MuhlenbergBethlehem18017NCT04402788Map
PALehigh Valley Hospital - MuhlenbergBethlehem18017NCT01810913Map
PALehigh Valley Hospital- MuhlenbergBethlehem18017NCT02693535Map
PABryn Mawr HospitalBryn Mawr19010NCT04402788Map
PACarlisle Regional Cancer CenterCarlisle17015NCT04402788Map
PACarlisle Regional Cancer CenterCarlisle17015NCT01810913Map
PAChristiana Care Health System-Concord Health CenterChadds Ford19317NCT04402788Map
PAChristiana Care Health System-Concord Health CenterChadds Ford19317NCT06632327Map
PAChambersburg HospitalChambersburg17201NCT04402788Map
PAWellSpan Medical Oncology and HematologyChambersburg17201NCT05058651Map
PAGeisinger Medical CenterDanville17822NCT04402788Map
PAGeisinger Medical CenterDanville17822NCT06632327Map
PAGeisinger Medical CenterDanville17822NCT07166406Map
PAGeisinger Cancer Center Dickson CityDickson City18519NCT04402788Map
PAGeisinger Cancer Center Dickson CityDickson City18519NCT06632327Map
PAPocono Medical CenterEast Stroudsburg18301NCT02693535Map
PAPocono Medical CenterEast Stroudsburg18301NCT01810913Map
PASaint Luke's Hospital-Anderson CampusEaston18045NCT01810913Map
PAEphrata Cancer CenterEphrata17522NCT04402788Map
PAEphrata Cancer CenterEphrata17522NCT05058651Map
PAUPMC Hillman Cancer Center ErieErie16505NCT04402788Map
PAUPMC Hillman Cancer Center ErieErie16505NCT01810913Map
PAUPMC Cancer Center at UPMC HorizonFarrell16121NCT04402788Map
PAUPMC Cancer Center at UPMC HorizonFarrell16121NCT01810913Map
PASt. Luke's Physician Group - St. Luke's Cancer Care AssociatesFountain Hill18015-1153NCT06712355Map
PAAdams Cancer CenterGettysburg17325NCT04402788Map
PAAdams Cancer CenterGettysburg17325NCT05058651Map
PAUPMC Cancer Centers - Arnold Palmer PavilionGreensburg15601NCT04402788Map
PAUPMC Cancer Centers - Arnold Palmer PavilionGreensburg15601NCT01810913Map
PAUPMC Hillman Cancer Center in Greenville/UPMC HorizonGreenville16125NCT04402788Map
PAMagee-Woman's HospitalHarrisburg17109NCT06031441Map
PAUPMC Pinnacle Cancer Center/Community Osteopathic CampusHarrisburg17109NCT04402788Map
PAUPMC Pinnacle Cancer Center/Community Osteopathic CampusHarrisburg17109NCT01810913Map
PAGeisinger Medical Center-Cancer Center HazletonHazleton18201NCT06632327Map
PALehigh Valley Hospital-HazletonHazleton18201NCT02693535Map
PAPenn State Milton S Hershey Medical CenterHershey17033-0850NCT04402788Map
PAIRMC Cancer CenterIndiana15701NCT04402788Map
PAIRMC Cancer CenterIndiana15701NCT01810913Map
PAUPMC-Johnstown/John P. Murtha Regional Cancer CenterJohnstown15901NCT01810913Map
PALancaster General Hospital - Ann B Barshinger Cancer InstituteLancaster17601NCT06362252Map
PASechler Family Cancer CenterLebanon17042NCT04402788Map
PASechler Family Cancer CenterLebanon17042NCT05058651Map
PAGeisinger Medical Oncology-LewisburgLewisburg17837NCT04402788Map
PAGeisinger Medical Oncology-LewisburgLewisburg17837NCT06632327Map
PAGeisinger Medical Oncology-LewisburgLewisburg17837NCT07166406Map
PAUPMC Cancer Center at UPMC McKeesportMcKeesport15132NCT01810913Map
PAUPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer PavilionMechanicsburg17050NCT04402788Map
PAUPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer PavilionMechanicsburg17050NCT01810913Map
PARiddle Memorial HospitalMedia19063NCT04402788Map
PAUPMC Cancer Center - MonroevilleMonroeville15146NCT04402788Map
PAUPMC Cancer Center - MonroevilleMonroeville15146NCT01810913Map
PAUPMC Hillman Cancer Center - MonroevilleMonroeville15146NCT04402788Map
PAUPMC Hillman Cancer Center in CoraopolisMoon Township15108NCT01810913Map
PAUPMC Hillman Cancer Center - New CastleNew Castle16105NCT04402788Map
PAPaoli Memorial HospitalPaoli19301NCT04402788Map
PAAbramson Cancer Center of the University of PennsylvaniaPhiladelphia19104-4283NCT05488522Map
PAAbramson Cancer Center of the University of PennsylvaniaPhiladelphia19104NCT04691817Map
PAChildren's Hospital of PhiladelphiaPhiladelphia19104NCT04796012Map
PAFox Chase Cancer CenterPhiladelphia19111NCT02693535Map
PAFox Chase Cancer CenterPhiladelphia19111NCT01810913Map
PAJefferson Health Honickman CenterPhiladelphia19107NCT06096779Map
PAJefferson Torresdale HospitalPhiladelphia19114NCT04402788Map
PATemple University HospitalPhiladelphia19140NCT01810913Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT04802759Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT04402788Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT01810913Map
PAThomas Jefferson University Hospital - CentralPhiladelphia19107NCT06362252Map
PAUniversity of Pennsylvania-Abramson Cancer CenterPhiladelphia19104NCT04434040Map
PAUniversity of Pennsylvania, Abramson Cancer CenterPhiladelphia19104NCT05733598Map
PAUniversity of Pennsylvania, Abramson Cancer CenterPhiladelphia19104NCT06362252Map
PAUniversity of Pennsylvania/Abramson Cancer CenterPhiladelphia19104NCT04402788Map
PAAllegheny General HospitalPittsburgh15212NCT01810913Map
PAAllegheny General HospitalPittsburgh15212NCT05168163Map
PAResearch SitePittsburgh15232NCT06921785Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05333458Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT04981509Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05001880Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT04402788Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT06287775Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT05538091Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT05733598Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT07235293Map
PAUPMC- Hillman Cancer CenterPittsburgh15232NCT06444815Map
PAUPMC-Magee Womens HospitalPittsburgh15213NCT01810913Map
PAUPMC-Passavant HospitalPittsburgh15237NCT04402788Map
PAUPMC-Passavant HospitalPittsburgh15237NCT01810913Map
PAUPMC-Saint Clair Hospital Cancer CenterPittsburgh15243NCT04402788Map
PAUPMC-Saint Clair Hospital Cancer CenterPittsburgh15243NCT01810913Map
PAUPMC-Saint MargaretPittsburgh15215NCT04402788Map
PAUPMC-Saint MargaretPittsburgh15215NCT01810913Map
PAUPMC-Shadyside HospitalPittsburgh15232NCT04402788Map
PAUPMC-Shadyside HospitalPittsburgh15232NCT01810913Map
PASaint Luke's Hospital - Upper Bucks CampusQuakertown18951NCT01810913Map
PAGuthrie Medical Group PC-Robert Packer HospitalSayre18840NCT04402788Map
PAUPMC Cancer Center at UPMC NorthwestSeneca16346NCT01810913Map
PASaint Luke's Hospital - Monroe CampusStroudsburg18360NCT01810913Map
PAUPMC Uniontown Hospital Radiation OncologyUniontown15401NCT01810913Map
PAUPMC Cancer Center-WashingtonWashington15301NCT04402788Map
PAUPMC Washington Hospital Radiation OncologyWashington15301NCT04402788Map
PAUPMC Washington Hospital Radiation OncologyWashington15301NCT01810913Map
PAWexford Health and Wellness PavilionWexford15090NCT01810913Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT04402788Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT06632327Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT07166406Map
PADivine Providence HospitalWilliamsport17754NCT04402788Map
PALankenau Medical CenterWynnewood19096NCT04402788Map
PACancer Care Associates of YorkYork17403NCT05058651Map
PAUPMC MemorialYork17408NCT04402788Map
PAWellSpan Health-York Cancer CenterYork17403NCT04402788Map
PAWellSpan Health-York Cancer CenterYork17403NCT05058651Map
PAWellSpan Health-York HospitalYork17403NCT04402788Map
RIMiriam HospitalProvidence02906NCT05968326Map
RIRhode Island HospitalProvidence02903NCT05317858Map
RIRhode Island HospitalProvidence02903NCT05968326Map
RISmilow Cancer Hospital Care Center - WesterlyWesterly02891NCT04402788Map
RISmilow Cancer Hospital Care Center - WesterlyWesterly02891NCT05058651Map
SCSC Cancer Specialists at St. Joseph's/Candler BlufftonBluffton29910NCT02693535Map
SCSt. Joseph's/Candler SmithBluffton29910NCT02693535Map
SCSummit Cancer Care at St. Josph's/Candler BlufftonBluffton29910NCT02693535Map
SCMedical University of South CarolinaCharleston29425NCT04402788Map
SCMedical University of South CarolinaCharleston29425NCT01810913Map
SCMedical University of South CarolinaCharleston29425NCT06632327Map
SCZai Lab Site 2012Charleston29425NCT06179069Map
SCMcLeod Regional Medical CenterFlorence29506NCT06632327Map
SCGibbs Cancer Center-GaffneyGaffney29341NCT06632327Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT01810913Map
SCPrisma Health Cancer Institute - FarisGreenville29605NCT01810913Map
SCSaint Francis Cancer CenterGreenville29607NCT04402788Map
SCSaint Francis Cancer CenterGreenville29607NCT06632327Map
SCSaint Francis HospitalGreenville29601NCT04402788Map
SCSaint Francis HospitalGreenville29601NCT06632327Map
SCSelf Regional HealthcareGreenwood29646NCT04402788Map
SCSelf Regional HealthcareGreenwood29646NCT06632327Map
SCGibbs Cancer Center-PelhamGreer29651NCT04402788Map
SCGibbs Cancer Center-PelhamGreer29651NCT01810913Map
SCGibbs Cancer Center-PelhamGreer29651NCT06632327Map
SCPrisma Health Cancer Institute - GreerGreer29650NCT01810913Map
SCSouth Carolina Cancer SpecialistsHilton Head Island29926NCT02693535Map
SCGSK Investigational SiteMyrtle Beach29572NCT06551142Map
SCLevine Cancer Institute-Rock HillRock Hill29732NCT04402788Map
SCLevine Cancer Institute-Rock HillRock Hill29732NCT05058651Map
SCRock Hill Radiation Therapy CenterRock Hill29730NCT04402788Map
SCRock Hill Radiation Therapy CenterRock Hill29730NCT01810913Map
SCPrisma Health Cancer Institute - SenecaSeneca29672NCT01810913Map
SCNorth Grove Medical ParkSpartanburg29303NCT06632327Map
SCSpartanburg Medical CenterSpartanburg29303NCT04402788Map
SCSpartanburg Medical CenterSpartanburg29303NCT01810913Map
SCSpartanburg Medical CenterSpartanburg29303NCT06632327Map
SCSpartanburg Medical Center - Mary Black CampusSpartanburg29307NCT06632327Map
SCSMC Center for Hematology Oncology UnionUnion29379NCT06632327Map
SDAvera Cancer Institute at PierrePierre57501NCT04402788Map
SDRapid City Regional HospitalRapid City57701NCT05058651Map
SDRapid City Regional HospitalRapid City57701NCT05168163Map
SDAvera Cancer InstituteSioux Falls57105NCT04402788Map
SDAvera Cancer Institute- Research ( Site 0104)Sioux Falls57105NCT07227597Map
SDSanford Cancer CenterSioux Falls57104NCT06646276Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT05001880Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT04402788Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT06632327Map
SDSanford Cancer Center Oncology Clinic and PharmacySioux Falls57104NCT02693535Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT05001880Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT04402788Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT01810913Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT06632327Map
SDAvera Cancer Institute at YanktonYankton57078NCT04402788Map
TNTennessee Oncology - Chattanooga Oncology & Hematology AssociatesChattanooga37404NCT03424005Map
TNBaptist Memorial Hospital and Cancer Center-ColliervilleCollierville38017NCT06632327Map
TNThe West ClinicGermantown38138NCT05733598Map
TNThe West ClinicGermantown38138NCT03424005Map
TNThe West Clinic - Memphis (Union Ave)Germantown38138NCT05581004Map
TNWest Cancer CenterGermantown38138NCT04802759Map
TNThe University of Tennessee Medical Center ( Site 0120)Knoxville37920NCT07227597Map
TNUniversity of Tennessee Medical CenterKnoxville37920NCT05733598Map
TNUniversity of Tennessee Medical CenterKnoxville37920NCT06712355Map
TNBaptist Clinical Research InstituteMemphis38120NCT04302025Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT04402788Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT06632327Map
TNSt. Jude Children's Research HospitalMemphis38105NCT05468359Map
TNMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #012Nashville37203NCT05434234Map
TNGSK Investigational SiteNashville37203NCT06551142Map
TNNashville General Hospital at MeharryNashville37208-2918NCT06096779Map
TNScri Oncology PartnersNashville37203NCT06362252Map
TNSCRI Oncology PartnersNashville37203NCT05581004Map
TNSCRI Oncology PartnersNashville37203NCT04929223Map
TNSCRI Oncology PartnersNashville37203NCT06031441Map
TNSCRI Oncology PartnersNashville37203NCT06646276Map
TNSCRI Oncology Partners ( Site 7000)Nashville37203NCT07227597Map
TNTennessee OncologyNashville37203NCT07291076Map
TNTennessee Oncology - Nashville / Sarah Cannon Research InstituteNashville37203NCT02693535Map
TNTennessee Oncology PLLCNashville37203NCT03424005Map
TNVanderbilt University Medical CenterNashville37212NCT03424005Map
TNVanderbilt University Medical CenterNashville37232NCT07291076Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT05501665Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT05058651Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT06110572Map
TNVanderbilt-Ingram Cancer CenterNashville37232NCT04434040Map
TXHendrick HealthAbilene79601NCT07195695Map
TXTexas Oncology - Abilene - Antilley Road /ID# 265820Abilene79606NCT06109272Map
TXResearch SiteAmarillo79124NCT06921785Map
TXGSK Investigational SiteAustin78705NCT06551142Map
TXResearch SiteAustin78705NCT06921785Map
TXTexas Oncology - Austin CentralAustin78745NCT06463665Map
TXTexas Oncology - Central/South TexasAustin78705NCT06646276Map
TXWorld Research LinkBaytown77521NCT06463665Map
TXTexas Oncology - Gulf CoastBeaumont77702NCT07226999Map
TXMD Anderson in The WoodlandsConroe77384NCT05001880Map
TXMD Anderson in The WoodlandsConroe77384NCT04402788Map
TXMD Anderson in The WoodlandsConroe77384NCT01810913Map
TXBaylor Scott and White Research Institute /ID# 260853Dallas76508-0001NCT06109272Map
TXGSK Investigational SiteDallas75230NCT06551142Map
TXHarold C. Simmons Comprehensive Cancer CenterDallas75390NCT05440708Map
TXLiver Institute at Methodist DallasDallas75203-1260NCT06096779Map
TXMary Crowley Cancer ResearchDallas75230NCT06444815Map
TXMoody Outpatient Center ? Parkland HealthDallas75235NCT06096779Map
TXParkland Health & Hospital SystemDallas75235NCT04524871Map
TXParkland Memorial HospitalDallas75235NCT05058651Map
TXTexas Oncology - Dallas - Worth Street /ID# 265806Dallas75246NCT06109272Map
TXTexas Oncology - DFWDallas75246NCT05703971Map
TXTexas Oncology (Worth) - USORDallas75246-2008NCT06096779Map
TXThe University of Texas Southwestern Medical CenterDallas75235NCT04796012Map
TXThe University of Texas Southwestern Medical Center at DallasDallas75390NCT04524871Map
TXUniversity of Texas Southwestern Medical CenterDallas75390-0001NCT06096779Map
TXUT Southwestern Simmons Cancer Center - RedBirdDallas75237NCT05058651Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT05058651Map
TXTexas Oncology - Denison Cancer CenterDenison75020-0084NCT06096779Map
TXTexas Oncology - Northeast TexasDenton76201NCT04929223Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT05058651Map
TXTexas Oncology - San AntonioFredericksburg78624NCT07226999Map
TXMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #014Houston77030NCT05434234Map
TXBaylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston77030NCT05058651Map
TXBen Taub General HospitalHouston77030NCT05058651Map
TXHouston Methodist HospitalHouston77030NCT06096779Map
TXHouston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113)Houston77030NCT07227597Map
TXHouston Methodist Hospital Cancer CenterHouston77030NCT05733598Map
TXHouston Methodist Research InstituteHouston77030NCT05185505Map
TXKelsey Research FoundationHouston77025-1669NCT06096779Map
TXM D Anderson Cancer CenterHouston77030NCT05333458Map
TXM D Anderson Cancer CenterHouston77030NCT05394337Map
TXM D Anderson Cancer CenterHouston77030NCT04981509Map
TXM D Anderson Cancer CenterHouston77030NCT05001880Map
TXM D Anderson Cancer CenterHouston77030NCT04402788Map
TXM D Anderson Cancer CenterHouston77030NCT01810913Map
TXM D Anderson Cancer CenterHouston77030NCT05019703Map
TXM D Anderson Cancer CenterHouston77030NCT05039281Map
TXM D Anderson Cancer CenterHouston77030NCT05092373Map
TXMD Anderson Cancer CenterHouston77030NCT05907980Map
TXMD Anderson Cancer CenterHouston77030NCT06439485Map
TXMD Anderson West HoustonHouston77079NCT05001880Map
TXMD Anderson West HoustonHouston77079NCT04402788Map
TXMD Anderson West HoustonHouston77079NCT01810913Map
TXMichael E Debakey VA Medical Center - NAVREF - PPDSHouston77030-4211NCT06096779Map
TXResearch SiteHouston77030NCT06921785Map
TXSite 1005Houston77030NCT07407933Map
TXTexas Children's HospitalHouston77030NCT04796012Map
TXTexas Oncology - Gulf CoastHouston77024NCT07226999Map
TXTexas Oncology - Gulf CoastHouston77054NCT07226999Map
TXThe University of Texas M. D. Anderson Cancer CenterHouston77030NCT07049848Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT02693535Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT06712355Map
TXThe University of Texas MD Anderson Cancer Center /ID# 277929Houston77030NCT07155174Map
TXU.T. MD Anderson Cancer CenterHouston77030NCT04812366Map
TXUniversity of Texas MD Anderson Cancer CenterHouston77030-4000NCT05440708Map
TXUniversity of Texas MD Anderson Cancer CenterHouston77030-4008NCT04302025Map
TXUniversity of Texas MD Anderson Cancer CenterHouston77030NCT06444815Map
TXMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #015Irving75039NCT05434234Map
TXMD Anderson League CityLeague City77573NCT05001880Map
TXMD Anderson League CityLeague City77573NCT04402788Map
TXMD Anderson League CityLeague City77573NCT01810913Map
TXDHR Health Institute for Research and DevelopmentMcAllen78504NCT05440708Map
TXTexas Oncology - San AntonioNew Braunfels78130NCT07226999Map
TXTexas Oncology - Gulf CoastPearland77584NCT07226999Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT05058651Map
TXMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #013San Antonio78229NCT05434234Map
TXGSK Investigational SiteSan Antonio78229NCT06551142Map
TXMays Cancer Center / University of Texas, San AntonioSan Antonio78229NCT05652686Map
TXResearch SiteSan Antonio78240NCT06921785Map
TXSouth Texas Accelerated Research Therapeutics (START)San Antonio98229NCT05581004Map
TXTexas Oncology - San AntonioSan Antonio78217NCT07226999Map
TXTexas Oncology - San AntonioSan Antonio78240NCT07226999Map
TXTexas Oncology - San AntonioSan Antonio78258NCT07226999Map
TXUniversity of Texas Health Science Center - San AntonioSan Antonio78229NCT05440708Map
TXMD Anderson in Sugar LandSugar Land77478NCT05001880Map
TXMD Anderson in Sugar LandSugar Land77478NCT04402788Map
TXMD Anderson in Sugar LandSugar Land77478NCT01810913Map
TXTexas Oncology - Gulf CoastSugar Land77479NCT07226999Map
TXTexas Oncology Cancer CenterSugar Land77479NCT06712355Map
TXThe University of Texas MD Anderson Cancer CenterTexas City77030NCT07235293Map
TXTexas Oncology - Gulf CoastThe Woodlands77380NCT07226999Map
TXMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #016Tyler75701NCT05434234Map
TXGSK Investigational SiteTyler75702NCT06551142Map
TXResearch SiteTyler75702NCT06921785Map
TXTexas Oncology - Northeast TexasTyler75702NCT05703971Map
TXTexas Oncology - Northeast TexasTyler75702NCT06646276Map
TXTexas Oncology - Gulf CoastWebster77598-4420NCT04929223Map
TXTexas Oncology - Gulf CoastWebster77598NCT07226999Map
UTCedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer CenterCedar City84720NCT02693535Map
UTIntermountain HealthcareMurray84107-5741NCT06096779Map
UTCommunity Cancer Trials of UtahOgden84405NCT07195695Map
UTHuntsman Cancer InstituteSalt Lake City84112NCT06069726Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT04402788Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT01810913Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05058651Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05168618Map
UTIntermountain HealthcareSalt Lake City84107NCT02693535Map
UTDixie Regional Medical Center-River Road CampusSt. George84770NCT02693535Map
UTIntermountain Cancer CenterSt. George84790NCT06096779Map
UTGSK Investigational SiteWest Valley City84119NCT06551142Map
VTCentral Vermont Medical Center/National Life Cancer TreatmentBerlin Corners05602NCT04402788Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT04402788Map
VTUniversity of Vermont Medical CenterBurlington05401NCT04402788Map
VTDartmouth Cancer Center - NorthSaint Johnsbury05819NCT04402788Map
VTDartmouth Cancer Center - NorthSaint Johnsbury05819NCT01810913Map
VTDartmouth Cancer Center - NorthSaint Johnsbury05819NCT05058651Map
VTDartmouth Cancer Center - NorthSaint Johnsbury05819NCT06632327Map
VAInova Alexandria HospitalAlexandria22304NCT07166406Map
VAResearch SiteArlington22201NCT06921785Map
VAOncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer CareBlacksburg24060NCT07226999Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT06287775Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT06632327Map
VAMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #017Fairfax22031NCT05434234Map
VAInova Fair Oaks HospitalFairfax22033NCT07166406Map
VAInova Schar Cancer InstituteFairfax22042NCT02693535Map
VAInova Schar Cancer InstituteFairfax22031NCT04402788Map
VAInova Schar Cancer InstituteFairfax22031NCT07166406Map
VAInova Schar Cancer Institute - Fair OaksFairfax22033NCT06789757Map
VANEXT OncologyFairfax22031NCT05907980Map
VANEXT OncologyFairfax22031NCT06332755Map
VANext VirginiaFairfax22031NCT06362252Map
VANEXT VirginiaFairfax22031NCT05652686Map
VASite 1002Fairfax22031NCT07407933Map
VAVirginia Cancer SpecialistsFairfax22031NCT06712355Map
VAVirginia Cancer Specialists - Fairfax /ID# 278298Fairfax22031NCT07155174Map
VAVirginia Cancer Specialists (Fairfax) - USORFairfax22031NCT04302025Map
VAVirginia Cancer Specialists, PCFairfax22031NCT05703971Map
VAZai Lab Site 2006Fairfax22031NCT06179069Map
VAInova Fairfax HospitalFalls Church22042NCT07166406Map
VAInova Health Care ServiceFalls Church22042NCT06789757Map
VAHematology Oncology Associates of Fredericksburg, Inc.Fredericksburg22408NCT06712355Map
VAInova Loudoun HospitalLeesburg20176NCT07166406Map
VAOncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer CareLow Moor24457NCT07226999Map
VAGSK Investigational SiteNorfolk23502NCT06551142Map
VABon Secours St. Mary's HospitalRichmond23226-1925NCT06096779Map
VAJohnston Willis HospitalRichmond23235NCT05317858Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT06287775Map
VAVCU Medical Center North HospitalRichmond23298-5028NCT06096779Map
VAVirginia Commonwealth University School of MedicineRichmond23298NCT06712355Map
VAOncology & Hematology Associates of Southwest Virginia, Inc.Roanoke24014NCT06646276Map
VAOncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer CareRoanoke24014NCT07226999Map
VAOncology and Hematology Associates of Southwest Virginia /ID# 265834Roanoke98684NCT06109272Map
VAOncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer CareSalem24153NCT07226999Map
VAResearch SiteSalem24153NCT06921785Map
VAShenandoah OncologyWinchester22601NCT06712355Map
VAOncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer CareWytheville24382NCT07226999Map
WANorthwest Medical SpecialtiesBonney Lake98391NCT02693535Map
WASwedish Cancer Institute - EdmondsEdmonds98026NCT06646276Map
WANorthwest Medical SpecialtiesFederal Way98003NCT02693535Map
WANorthwest Medical SpecialtiesGig Harbor98332NCT02693535Map
WAPeaceHealth Saint John Medical CenterLongview98632NCT01810913Map
WASkagit Regional Health Cancer Care CenterMount Vernon98274NCT01810913Map
WANorthwest Medical SpecialtiesOlympia98502NCT02693535Map
WANorthwest Medical SpecialtiesPuyallup98373NCT02693535Map
WAFred Hutchinson Cancer CenterSeattle98109NCT04812366Map
WAFred Hutchinson Cancer CenterSeattle98109NCT05058651Map
WAFred Hutchinson Cancer Research CenterSeattle98109NCT05968326Map
WASeattle Children'sSeattle98105NCT04796012Map
WASwedish Cancer InstituteSeattle98104NCT02693535Map
WASwedish Medical CenterSeattle98104NCT06646276Map
WAUniversity of Washington Medical Center - MontlakeSeattle98195NCT01810913Map
WAUniversity of Washington Medical Center - MontlakeSeattle98195NCT05058651Map
WAVirginia Mason Medical CenterSeattle98101NCT05440708Map
WAVirginia Mason Medical CenterSeattle98101NCT06096779Map
WASaint Joseph Medical Center Hematology and Oncology - SilverdaleSilverdale98383NCT06632327Map
WAMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #018Spokane99208NCT05434234Map
WASummit Cancer Centers - North SpokaneSpokane99208NCT05440708Map
WAMediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #019Tacoma98405NCT05434234Map
WANorthwest Medical SpecialtiesTacoma98405NCT02693535Map
WALegacy Cancer Institute Medical Oncology and Day TreatmentVancouver98684NCT04402788Map
WALegacy Cancer Institute Medical Oncology and Day TreatmentVancouver98684NCT06632327Map
WALegacy Salmon Creek HospitalVancouver98686NCT04402788Map
WALegacy Salmon Creek HospitalVancouver98686NCT06632327Map
WANorthwest Cancer Specialists, P.C.-VancouverVancouver98684NCT06362252Map
WAWenatchee Valley Hospital and ClinicsWenatchee98801NCT01810913Map
WVUnited Hospital CenterBridgeport26330NCT05058651Map
WVWest Virginia University Charleston DivisionCharleston25304NCT04402788Map
WVWest Virginia University HealthcareMorgantown26506NCT04402788Map
WVWest Virginia University HealthcareMorgantown26506NCT01810913Map
WVWest Virginia University HealthcareMorgantown26506NCT05058651Map
WVCamden Clark Medical CenterParkersburg26101NCT01810913Map
WVWheeling Hospital/Schiffler Cancer CenterWheeling26003NCT04402788Map
WVWheeling Hospital/Schiffler Cancer CenterWheeling26003NCT01810913Map
WILanglade Hospital and Cancer CenterAntigo54409NCT04402788Map
WILanglade Hospital and Cancer CenterAntigo54409NCT01810913Map
WIThedaCare Regional Cancer CenterAppleton54911NCT05001880Map
WIThedaCare Regional Cancer CenterAppleton54911NCT06632327Map
WIDuluth Clinic AshlandAshland54806NCT07166406Map
WINorthwest Wisconsin Cancer CenterAshland54806NCT07166406Map
WIThedaCare Cancer Care - BerlinBerlin54923NCT06632327Map
WIAurora Cancer Care - BurlingtonBurlington53105NCT02693535Map
WIMarshfield Clinic-Chippewa CenterChippewa Falls54729NCT06632327Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT05001880Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT04402788Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT05058651Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT06632327Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT07166406Map
WIAurora Health Care - Germantown Health CenterGermantown53022NCT02693535Map
WIAurora Cancer Care - GraftonGrafton53024NCT02693535Map
WIAurora BayCare Medical CenterGreen Bay54311NCT02693535Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT06632327Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT04402788Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT06632327Map
WIEssentia Health-Hayward ClinicHayward54843NCT07166406Map
WIUniversity of Wisconsin Carbone Cancer Center - Johnson CreekJohnson Creek53038NCT01810913Map
WIAurora Cancer Care - Kenosha SouthKenosha53142NCT02693535Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT05058651Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT06632327Map
WIMarshfield Medical Center - LadysmithLadysmith54848NCT06632327Map
WIUniversity of WisconsinMadison53705NCT04919382Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT01810913Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT01810913Map
WIAurora Bay Area Medical CenterMarinette54143NCT02693535Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT05001880Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT04402788Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT05058651Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT06632327Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT07166406Map
WIFroedtert Menomonee Falls HospitalMenomonee Falls53051NCT04402788Map
WIFroedtert Menomonee Falls HospitalMenomonee Falls53051NCT01810913Map
WIFroedtert Menomonee Falls HospitalMenomonee Falls53051NCT06632327Map
WIAurora Cancer Care MilwaukeeMilwaukee53209NCT02693535Map
WIAurora Sinai Medical CenterMilwaukee53223NCT02693535Map
WIAurora St. Luke's Medical CenterMilwaukee53215NCT02693535Map
WIAurora West Allis Medical CenterMilwaukee53227NCT02693535Map
WIFroedtert and the Medical College of Wisconsin LAPSMilwaukee53226NCT05168163Map
WIMedical College of WisconsinMilwaukee53226NCT04402788Map
WIMedical College of WisconsinMilwaukee53226NCT01810913Map
WIMedical College of WisconsinMilwaukee53226NCT05058651Map
WIMedical College of WisconsinMilwaukee53226NCT05168163Map
WIMedical College of WisconsinMilwaukee53226NCT06362252Map
WIMedical College of WisconsinMilwaukee53226NCT06632327Map
WIResearch SiteMilwaukee53226NCT06921785Map
WIZablocki Veterans Administration Medical CenterMilwaukee53295NCT06632327Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT05001880Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT04402788Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT05058651Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT06632327Map
WIProHealth D N Greenwald CenterMukwonago53149NCT06632327Map
WIProHealth D N Greenwald CenterMukwonago53149NCT07166406Map
WIThedaCare Regional Medical Center - NeenahNeenah54956NCT06632327Map
WIMarshfield Medical Center - NeillsvilleNeillsville54456NCT06632327Map
WIThedaCare Cancer Care - New LondonNew London54961NCT06632327Map
WICancer Center of Western WisconsinNew Richmond54017NCT01810913Map
WICancer Center of Western WisconsinNew Richmond54017NCT06632327Map
WIDrexel Town Square Health CenterOak Creek53154NCT04402788Map
WIDrexel Town Square Health CenterOak Creek53154NCT01810913Map
WIDrexel Town Square Health CenterOak Creek53154NCT06632327Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT06632327Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT07166406Map
WISaint Vincent Hospital Cancer Center at Oconto FallsOconto Falls54154NCT06632327Map
WIThedaCare Cancer Care - OshkoshOshkosh54904NCT06632327Map
WIVince Lombardi Cancer Clinic - OshkoshOshkosh54904NCT02693535Map
WIAurora Cancer Care - RacineRacine53406NCT02693535Map
WIAspirus Cancer Care - James Beck Cancer CenterRhinelander54501NCT04402788Map
WIAspirus Cancer Care - James Beck Cancer CenterRhinelander54501NCT01810913Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT05001880Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT04402788Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT05058651Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT06632327Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT07166406Map
WIThedaCare Cancer Care - ShawanoShawano54166NCT06632327Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT04402788Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT06632327Map
WISheboygan Physicians GroupSheboygan53081NCT06632327Map
WIVince Lombardi Cancer CenterSheboygan53081NCT02693535Map
WIEssentia Health-Spooner ClinicSpooner54801NCT07166406Map
WIAspirus Cancer Care - Stevens PointStevens Point54481NCT04402788Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05001880Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT04402788Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05058651Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT06632327Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT07166406Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT04402788Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT06632327Map
WIAurora Medical Center in SummitSummit53066NCT02693535
WIEssentia Health Saint Mary's Hospital - SuperiorSuperior54880NCT07166406Map
WIVince Lombardi Cancer Clinic - Two RiversTwo Rivers54241NCT02693535Map
WIProHealth Waukesha Memorial HospitalWaukesha53188NCT06632327Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT06632327Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT07166406Map
WIThedaCare Cancer Care - WaupacaWaupaca54981NCT06632327Map
WIAspirus Regional Cancer CenterWausau54401NCT04402788Map
WIAspirus Regional Cancer CenterWausau54401NCT01810913Map
WIMarshfield Clinic-Wausau CenterWausau54401NCT06632327Map
WIAurora Cancer Care - Milwaukee WestWauwatosa53226NCT02693535Map
WIFroedtert West Bend Hospital/Kraemer Cancer CenterWest Bend53095NCT04402788Map
WIFroedtert West Bend Hospital/Kraemer Cancer CenterWest Bend53095NCT01810913Map
WIFroedtert West Bend Hospital/Kraemer Cancer CenterWest Bend53095NCT06632327Map
WIMarshfield Medical Center - WestonWeston54476NCT05001880Map
WIMarshfield Medical Center - WestonWeston54476NCT04402788Map
WIMarshfield Medical Center - WestonWeston54476NCT05058651Map
WIMarshfield Medical Center - WestonWeston54476NCT06632327Map
WIMarshfield Medical Center - WestonWeston54476NCT07166406Map
WIAspirus Cancer Care - Wisconsin RapidsWisconsin Rapids54494NCT04402788Map
WIAspirus Cancer Care - Wisconsin RapidsWisconsin Rapids54494NCT01810913Map
WIMarshfield Clinic - Wisconsin Rapids CenterWisconsin Rapids54494NCT06632327Map
WYMemorial Hospital of Laramie CountyCheyenne82001NCT06632327Map
WYBillings Clinic-CodyCody82414NCT06632327Map

Atezolizumab clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingcompletedterminatedwithdrawnsuspendednot yet recruitingunknownapproved for marketingno longer availableTotal
Early P131123111
P122285523523138
P1/P230133225512108
P271788543201718323
P2/P3942116
P315304312141106
P431217
N/A94122441137

Recruiting Atezolizumab clinical trials (180)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT04817956IMPRESS-NImproving Public Cancer Care by Implementing Precision Medicine in NorwayP2Cancer Metastatic3,000Apr 2021
NCT05620771Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-riskP2Hepatocellular Carcinoma200Nov 2022
NCT05468359Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsP1/P2Refractory Solid Tumor64Nov 2022
NCT07195695Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsP3Non-small Cell Lung Cancer400Jan 2026
NCT07153445ATHENEANeoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)P2Non Small Cell Lung Cancer97Jul 2025
NCT07293468BIIRTHComparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)P2/P3Hepatocellular Carcinoma (HCC)106Apr 2024
NCT06725121MacroTransUsing Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before TransplantP1/P2Hepatocellular Carcinoma (HCC)48Dec 2024
NCT07226999Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerP2/P3Small Cell Lung Cancer (SCLC)550Dec 2025
NCT05538091Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal CancerP2Platinum-Resistant Fallopian Tube Carcinoma48May 2023
NCT05862285UmbrellaMAXA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyP3Cancer100Jun 2023
NCT06043674Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationP2Chronic Lymphocytic Leukemia70Jan 2024
NCT05096715Atezolizumab+Bevacizumab+SBRT in Unresectable HCCP1Unresectable Hepatocellular Carcinoma20Aug 2022
NCT07322341SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung CancerP2Advanced Lung Non-Small Cell Carcinoma32Sep 2026
NCT07291076HCCA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)P1/P2Hepatocellular Carcinoma (HCC)198Mar 2026
NCT07155174SEZanneA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerP2Small Cell Lung Cancer180Nov 2025
NCT06646276TIGOSA Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).P3Extensive-Stage Small Cell Lung Cancer530Feb 2025
NCT06339424PhotonABAtezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular CarcinomaP2Hepatocellular Carcinoma45Mar 2024
NCT04727307AB-LATE02Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II TrialP2Hepatocellular Carcinoma202Feb 2021
NCT03548428StereosarcStereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)P2Sarcoma103Jun 2020
NCT05968326IMCODE003A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACP2Adenocarcinoma, Pancreatic Ductal260Oct 2023
NCT07170592A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor PatientsP1Treatment-Refractory Solid Tumors24Jan 2027
NCT07190833A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)P1Treatment-Refractory Solid Tumors27Mar 2026
NCT07263438PhenixEfficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 TrialP2Glioblastoma59Nov 2025
NCT06618664A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular CarcinomaP3Advanced Hepatocellular Carcinoma590Oct 2024
NCT05332561COGNITION-GUIDEGenomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)P2Early-stage Breast Cancer240Jun 2023
NCT07227597MK-6070A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)P1/P2Small Cell Lung Cancer Extensive Stage170Jan 2026
NCT07317414β-alanine in the Treatment of Advanced Hepatocellular CarcinomaP2Hepatocellular Carcinoma158Dec 2025
NCT07018947ASPIREStudy to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCCP2Resectable Hepatocellular Carcinoma90Nov 2025
NCT07239245ATTACHStudy to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular CarcinamoP2Resectable Hepatocellular Carcinoma With High Risk of Recurrence30Nov 2025
NCT06109272LIVIGNO-2A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)P2/P3Hepatocellular Carcinoma660Jan 2024
NCT06133062ProtonABAtezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular CarcinomaP2Hepatocellular Carcinoma Non-resectable45Nov 2023
NCT03424005Morpheus-panBCA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerP1/P2Metastatic Breast Cancer792Mar 2018
NCT04929223INTRINSICA Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)P1Metastatic Colorectal Cancer542Oct 2021
NCT06680258A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyP3Hepatocellular Carcinoma (HCC)740Dec 2025
NCT04302025NAUTIKA1A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)P2Non-small Cell Lung Cancer99Nov 2020
NCT06632327Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerP3Resectable Lung Non-Small Cell Carcinoma1,100Dec 2024
NCT04341181ProTargetProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingP2Cancer300Aug 2020
NCT05300282FIL_A-BEGEVStudy of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma PatientsP1/P2Relapsed or Refractory Hodgkin's Lymphoma122Feb 2023
NCT06342037TONIC-3NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialP2Metastatic Breast Cancer60Jun 2024
NCT06921785ARTEMIDE-HCC01Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaP3Hepatocellular Carcinoma1,220May 2025
NCT05528952TERTIOEvaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular CarcinomaP2Hepatocellular Carcinoma105Sep 2022
NCT06439485Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 FusionP1/P2Advanced Cholangiocarcinoma25Nov 2024
NCT07545954DSP-0390 in Combination With Atezolizumab for Small Cell Lung CancerP1Small-cell Lung Cancer20Jul 2026
NCT07113691TIARAIadademstat + SBRT With Atezo in ES-SCLCP1Extensive Stage Small Cell Lung Cancer (ES-SCLC)15Jan 2026
NCT07049848SATURN-STSSATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue SarcomaP2Soft Tissue Sarcoma50Sep 2025
NCT07461675Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver ResectionP3Hepato Cellular Carcinoma (HCC)30Mar 2026
NCT07281664Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular CarcinomaN/AHepatocellular Carcinoma30Jan 2026
NCT06692491SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGSP2Rare Tumour200Jan 2025
NCT07339059Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerP2Small Cell Lung Cancer ( SCLC )35Jun 2026
NCT05770102DETERMINEDETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) DispositionP2/P3Malignancy30Oct 2023
NCT05722886DETERMINEDETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolP2/P3Haematological Malignancy825Mar 2023
NCT05312671Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder CancerP2Small Cell Neuroendocrine Carcinoma of Bladder63Jun 2022
NCT07388524Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialP3Lung Non-Small Cell Carcinoma336Jun 2026
NCT07543510Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular CarcinomaN/AHepatocellular Carcinoma38May 2026
NCT05423210Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma MultiformeEarly P1Glioblastoma Multiforme12Oct 2022
NCT03942328Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerP1/P2Stage III Hepatocellular Carcinoma AJCC v885Sep 2019
NCT05984511TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTTN/AHepatocellular Carcinoma234Aug 2023
NCT06463665VIRO-25Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerP2Advanced Non-squamous Non-small-cell Lung Cancer142Sep 2024
NCT07472517DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemotherapyP3Small Cell Lung Cancer (SCLC)670Apr 2026
NCT06287775Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerP1/P2Extensive Stage Lung Small Cell Carcinoma45Apr 2025
NCT04996017AtezoMesoAtezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)P3Mesotheliomas Pleural162Dec 2021
NCT06551142PanTumor-101A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)P1Neoplasms845Sep 2024
NCT06663098CARRY-ONAtezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).P2Extensive Stage Small Cell Lung Cancer (ES-SCLC)142Jan 2025
NCT04802759A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerP1/P2Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer316Jun 2021
NCT06733038AtezoTRIBE2FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.P3Colorectal Cancer238Nov 2024
NCT06712355Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerP3Extensive-stage Small-cell Lung Cancer621Feb 2025
NCT07166406Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialP3Advanced Hepatocellular Carcinoma226Feb 2026
NCT07407933A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid TumorsP1/P2Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma118Mar 2026
NCT05703997FASTIMMUNEFASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy InductionP2Small Cell Lung Carcinoma20Jan 2023
NCT07276100Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and BevacizumabP2Hepato Cellular Carcinoma (HCC)15Jan 2026
NCT07172412Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerP2Extensive Stage Lung Small Cell Cancer165Nov 2025
NCT07284121A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeLung Cancer, Hepatocellular Carcinoma700Jul 2025
NCT06031233MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieP4Oncology776Sep 2023
NCT05482516MRD-GIEvaluating Novel Therapies in ctDNA Positive GI CancersP3Colon Adenocarcinoma20Mar 2023
NCT05394337Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial CarcinomaP1/P2Metastatic Malignancy10Feb 2023
NCT02693535TAPURTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerP2Lymphoma, Non-Hodgkin4,200Mar 2016
NCT04919382Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung CancerP2Extensive Stage Lung Small Cell Carcinoma56Jan 2022
NCT06719336STONE-001Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)P3Extensive-stage Small Cell Lung Cancer182Dec 2024
NCT06717243STRATUSGenomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)Small Cell Lung Cancer111Feb 2025
NCT06161532SMARTSacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...P2Small Cell Carcinoma of the Bladder60Aug 2024
NCT06003621MoST-TAPTiragolumab and Atezolizumab in Advanced Pan-cancer PatientsP2Solid Tumor, Adult96Dec 2023
NCT05058651Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the LungP2/P3Advanced Extrapulmonary Neuroendocrine Carcinoma189Jun 2022
NCT05652686PT217A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)P1/P2Small Cell Lung Cancer (SCLC)203Sep 2023
NCT06294548A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCCP1/P2Hepatocellular Carcinoma45Jul 2025
NCT07059494Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver TransplantP4Hepatocellular Carcinoma40Jun 2026
NCT06823375SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein ThrombosisP2HCC40Jul 2025
NCT05542407ONC201 and Atezolizumab in Obesity-Driven Endometrial CancerP1Endometrial Cancer58Oct 2023
NCT05581004A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsP1Locally Advanced or Metastatic Solid Tumors450Oct 2022
NCT06908993COMETTepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedP3Advanced Non Small Cell Lung Cancer133Dec 2025
NCT05733598Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCP2Hepatocellular Carcinoma60Aug 2024
NCT04423185PLATFORM Study of Precision Medicine for Rare TumorsP2Rare Tumor770Aug 2020
NCT07093762Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLCNon Small Cell Lung Cancer35Aug 2025
NCT05859217Cabatezo-1A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)P2Lung Cancer40Dec 2024
NCT06110572TESSERACTPhase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body IrradiationP1/P2Extensive Stage Lung Small Cell Carcinoma18Apr 2024
NCT05661188TIRANUSTiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)P2Squamous Cell Carcinoma of the Anal Canal45Feb 2023
NCT03708224Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckP2Cancer55Mar 2019
NCT06478693A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCCP1Hepatocellular Carcinoma70Jul 2024
NCT05690048FLORAFecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)P2Immunotherapy48Jul 2025
NCT06332755LB-LR1109Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLCP1Non-small Cell Lung Cancer(NSCLC)76Jun 2024
NCT06066138A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingP1Locally Advanced Alveolar Soft Part Sarcoma30Nov 2025
NCT05377034STRATUMMultinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC PatientsP2Locally Advanced Hepatocellular Carcinoma100Oct 2022
NCT06789757(HCC)The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)P2Hepatocellular Carcinoma19Feb 2025
NCT06731270Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent ImmunotherapyP2Advanced Lung Non-Small Cell Carcinoma20Apr 2025
NCT06069726MOABA Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB TrialP2Recurrent Glioblastoma80Mar 2024
NCT06584071A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCP1/P2HCC140Dec 2024
NCT06444815STEALTH-001A Study of VET3-TGI in Patients With Solid TumorsP1Solid Tumor, Adult60Sep 2024
NCT06031441A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsP1Locally Advanced Solid Tumors250Nov 2023
NCT05019703Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyP2Locally Advanced Osteosarcoma40Apr 2023
NCT05039281Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaP1/P2Recurrent Glioblastoma6Sep 2022
NCT04981509Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerP2Hereditary Leiomyomatosis and Renal Cell Carcinoma65Jun 2022
NCT04819243Young-PALETTAPALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo StudyP2Premenopausal HR+/HER2- Metastatic Breast Cancer178Aug 2021
NCT03915678AGADIRAtezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid TumorsP2Solid Tumor, Adult247Mar 2021
NCT02925234DRUPThe Drug Rediscovery Protocol (DRUP Trial)P2Cancer1,550Aug 2016
NCT06096779KirrosA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisP2Hepatocellular Carcinoma30Jul 2024
NCT04434040ASPRIAAtezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)P2Breast Cancer40Jul 2020
NCT06616623Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerP1Metastatic Lung Non-Small Cell Carcinoma24Dec 2024
NCT05317858LIMITLESSBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsP3Brain Tumor30Aug 2022
NCT05765084Immuno-MESODECIntegration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural MesotheliomaP1/P2Malignant Pleural Mesothelioma15Feb 2023
NCT05185505Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan CriteriaP4Hepatocellular Carcinoma24Jan 2023
NCT05152472ATEZOGISTA Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard TreatmentsP2Unresectable Gastrointestinal Stromal Tumor (GIST)110Jan 2022
NCT04486352EndoMAPA Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerP1/P2Endometrial Cancer148Oct 2021
NCT04273061CAPTIV-8Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible SensitivityP2Breast Cancer200Jun 2020
NCT05434234A Study of YL201 in Patients With Advanced Solid TumorsP1/P2Advanced Solid Tumor312May 2022
NCT05483400TIRACANOpen Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid TumorsP2Head and Neck Neoplasms97Oct 2023
NCT04691817Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based TherapyP1/P2Lung Cancer, Nonsmall Cell28Jul 2023
NCT04524871MORPHEUS-LIVERA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)P1/P2Advanced Liver Cancers518Nov 2020
NCT05085496Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCCP1Locally Advanced Skin Squamous Cell Carcinoma12Apr 2022
NCT05703971Acclaim-3Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC PatientsP1/P2Small Cell Lung Cancer Extensive Stage62May 2024
NCT04467723Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLCP1/P2NSCLC Stage IV25May 2022
NCT06179069A Study of ZL-1310 in Subjects With Small Cell Lung CancerP1SCLC339Jan 2024
NCT04803994TACEThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular CarcinomaP3Hepatocellular Carcinoma434Jul 2021
NCT04696575Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung CancerP2Extensive Stage Lung Small Cell Carcinoma28Jul 2021
NCT06492954AflacST2301Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaP1Osteosarcoma12Jul 2026
NCT06830694AMG757Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI TreatmentP2Small Cell Carcinoma of Lung50May 2025
NCT07157969ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCCP2HCC - Hepatocellular Carcinoma300Feb 2025
NCT05944237HTL0039732 in Participants With Advanced Solid TumoursP1/P2Neoplasms150Jul 2023
NCT05797493PICASSOPanomic Approach to Immune-Connected Assays in Small Cell Lung CancerSmall Cell Lung Cancer100Oct 2022
NCT05000294Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesP1/P2Bile Duct Cancer29Dec 2021
NCT05333458Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM TrialP2Advanced Alveolar Soft Part Sarcoma27Aug 2022
NCT07235293A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.P2Colorectal Cancer90Jan 2026
NCT04402788Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR TrialP2/P3Extensive Stage Lung Small Cell Carcinoma138Jan 2021
NCT03821246Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical ProstatectomyP2Prostate Adenocarcinoma68Oct 2019
NCT05516628EMPHASISDeep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular CarcinomaP2Hepatocellular Carcinoma30Feb 2023
NCT05525858KOSMOSIIKPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors IISolid Tumor1,000Sep 2022
NCT06302426Trial of INI-4001 in Patients With Advanced Solid TumoursP1Advanced Solid Tumor50Jul 2024
NCT06157827A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaP1/P2Advanced Neuroendocrine Carcinoma178Dec 2023
NCT05440708A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaP1/P2Hepatocellular Carcinoma193Mar 2023
NCT07192185Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & BevacizumabP2Hepatocellular Carcinoma (HCC)30Sep 2025
NCT06867432Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular CarcinomaP2Hepatocellular Carcinoma20Mar 2025
NCT07538128Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent GlioblastomaEarly P1Recurrent Glioblastoma10Jan 2025
NCT06690840AZALEAAtezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer PatientsP2Triple Negative Breast Cancer45Mar 2025
NCT05501665Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerP1/P2Lung Non-Small Cell Carcinoma25May 2023
NCT06807632A Study of Valemetostat in Combination With Atezolizumab in People With Lung CancerP1Extensive-stage Small-cell Lung Cancer24Jan 2025
NCT04796012VITASVITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid TumorsP1/P2Solid Tumor23Apr 2023
NCT05168618AtezoCabCabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerP2Castration-Resistant Prostate Carcinoma33Mar 2022
NCT01810913Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerP2/P3Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma613Mar 2013
NCT05907980A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid TumorsP1Solid Tumor219May 2023
NCT05488522SBRT With Atezo/Bev for HCCP1Hepatocellular Carcinoma18Sep 2022
NCT05168163Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerP2Locally Advanced Hepatocellular Carcinoma122May 2022
NCT06362252A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)P1/P2Extensive Stage-small Cell Lung Cancer123Jul 2024
NCT04865250iRePPredicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLCP2NSCLC Stage II20Jan 2021
NCT06771518Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With AtezolizumabP2Small Cell Lung Cancer37Dec 2021
NCT03767075BoBA Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)P2Advanced Solid Tumor1,000Dec 2018
NCT05159245FINPROVEThe Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsP2Advanced Cancer250Dec 2021
NCT05092373TTFPhase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxP1Advanced Breast Carcinoma43Apr 2022
NCT07285850ABATE-MASLDThe Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLDP2/P3HCC - Hepatocellular Carcinoma20Oct 2025
NCT05001880Chemotherapy With or Without Immunotherapy for Peritoneal MesotheliomaP2Peritoneal Malignant Mesothelioma66Mar 2022
NCT06012734CoLBAtLB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer PatientsP1Metastatic Microsatellite-stable Colorectal Cancer37Jun 2024
NCT06971237IMSIRTSIRT and Peri-immunotherapy : a New ConceptAdvanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy60Jun 2025
NCT06097962Safety and Efficacy of NK510 to Treat NSCLCEarly P1NSCLC12Jul 2023
NCT04624399ABACUS-2Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial CancerP2Urogenital Cancer58Jun 2021
NCT04812366GUNSGenomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerP2Prostate Cancer315Sep 2021
NCT05992220ALERT-HCCAtezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular InvasionP2Hepatocellular Carcinoma138Oct 2022
NCT05751343Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical TrialP2Hepatocellular Carcinoma55Mar 2023
NCT06323382Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma240Jan 2021
NCT05713994CCGLC-001Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular CarcinomaHepatocellular Carcinoma Non-resectable300May 2020
NCT06780826A Study on the Efficacy of Atezolizumab Combined with ChemotherapyLung Cancer, Small Cell1,430Aug 2024
NCT05295212Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIBP2Non Small Cell Lung Cancer120Feb 2023
NCT04224636DEMANDAtezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/BevacizumabP2Hepatocellular Carcinoma Non-resectable106Jun 2020
NCT05717738CCGLC-008Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular CarcinomaHepatocellular Carcinoma Non-resectable300Jan 2022

Atezolizumab clinical trials by indication

Hepatocellular Carcinoma (43)

NCTAcronymPhaseStatusTitle
NCT05620771P2recruitingTherasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
NCT06339424PhotonABP2recruitingAtezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
NCT04727307AB-LATE02P2recruitingNeoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
NCT07317414P2recruitingβ-alanine in the Treatment of Advanced Hepatocellular Carcinoma
NCT06109272LIVIGNO-2P2/P3recruitingA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT06921785ARTEMIDE-HCC01P3recruitingPhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT05528952TERTIOP2recruitingEvaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT07281664N/Anot yet recruitingTransarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
+ 35 more, see All trials below.

Breast Cancer (24)

NCTAcronymPhaseStatusTitle
NCT04873362AstefaniaP3active not recruitingA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT01898117Triple-BP2active not recruitingTriple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
NCT04434040ASPRIAP2recruitingAtezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
NCT04273061CAPTIV-8P2recruitingInvestigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
NCT04759248ATREZZOP2active not recruitingStudy With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer
NCT04158258N/Aactive not recruitingA Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
NCT04732598AMBITIONP3completedA Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
NCT03483012P2completedAtezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
+ 16 more, see All trials below.

Non-Small Cell Lung Cancer (22)

NCTAcronymPhaseStatusTitle
NCT03228667P2active not recruitingQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT04449874P1active not recruitingA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT02486718MPDL3280AP3active not recruitingStudy to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT05047250P3active not recruitingA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
NCT03178552B-FASTP2/P3active not recruitingA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04294810SKYSCRAPER-01P3completedA Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
NCT05240131NSCLCP1/P2unknownA Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
NCT03735121P3completedA Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
+ 14 more, see All trials below.

Urothelial Carcinoma (20)

NCTAcronymPhaseStatusTitle
NCT03170960P1active not recruitingStudy of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03093922P2active not recruitingA Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
NCT03782207IMrealN/Aactive not recruitingA Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
NCT03869190MORPHEUS-UCP1/P2completedStudy Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
NCT03502785P1/P2completedINO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
NCT03473756FORT-2P1completedPhase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
NCT02807636IMvigor130P3completedStudy of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
NCT03511391CHEERSP2completedCHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors
+ 12 more, see All trials below.

Non-small Cell Lung Cancer (15)

NCTAcronymPhaseStatusTitle
NCT07195695P3recruitingBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT04302025NAUTIKA1P2recruitingA Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
NCT05825625P2active not recruitingNeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
NCT05867121P1active not recruitingA Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
NCT05007769RANP2withdrawnRamucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
NCT03563716P2completedA Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT05746481NSCLCP2terminatedTiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
NCT04911166P1terminatedPhase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
+ 7 more, see All trials below.

Non Small Cell Lung Cancer (12)

NCTAcronymPhaseStatusTitle
NCT07153445ATHENEAP2recruitingNeoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
NCT07093762N/Anot yet recruitingEfficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC
NCT05781308ADAPTABLEP2active not recruitingCombination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
NCT03520686P3terminatedNogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT05295212P2recruitingAtezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB
NCT04432207P1terminatedA Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
NCT03836066TELMAP2completedAtezolizumab Plus Bevacizumab in First Line NSCLC Patients
NCT04512430P2terminatedNeo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
+ 4 more, see All trials below.

Cancer (12)

NCTAcronymPhaseStatusTitle
NCT05862285UmbrellaMAXP3recruitingA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT04341181ProTargetP2recruitingProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
NCT03148418P3active not recruitingA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT06754501P2active not recruitingA Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
NCT03768063IMbrella BP3active not recruitingA Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03708224P2recruitingPreoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT02925234DRUPP2recruitingThe Drug Rediscovery Protocol (DRUP Trial)
NCT05694013ORIGAMAP2/P3terminatedClinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice
+ 4 more, see All trials below.

Solid Tumor (12)

NCTAcronymPhaseStatusTitle
NCT05525858KOSMOSIIN/ArecruitingKPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
NCT04796012VITASP1/P2recruitingVITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
NCT05907980P1recruitingA Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
NCT03673787IceCAPP1/P2active not recruitingA Trial of Ipatasertib in Combination With Atezolizumab
NCT04185831MEGALiTP2active not recruitingA MolEcularly Guided Anti-Cancer Drug Off-Label Trial
NCT06416436P1withdrawnDose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
NCT04101357P1/P2terminatedSafety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
NCT04276376ARIANESP2terminatedEfficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
+ 4 more, see All trials below.

Bladder Cancer (12)

NCTAcronymPhaseStatusTitle
NCT04138628TOMBOLAP2active not recruitingTreatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy
NCT04630730P2active not recruitingIntravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
NCT03697850BladderSparP2active not recruitingAtezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
NCT03799835ALBANP3active not recruitingAtezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
NCT04186013P2active not recruitingEfficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer
NCT02989584P1/P2active not recruitingA Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
NCT04289779ABATEP2active not recruitingStudy of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
NCT02108652P2completedA Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
+ 4 more, see All trials below.

Solid Tumors (11)

NCTAcronymPhaseStatusTitle
NCT04589845TAPISTRYP2active not recruitingTumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT06331598IMperatorP2withdrawnA Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
NCT04250155P1active not recruitingAn Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT04303858RO7284755P1terminatedA Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
NCT04857138P1completedA Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
NCT04642365P1terminatedA Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
NCT03264066P2completedA Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
NCT02650713CEAP1completedA Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
+ 3 more, see All trials below.

Advanced Solid Tumor (11)

NCTAcronymPhaseStatusTitle
NCT05434234P1/P2recruitingA Study of YL201 in Patients With Advanced Solid Tumors
NCT05878691P1active not recruitingA Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
NCT06302426P1recruitingTrial of INI-4001 in Patients With Advanced Solid Tumours
NCT03767075BoBP2recruitingA Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
NCT04896697XTX101P1/P2active not recruitingVilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
NCT04440735P1/P2active not recruitingA Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
NCT05109442P1/P2terminatedStudy to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
NCT05253053P1/P2completedTo Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
+ 3 more, see All trials below.

Carcinoma, Non-Small-Cell Lung (11)

NCTAcronymPhaseStatusTitle
NCT03337698Morpheus LungP1/P2terminatedA Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
NCT04471428CONTACT-01P3completedStudy of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
NCT04984811P2terminatedNT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NCT04194203P3completedA Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
NCT04426825P2completedA Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
NCT02813785IMpower210P3completedA Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
NCT03102242P2completedAtezolizumab Immunotherapy in Patients With Advanced NSCLC
NCT03285763TAILP4completedA Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
+ 3 more, see All trials below.

Colorectal Cancer (10)

NCTAcronymPhaseStatusTitle
NCT06733038AtezoTRIBE2P3recruitingFOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
NCT05999812P2active not recruitingClinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
NCT07235293P2recruitingA Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
NCT05118724ANTONIOP2active not recruitingAtezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin
NCT05425940STELLAR-303P3active not recruitingStudy of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT03866239P1terminatedA Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
NCT03555149P1/P2terminatedA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
NCT02291289MODULP2completedA Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
+ 2 more, see All trials below.

Small Cell Lung Cancer (10)

NCTAcronymPhaseStatusTitle
NCT07155174SEZanneP2recruitingA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT06898957(DeLLphi-310)P1active not recruitingStudy of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06717243STRATUSN/ArecruitingGenomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
NCT05797493PICASSON/ArecruitingPanomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
NCT06771518P2recruitingAssociation of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
NCT04256421SKYSCRAPER-02P3completedA Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04730999CeLEBrATEP2completedEfficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer
NCT03059667P2completedImmunotherapy as Second-line in Patient With Small Cell Lung Cancer
+ 2 more, see All trials below.

Extensive Stage Lung Small Cell Carcinoma (9)

NCTAcronymPhaseStatusTitle
NCT06287775P1/P2recruitingTesting the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
NCT04919382P2recruitingTemozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
NCT06110572TESSERACTP1/P2recruitingPhase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
NCT04696575P2recruitingLamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
NCT04402788P2/P3recruitingTesting the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
NCT04560972LB-100P1active not recruitingLB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer
NCT04334941P2active not recruitingTesting Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
NCT05191797P1/P2terminatedBomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
+ 1 more, see All trials below.

Melanoma (8)

NCTAcronymPhaseStatusTitle
NCT04722575NEO-TIMP2active not recruitingCombination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
NCT04107168N/AunknownMicrobiome Immunotherapy Toxicity and Response Evaluation
NCT03289962RO7198457P1completedA Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
NCT04096638P1completedSafety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
NCT02908672P3completedA Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
NCT05116202P1/P2completedA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
NCT04091217P2completedAtezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
NCT03901573P1/P2terminatedHigh-Risk Skin Cancers With Atezolizumab Plus NT-I7

Hepatocellular Carcinoma (HCC) (7)

NCTAcronymPhaseStatusTitle
NCT07293468BIIRTHP2/P3recruitingComparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
NCT06725121MacroTransP1/P2recruitingUsing Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
NCT07291076HCCP1/P2recruitingA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT06680258P3not yet recruitingA Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
NCT07192185P2recruitingSystemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
NCT05022927P1active not recruitingA Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
NCT07272265N/AcompletedThe Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

Triple Negative Breast Cancer (7)

NCTAcronymPhaseStatusTitle
NCT03756298P2active not recruitingEfficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT03281954P3active not recruitingClinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT06690840AZALEAP2recruitingAtezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
NCT05498896BARBICANP2active not recruitingInvestigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
NCT03206203P2completedCarboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
NCT03498716IMpassion030P3terminatedA Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
NCT02425891P3completedA Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Neoplasms (7)

NCTAcronymPhaseStatusTitle
NCT06551142PanTumor-101P1recruitingA Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
NCT05944237P1/P2recruitingHTL0039732 in Participants With Advanced Solid Tumours
NCT05112965P3active not recruitingAn Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
NCT02091141P2completedMy Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
NCT02825940IMYO29233P1completedA Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors
NCT02410512P1completedA Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT01688206RO5520985P1completedA Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Lung Non-Small Cell Carcinoma (6)

NCTAcronymPhaseStatusTitle
NCT04989283P2withdrawnTesting the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
NCT07388524P3not yet recruitingTesting the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
NCT05340309P2active not recruitingSubcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
NCT04214262P3active not recruitingTesting the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT05501665P1/P2recruitingSplit Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
NCT04310020P2active not recruitingStudy of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

Advanced Hepatocellular Carcinoma (6)

NCTAcronymPhaseStatusTitle
NCT06618664P3recruitingA Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
NCT07166406P3recruitingTesting Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT05097911P1active not recruitingPhase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.
NCT06323382N/ArecruitingLocoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
NCT05173298HCCN/AunknownPredictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
NCT04862949N/AcompletedOrgan-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Metastatic Breast Cancer (6)

NCTAcronymPhaseStatusTitle
NCT03424005Morpheus-panBCP1/P2recruitingA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT06342037TONIC-3P2recruitingNOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
NCT05266937P2unknownAtezolizumab Plus CArboplatin Plus Nab-paclitaxel
NCT04740918KATE3P3terminatedA Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
NCT04408118ATRACTIBP2completedFirst Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
NCT02924883KATE2P2completedA Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy

Carcinoma, Hepatocellular (6)

NCTAcronymPhaseStatusTitle
NCT04180072N/Aactive not recruitingAtezolizumab Plus Bevacizumab With HCC and HBV Infection
NCT04102098IMbrave050P3active not recruitingA Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
NCT05908786P1/P2completedA Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
NCT04487067AMETHISTAP3completedA Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
NCT04732286P3terminatedA Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
NCT03434379IMbrave150P3completedA Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Renal Cell Carcinoma (6)

NCTAcronymPhaseStatusTitle
NCT04006522P2active not recruiting89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
NCT03693573P3withdrawnA Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
NCT03024996IMmotion010P3terminatedA Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
NCT02420821IMmotion151P3completedA Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
NCT03063762RCCP1completedStudy to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
NCT01984242IMmotion150P2completedA Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

Small-cell Lung Cancer (5)

NCTAcronymPhaseStatusTitle
NCT07545954P1not yet recruitingDSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
NCT03540420ACHILESP2active not recruitingAtezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
NCT04923776P2terminatedLiver Directed RT + Chemo-immunotherapy for ES-SCLC
NCT04696939P2unknownCombined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
NCT04610684SCLCP2terminatedChemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Unresectable Hepatocellular Carcinoma (5)

NCTAcronymPhaseStatusTitle
NCT05096715P1recruitingAtezolizumab+Bevacizumab+SBRT in Unresectable HCC
NCT06117891REFINE-ION/Aactive not recruitingAn Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
NCT04770896IMbrave251P3active not recruitingA Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04829383AB7P2active not recruitingA Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
NCT06503250N/AcompletedA Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization

Endometrial Cancer (5)

NCTAcronymPhaseStatusTitle
NCT05542407P1recruitingONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT04486352EndoMAPP1/P2recruitingA Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT03526432P2active not recruitingPhase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
NCT03694262EndoBARRP2completedThe EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
NCT03603184AtTEndP3completedAtezolizumab Trial in Endometrial Cancer - AtTEnd

Small Cell Lung Carcinoma (5)

NCTAcronymPhaseStatusTitle
NCT05703997FASTIMMUNEP2not yet recruitingFASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
NCT05224141MK-7684AP3active not recruitingPembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT04665856SKYSCRAPER-02CP3active not recruitingStudy of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04028050MAURISP3completedA Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
NCT02763579IMpower133P3completedA Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Extensive Stage Small Cell Lung Cancer (5)

NCTAcronymPhaseStatusTitle
NCT05142696P1/P2active not recruitingA Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05361395ES-SCLCP1active not recruitingFirst-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NCT05468489P3active not recruitingTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05055947N/AcompletedEfficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer
NCT05055999N/AcompletedTumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

Ovarian Cancer (5)

NCTAcronymPhaseStatusTitle
NCT04931342BOUQUETP2active not recruitingA Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
NCT03363867BEACONP2unknownBEACON - ABC in Recurrent Platinum Resistant HGSOC
NCT02891824ATALANTEP3completedATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab
NCT03038100IMagyn050P3completedA Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03394885AdORNP1/P2completedAtezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer

Malignant Melanoma (5)

NCTAcronymPhaseStatusTitle
NCT02902029ImmunoCobiVemP2completedEvaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
NCT04123470P1/P2completedA Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
NCT03178851P1completedCobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
NCT02303951NEO-VCP2terminatedNeoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC
NCT01656642P1completedA Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Small Cell Lung Cancer Extensive Stage (4)

NCTAcronymPhaseStatusTitle
NCT07227597MK-6070P1/P2recruitingA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT05703971Acclaim-3P1/P2recruitingQuaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
NCT06939036SANTANA-225P1/P2terminatedStudy of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
NCT04462276TREASUREP2completedThoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease

Advanced Solid Tumors (4)

NCTAcronymPhaseStatusTitle
NCT04185883P1active not recruitingSotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT05487235P1completedA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06719973P1withdrawnPhase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
NCT03841110P1completedFT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma (4)

NCTAcronymPhaseStatusTitle
NCT05935774P2withdrawnOT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
NCT06616623P1recruitingVismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
NCT04919369ATRAP1active not recruitingAll-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
NCT03600701P2active not recruitingAtezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Solid Tumor, Adult (4)

NCTAcronymPhaseStatusTitle
NCT06003621MoST-TAPP2recruitingTiragolumab and Atezolizumab in Advanced Pan-cancer Patients
NCT06444815STEALTH-001P1recruitingA Study of VET3-TGI in Patients With Solid Tumors
NCT03915678AGADIRP2recruitingAtezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
NCT05276284TEMPLEP1/P2completedThiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy

Non-small Cell Lung Cancer (NSCLC) (4)

NCTAcronymPhaseStatusTitle
NCT06267001SKYSCRAPER-15P3terminatedA Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
NCT04619797SKYSCRAPER-06P2/P3completedA Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04267237P2withdrawnA Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
NCT04513925SKYSCRAPER-03P3completedA Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Hepatocellular Carcinoma Non-resectable (4)

NCTAcronymPhaseStatusTitle
NCT06133062ProtonABP2recruitingAtezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
NCT05713994CCGLC-001N/ArecruitingCombined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
NCT04224636DEMANDP2recruitingAtezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab
NCT05717738CCGLC-008N/ArecruitingCombined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Squamous Cell Carcinoma of Head and Neck (4)

NCTAcronymPhaseStatusTitle
NCT04665843SKYSCRAPER-09P2completedA Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
NCT03829501KY1044P1/P2terminatedA Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
NCT05053737P1completedRadiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC
NCT04939480PIONEERP2completedWindow of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN

Metastatic Colorectal Cancer (4)

NCTAcronymPhaseStatusTitle
NCT04929223INTRINSICP1recruitingA Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT03340558ATELIERP2withdrawnAtezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer
NCT04659382SIRTCIP2unknownStudy to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
NCT03721653AtezoTRIBEP2completedFOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Triple-Negative Breast Cancer (4)

NCTAcronymPhaseStatusTitle
NCT04148911EL1SSARP3completedA Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
NCT04584112P1completedA Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
NCT04177108P3completedA Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT03125902IMpassion131P3completedA Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Cervical Cancer (4)

NCTAcronymPhaseStatusTitle
NCT03614949P2active not recruitingSBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
NCT03340376P2active not recruitingDoxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer
NCT04300647SKYSCRAPER-04P2completedA Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
NCT04405349P2completedInvestigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

Advanced Lung Non-Small Cell Carcinoma (3)

NCTAcronymPhaseStatusTitle
NCT07322341P2not yet recruitingSX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
NCT06731270P2recruitingDiclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
NCT05334329NKP1active not recruitingGenetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Small Cell Lung Cancer (SCLC) (3)

NCTAcronymPhaseStatusTitle
NCT07226999P2/P3recruitingSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
NCT07472517P3recruitingDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
NCT05652686PT217P1/P2recruitingA Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

HCC - Hepatocellular Carcinoma (3)

NCTAcronymPhaseStatusTitle
NCT07157969P2recruitingICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
NCT07285850ABATE-MASLDP2/P3recruitingThe Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
NCT05665348TRIPLETP2/P3completedStudy Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Squamous Cell Carcinoma (3)

NCTAcronymPhaseStatusTitle
NCT05681039OCSCCP2active not recruitingPhase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
NCT06762808P2withdrawnPhase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
NCT05038657AURORAP2unknownAtezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).

Recurrent Glioblastoma (3)

NCTAcronymPhaseStatusTitle
NCT06069726MOABP2recruitingA Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
NCT05039281P1/P2recruitingAtezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
NCT07538128Early P1recruitingEvaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Lung Cancer (3)

NCTAcronymPhaseStatusTitle
NCT06572722ECTOP-1030P2withdrawnPerioperative Immunotherapy for NSCLC (ECTOP-1030)
NCT05859217Cabatezo-1P2not yet recruitingA Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
NCT04367311NSCLCP2active not recruitingAdjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Extensive-stage Small Cell Lung Cancer (3)

NCTAcronymPhaseStatusTitle
NCT06719336STONE-001P3not yet recruitingAddition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)
NCT04487756VENEZO-LUNGP1/P2completedCombination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer
NCT04373369P2terminatedVorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Gastric Cancer (3)

NCTAcronymPhaseStatusTitle
NCT03421288DANTEP2active not recruitingStudy of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
NCT04661150P2active not recruitingA Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
NCT06098898Early P1unknownSafety and Efficacy of NK510 to Treat Gastric Cancer

NSCLC Stage IV (3)

NCTAcronymPhaseStatusTitle
NCT04467723P1/P2recruitingCombination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
NCT04549428P2terminatedAtezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
NCT03713944P2terminatedCarboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

Carcinoma, Small Cell Lung (3)

NCTAcronymPhaseStatusTitle
NCT04253145P1/P2unknownStudy to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
NCT04622228MatchP2completedStudy of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
NCT04308785P2terminatedA Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

Pancreatic Cancer (3)

NCTAcronymPhaseStatusTitle
NCT04820179P2active not recruitingAtezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
NCT04161755P1active not recruitingStudy of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
NCT02705196P1/P2completedLOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Prostate Cancer (3)

NCTAcronymPhaseStatusTitle
NCT04751929P2active not recruitingAbemaciclib With or Without Atezolizumab for mCRPC
NCT04812366GUNSP2recruitingGenomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
NCT04272645P2withdrawnAbemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Esophageal Cancer (3)

NCTAcronymPhaseStatusTitle
NCT04540211SKYSCRAPER-08P3completedA Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
NCT05007613P2completedSecond-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
NCT03818997DYNAMICP2withdrawnCombination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer

Acute Myeloid Leukemia (3)

NCTAcronymPhaseStatusTitle
NCT03922477P1terminatedA Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
NCT03154827AMLP1/P2terminatedSafety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
NCT02892318AMLP1completedA Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

Multiple Myeloma (3)

NCTAcronymPhaseStatusTitle
NCT04045028PKP1terminatedA Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT03312530P1/P2completedA Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
NCT02431208MMP1completedA Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT02220842MPDL3280AP1completedA Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
NCT03465891P2terminatedStudy of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
NCT02729896FLP1/P2completedA Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Treatment-Refractory Solid Tumors (2)

NCTAcronymPhaseStatusTitle
NCT07170592P1not yet recruitingA Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
NCT07190833P1recruitingA Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Hepato Cellular Carcinoma (HCC) (2)

NCTAcronymPhaseStatusTitle
NCT07461675P3not yet recruitingEffects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
NCT07276100P2recruitingFecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

Extensive Stage Small Cell Lung Cancer (ES-SCLC) (2)

NCTAcronymPhaseStatusTitle
NCT07113691TIARAP1recruitingIadademstat + SBRT With Atezo in ES-SCLC
NCT06663098CARRY-ONP2recruitingAtezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Resectable Hepatocellular Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT07018947ASPIREP2not yet recruitingStudy to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
NCT04721132P2active not recruitingAtezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Glioblastoma (2)

NCTAcronymPhaseStatusTitle
NCT07263438PhenixP2recruitingEfficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
NCT03174197P1/P2completedAtezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

HCC (2)

NCTAcronymPhaseStatusTitle
NCT06823375P2recruitingSBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
NCT06584071P1/P2not yet recruitingA Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Solid Cancer (2)

NCTAcronymPhaseStatusTitle
NCT06771622P1/P2active not recruitingSafety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
NCT03721679P1/P2terminatedPoly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Extensive-stage Small-cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT06712355P3recruitingSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06807632P1recruitingA Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

Triple Negative Breast Neoplasms (2)

NCTAcronymPhaseStatusTitle
NCT06067061neoBREASTIMP1/P2terminated"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
NCT03371017IMpassion132P3completedA Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

Chronic Lymphocytic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT06043674P2recruitingPhase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
NCT02846623P2active not recruitingAtezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

NSCLC (2)

NCTAcronymPhaseStatusTitle
NCT05798663P2active not recruitingAtezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
NCT06097962Early P1recruitingSafety and Efficacy of NK510 to Treat NSCLC

Head and Neck Neoplasms (2)

NCTAcronymPhaseStatusTitle
NCT05483400TIRACANP2recruitingOpen Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
NCT03818061ATHENAP2completedAtezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

Early-stage Breast Cancer (2)

NCTAcronymPhaseStatusTitle
NCT05332561COGNITION-GUIDEP2recruitingGenomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
NCT03894007PREDIXIIHER2P2terminatedImproving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

Platinum-Resistant Fallopian Tube Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT05538091P2recruitingVismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT03206047P1/P2completedAtezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Squamous Cell Carcinoma of the Head and Neck (2)

NCTAcronymPhaseStatusTitle
NCT03946358VolATILP2completedCombination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
NCT05459129P1/P2completedA Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Colon Adenocarcinoma (2)

NCTAcronymPhaseStatusTitle
NCT05482516MRD-GIP3recruitingEvaluating Novel Therapies in ctDNA Positive GI Cancers
NCT02912559P3active not recruitingCombination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Malignant Pleural Mesothelioma (2)

NCTAcronymPhaseStatusTitle
NCT05765084Immuno-MESODECP1/P2recruitingIntegration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
NCT04480372ORIGINP2completedSAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Advanced Breast Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT05092373TTFP1recruitingPhase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT05238831ACTEarly P1withdrawnSMMART Adaptive Clinical Treatment (ACT) Trial

Locally Advanced Hepatocellular Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT05377034STRATUMP2recruitingMultinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
NCT05168163P2recruitingAtezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Neoplasm (2)

NCTAcronymPhaseStatusTitle
NCT05450562P1/P2terminatedDose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
NCT03637764SAR650984P1/P2terminatedSafety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Locally Advanced Bladder Urothelial Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT04637594IMAGINEP3active not recruitingTrying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT03237780P2active not recruitingAtezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Rectal Neoplasms (2)

NCTAcronymPhaseStatusTitle
NCT05009069P2active not recruitingA Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
NCT03127007R-IMMUNEP1/P2completedSafety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer

Colorectal Neoplasms (2)

NCTAcronymPhaseStatusTitle
NCT05141721P2/P3active not recruitingA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
NCT03698461CLIMBP2completedTreatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

Large Cell Neuroendocrine Carcinoma of the Lung (2)

NCTAcronymPhaseStatusTitle
NCT05470595LCNEC-ALPINEP2active not recruitingA Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
NCT06049966LANCEP1completedAtezolizumab in Large Cell Neuroendocrine Carcinoma

Small-Cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04471727P1/P2active not recruitingA Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
NCT05091567IMforteP3active not recruitingA Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

Biliary Tract Cancer (2)

NCTAcronymPhaseStatusTitle
NCT05052099COMBATBILP1/P2completedPhase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer
NCT04677504P2completedA Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

Follicular Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT04962126FLUOROP2active not recruitingFrontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
NCT03276468P2completedEvaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Anatomic Stage IV Breast Cancer AJCC v8 (2)

NCTAcronymPhaseStatusTitle
NCT03853707P1/P2completedIpatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT04639245P1/P2terminatedGenetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC) (2)

NCTAcronymPhaseStatusTitle
NCT04832854P2terminatedA Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
NCT03559647N/AcompletedThe Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Metastatic Triple Negative Breast Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04739670BELLAP2unknownEvaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
NCT03256344P1completedStudy of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Triple-negative Breast Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04770272neoMonoP2terminatedStudy to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy
NCT03197935IMpassion031P3completedA Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Metastatic Prostate Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04446117CONTACT-02P3active not recruitingStudy of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04262154P2active not recruitingStudy of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Clinical Stage III Cutaneous Melanoma AJCC v8 (2)

NCTAcronymPhaseStatusTitle
NCT04356729P2active not recruitingA Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
NCT03554083P2completedVemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Carcinoma, Renal Cell (2)

NCTAcronymPhaseStatusTitle
NCT04338269CONTACT-03P3terminatedA Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
NCT02543645P1terminatedA Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Sarcoma (2)

NCTAcronymPhaseStatusTitle
NCT03548428StereosarcP2recruitingStereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)
NCT02609984P2terminatedStudy to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Metastatic Melanoma (2)

NCTAcronymPhaseStatusTitle
NCT04109456P1completedIN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
NCT03625141P2completedA Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Malignant Glioma (2)

NCTAcronymPhaseStatusTitle
NCT04160494P1active not recruitingD2C7-IT With Atezolizumab for Recurrent Gliomas
NCT03973879P1/P2withdrawnCombination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Sarcoma,Soft Tissue (2)

NCTAcronymPhaseStatusTitle
NCT03474094RT-ImmuneP2active not recruitingClinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
NCT04216953COTESARCP1/P2completedMEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

Anatomic Stage III Breast Cancer AJCC v8 (2)

NCTAcronymPhaseStatusTitle
NCT02849496P2active not recruitingTesting Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
NCT04249167Early P1withdrawnCryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

NSCLC Stage IIIB (2)

NCTAcronymPhaseStatusTitle
NCT04042558GFPC 06-2018P2completedA Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
NCT03647956P2unknownAtezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Cervical Adenocarcinoma (2)

NCTAcronymPhaseStatusTitle
NCT03738228P1completedAtezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
NCT02921269P2completedAtezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Recurrent Ovarian Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT03353831P3completedAtezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
NCT03598270ANITAP3completedPlatinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

Metastatic Cancer (2)

NCTAcronymPhaseStatusTitle
NCT03693014P2active not recruitingA Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
NCT03024437P1/P2terminatedAtezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

HER2-positive Breast Cancer (2)

NCTAcronymPhaseStatusTitle
NCT03125928P2active not recruitingClinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
NCT03650348P1completedPRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Lymphoma, Non-Hodgkin (2)

NCTAcronymPhaseStatusTitle
NCT02693535TAPURP2recruitingTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT03369964P1withdrawnA Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Carcinoma, Transitional Cell (2)

NCTAcronymPhaseStatusTitle
NCT02451423P2completedNeoadjuvant Atezolizumab in Localized Bladder Cancer
NCT02450331IMvigor010P3terminatedA Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

Tumors (2)

NCTAcronymPhaseStatusTitle
NCT02458638P2completedA Study of Atezolizumab in Advanced Solid Tumors
NCT01375842P1completedA Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Cancers (2)

NCTAcronymPhaseStatusTitle
NCT02323191P1completedA Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
NCT02174172P1completedA Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Small Cell Lung Cancer ( SCLC ) (1)

NCTAcronymPhaseStatusTitle
NCT07339059P2recruitingStudy of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Osteosarcoma (1)

NCTAcronymPhaseStatusTitle
NCT06492954AflacST2301P1recruitingAtezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT07407933P1/P2recruitingA Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Advanced Non Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06908993COMETP3recruitingTepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Extensive Stage Lung Small Cell Cancer (1)

NCTAcronymPhaseStatusTitle
NCT07172412P2not yet recruitingOpen-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Resectable Hepatocellular Carcinoma With High Risk of Recurrence (1)

NCTAcronymPhaseStatusTitle
NCT07239245ATTACHP2recruitingStudy to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Locally Advanced Alveolar Soft Part Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT06066138P1recruitingA Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Soft Tissue Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT07049848SATURN-STSP2recruitingSATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

Microsatellite Stable Metastatic Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06603818MSSP2withdrawnImmunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Immunotherapy (1)

NCTAcronymPhaseStatusTitle
NCT05690048FLORAP2recruitingFecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

Lung Cancer, Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT07284121N/ArecruitingA Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy (1)

NCTAcronymPhaseStatusTitle
NCT06971237IMSIRTN/Anot yet recruitingSIRT and Peri-immunotherapy : a New Concept

Small Cell Carcinoma of Lung (1)

NCTAcronymPhaseStatusTitle
NCT06830694AMG757P2recruitingClinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

Recurrent Glioblastoma, IDH-Wildtype (1)

NCTAcronymPhaseStatusTitle
NCT06328036P2withdrawnTesting the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Advanced Solid Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT06760481TIGERP1active not recruitingPhase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Microsatellite Stable (MSS) Colorectal Cancer (CRC) (1)

NCTAcronymPhaseStatusTitle
NCT06784947P2active not recruitingTrial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

Extensive-Stage Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06646276TIGOSP3recruitingA Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Metastatic Cancer Lung (1)

NCTAcronymPhaseStatusTitle
NCT06713798INDIGOP2withdrawnTargeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

Rare Tumour (1)

NCTAcronymPhaseStatusTitle
NCT06692491SPRINGP2not yet recruitingStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Solid Tumour (1)

NCTAcronymPhaseStatusTitle
NCT06488716P1terminatedA Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Resectable Lung Non-Small Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06632327P3recruitingComparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Advanced Cholangiocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06439485P1/P2recruitingPhase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Advanced Non-squamous Non-small-cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06463665VIRO-25P2recruitingEfficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Cancer-Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT06537310P1active not recruitingA Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Lung Cancer, Small Cell (1)

NCTAcronymPhaseStatusTitle
NCT06780826N/ArecruitingA Study on the Efficacy of Atezolizumab Combined with Chemotherapy

Small Cell Carcinoma of the Bladder (1)

NCTAcronymPhaseStatusTitle
NCT06161532SMARTP2recruitingSacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Extensive Stage-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06362252P1/P2recruitingA Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Metastatic Microsatellite-stable Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06012734CoLBAtP1recruitingLB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

Non-small Cell Lung Cancer(NSCLC) (1)

NCTAcronymPhaseStatusTitle
NCT06332755LB-LR1109P1recruitingStudy to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

HPV-Related Cervical Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06099418P2withdrawnEfficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Small Cell Lung Carcinoma (SCLC) (1)

NCTAcronymPhaseStatusTitle
NCT06077500DAREONᵀᴹ-8P1active not recruitingDAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

SCLC (1)

NCTAcronymPhaseStatusTitle
NCT06179069P1recruitingA Study of ZL-1310 in Subjects With Small Cell Lung Cancer

PIK3CA-Mutated Cancers (1)

NCTAcronymPhaseStatusTitle
NCT06496568P1active not recruitingA Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Advanced Neuroendocrine Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06157827P1/P2recruitingA Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Clinical Stage I Gastric Cancer AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT05836584GEJP2active not recruitingTesting Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Non-Small Cell Lung Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT05689671ANTELOPEP4active not recruitingPemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Recurrent Liver Cancer After Liver Transplantation (1)

NCTAcronymPhaseStatusTitle
NCT05833126P2unknownHepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

Locally Advanced Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT06031441P1recruitingA Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Oropharynx Cancer, Stage I (1)

NCTAcronymPhaseStatusTitle
NCT06254911P2suspendedPre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

Malignancy (1)

NCTAcronymPhaseStatusTitle
NCT05770102DETERMINEP2/P3recruitingDETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Adenocarcinoma, Pancreatic Ductal (1)

NCTAcronymPhaseStatusTitle
NCT05968326IMCODE003P2recruitingA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Bladder Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05564416P2withdrawnTesting Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Advanced Rare Malignant Solid Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT05715281P2active not recruitingTesting the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Oncology (1)

NCTAcronymPhaseStatusTitle
NCT06031233MINUTEP4recruitingEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Metastatic Pancreatic Ductal Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06390059EF-39 PANOVA-4P2completedEF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06006286P1/P2withdrawnA Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Cholangiocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05510427P1withdrawnPhase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Lung Cancer, Nonsmall Cell (1)

NCTAcronymPhaseStatusTitle
NCT04691817P1/P2recruitingTocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Refractory Metastatic Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05733611P2terminatedRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

PD-L1-selected Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT05661578SKYSCRAPER-11P2completedA Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Locally Advanced Osteosarcoma (1)

NCTAcronymPhaseStatusTitle
NCT05019703P2recruitingAtezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Urothelial Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05645692P2active not recruitingA Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Metastatic Papillary Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05411081P2active not recruitingTesting Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Liver Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05717400P4terminatedImproving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT05063552P2/P3active not recruitingTesting the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Haematological Malignancy (1)

NCTAcronymPhaseStatusTitle
NCT05722886DETERMINEP2/P3recruitingDETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Relapsed or Refractory Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05300282FIL_A-BEGEVP1/P2recruitingStudy of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Metastatic Malignancy (1)

NCTAcronymPhaseStatusTitle
NCT05394337P1/P2recruitingNeoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Idiopathic Pulmonary Fibrosis (1)

NCTAcronymPhaseStatusTitle
NCT05515627P1active not recruitingAtezolizumab for Idiopathic Pulmonary Fibrosis

Squamous Cell Carcinoma of the Anal Canal (1)

NCTAcronymPhaseStatusTitle
NCT05661188TIRANUSP2recruitingTiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)

BCLC Stage B Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05327738P2withdrawnYttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Combined Hepatocellular Carcinoma and Cholangiocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05211323P2active not recruitingA Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Metastatic Non Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05259319IMMUNOs-SBRTP1unknownStudy Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)

Atypical Teratoid/Rhabdoid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT05286801P1/P2active not recruitingTiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Stage II Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT05060003P2terminatedTiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Refractory Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT05468359P1/P2recruitingSafety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Glioblastoma Multiforme (1)

NCTAcronymPhaseStatusTitle
NCT05423210Early P1recruitingAtezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme

Locally Advanced or Metastatic Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT05581004P1recruitingA Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

SCLC,Extensive Stage (1)

NCTAcronymPhaseStatusTitle
NCT05595460P1active not recruitingStudy of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Advanced Alveolar Soft Part Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT05333458P2recruitingTesting Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Brain Tumor (1)

NCTAcronymPhaseStatusTitle
NCT05317858LIMITLESSP3recruitingBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Advanced Extrapulmonary Neuroendocrine Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05058651P2/P3recruitingEvaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Small Cell Neuroendocrine Carcinoma of Bladder (1)

NCTAcronymPhaseStatusTitle
NCT05312671P2recruitingAtezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Hereditary Leiomyomatosis and Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04981509P2recruitingTesting of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Colorectal Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT05243862P2active not recruitingSafety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

Colonic Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT05456165P2withdrawnStudy of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Non-Hodgkin Lymphoma, Follicular Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05315713P1/P2terminatedAn Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Intrahepatic Cholangiocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05174650P2active not recruitingTreatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Locally Advanced Skin Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05085496P1recruitingRadiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC

Peritoneal Malignant Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT05001880P2recruitingChemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Diffuse Astrocytoma, IDH-Wildtype (1)

NCTAcronymPhaseStatusTitle
NCT04729959P2active not recruitingTesting the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Castration-Resistant Prostate Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05168618AtezoCabP2recruitingCabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Gastric and Gastroesophageal Junction Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05251948P1/P2terminatedAn Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

Unresectable Gastrointestinal Stromal Tumor (GIST) (1)

NCTAcronymPhaseStatusTitle
NCT05152472ATEZOGISTP2recruitingA Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Non-squamous Non-small-cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04958811P2active not recruitingTiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Metastatic Distal Bile Duct Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04941287P2active not recruitingTesting A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Mesotheliomas Pleural (1)

NCTAcronymPhaseStatusTitle
NCT04996017AtezoMesoP3recruitingAtezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Advanced Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05159245FINPROVEP2recruitingThe Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck (1)

NCTAcronymPhaseStatusTitle
NCT05110781P2terminatedAtezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

Bile Duct Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05000294P1/P2recruitingAtezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Anal Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT07280377GOBLETP1/P2active not recruitingA Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Metastatic or Locally Advanced Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT04551521CRAFTP2completedCRAFT: The NCT-PMO-1602 Phase II Trial

Locally Advanced Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT04975958P1completedDouble/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Premenopausal HR+/HER2- Metastatic Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04819243Young-PALETTAP2recruitingPALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

Stomach Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT04933227GEJP2terminatedA Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Ovarian Endometrioid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT04510584P2withdrawnMaintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Carcinoma, Non-Small Cell Lung (1)

NCTAcronymPhaseStatusTitle
NCT04611776CATHAYAP2withdrawnA Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04802759P1/P2recruitingA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Cutaneous Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04710498P2completedNeoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

Urogenital Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04624399ABACUS-2P2recruitingNeoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer

Lung Diseases (1)

NCTAcronymPhaseStatusTitle
NCT04776447APOLOP2active not recruitingAtezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

Muscle-invasive Bladder Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04660344IMvigor011P3active not recruitingA Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

Venous Thrombosis (1)

NCTAcronymPhaseStatusTitle
NCT04649489TALENTOPP3active not recruitingA Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

Advanced Bladder Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04902040P1/P2terminatedPlinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT04817956IMPRESS-NP2recruitingImproving Public Cancer Care by Implementing Precision Medicine in Norway

Gastric Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04739202IMMUNOGASTP2completedPersonalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

Chronic Phase-Chronic Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT04793399P1/P2terminatedSafety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients

Head and Neck Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT04477759DEHARTP1completedDose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer

Advanced Unresectable or Metastatic Solid Malignancy (1)

NCTAcronymPhaseStatusTitle
NCT04632992MyTACTICP2completedA Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

NSCLC Stage II (1)

NCTAcronymPhaseStatusTitle
NCT04865250iRePP2recruitingPredicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

Locally Advanced or Metastatic Urothelial Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04602078AUREAP2completedStudy of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

Advanced Liver Cancers (1)

NCTAcronymPhaseStatusTitle
NCT04524871MORPHEUS-LIVERP1/P2recruitingA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Central Chondrosarcoma, Grade 2 (1)

NCTAcronymPhaseStatusTitle
NCT04458922P2active not recruitingTesting Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC (1)

NCTAcronymPhaseStatusTitle
NCT04245085ABC-lungP2completedABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Esophageal Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04543617SKYSCRAPER-07P3active not recruitingA Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Cutaneous Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT04020809P1active not recruitingNeoadjuvant Atezolizumab in Cutaneous Melanoma

Malignant Pleural Mesothelioma, Advanced (1)

NCTAcronymPhaseStatusTitle
NCT03786419P2withdrawnA Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Rare Tumor (1)

NCTAcronymPhaseStatusTitle
NCT04423185P2recruitingPLATFORM Study of Precision Medicine for Rare Tumors

Advanced Malignant Skin Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT04387084P1active not recruitingShort-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Carcinoma, Thymic (1)

NCTAcronymPhaseStatusTitle
NCT04321330P2completedA Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

Castration-Resistant Prostatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04404140P1terminatedA Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

NSCLC Stage IIIB~IV (1)

NCTAcronymPhaseStatusTitle
NCT04147351P2completedA Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Non-small-cell Lung Cancer Patients (1)

NCTAcronymPhaseStatusTitle
NCT03896074BEATP2active not recruitingAtezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)

Gastrointestinal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04214418MEKiAUTOP1/P2terminatedStudy of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

Metastatic Esophageal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04166721P1/P2active not recruitingWaKING: Wnt and checKpoint INhibition in Gastric Cancer

Invasive Bladder Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04134000BladderGATEP1unknownAtezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

Adult Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT04084951P1completedStudy of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

SCLC, Extensive Stage (1)

NCTAcronymPhaseStatusTitle
NCT04221529SPACEP2completedPatients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Lung Neoplasm Malignant (1)

NCTAcronymPhaseStatusTitle
NCT04059887BUDDYP4completedEvaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]

Metastatic Solid Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT04167137P1terminatedSafety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

Tumor, Solid (1)

NCTAcronymPhaseStatusTitle
NCT04196530EIK1001P1completedBDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

Breast Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT05609903AnastaseN/AcompletedAtezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer

Pancreatic Ductal Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03979066NEOiPANCP2terminatedStudy Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma

Prostate Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03821246P2recruitingNeoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Rectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04017455TARZANP2active not recruitingNeoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)

CLL Transformation (1)

NCTAcronymPhaseStatusTitle
NCT04082897MOLTOP2active not recruitingObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Stage III Hepatocellular Carcinoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT03942328P1/P2recruitingModified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Refractory Lung Non-Small Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04081688P1terminatedAtezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Limited Stage Lung Small Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03811002MPDL3280AP3active not recruitingTesting the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Non Small Cell Lung Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT03977194ELDERLYP3active not recruitingAtezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Recurrent B-Cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03892525P1terminatedStudy of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

Acute Myeloid Leukemia (AML) (1)

NCTAcronymPhaseStatusTitle
NCT03730012FLT3P1/P2completedA Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Advanced Bladder Urothelial Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03513952P2completedAtezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Bladder Urothelial Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03775265P3active not recruitingChemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Select Advanced Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT03973333P1/P2withdrawnSafety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Urothelial/Bladder Cancer, Nos (1)

NCTAcronymPhaseStatusTitle
NCT03359239P1completedAtezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

Pleural Mesothelioma Malignant Advanced (1)

NCTAcronymPhaseStatusTitle
NCT03762018BEAT-mesoP3completedBEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Metastatic Breast Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03199885P3terminatedTesting the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Neoplasm Malignant (1)

NCTAcronymPhaseStatusTitle
NCT03845166STELLAR-001P1active not recruitingA Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Advanced Malignant Solid Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT03830918P1/P2active not recruitingNiraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Clinical Stage II Esophageal Adenocarcinoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT03784326P2active not recruitingPhase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Mesothelioma, Malignant (1)

NCTAcronymPhaseStatusTitle
NCT03654833MiSTP2unknownMesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

OVARIAN CANCER (1)

NCTAcronymPhaseStatusTitle
NCT03695380P1completedA Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Penile Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03686332PERICLESP2completedPEnile Cancer Radio- and Immunotherapy CLinical Exploration Study

Carcinoma of the Cervix, Stage IVB (1)

NCTAcronymPhaseStatusTitle
NCT03556839BEATccP3completedPlatinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

Lymphoma, T-Cell, Cutaneous (1)

NCTAcronymPhaseStatusTitle
NCT03357224PARCTP2terminatedPARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)

Recurrent Diffuse Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03321643P1active not recruitingTesting the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Invasive Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03595592APTneoP3active not recruitingNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

NHL (1)

NCTAcronymPhaseStatusTitle
NCT03463057HO151DLBCLP2active not recruitingThe Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

Locally Advanced Cervical Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03612791ATEZOLACCP2completedTrial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab

Mesothelin Positive (1)

NCTAcronymPhaseStatusTitle
NCT03455556P1terminatedAnetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Metastatic Castration-Resistant Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03568656P1/P2completedStudy to Evaluate CCS1477 in Advanced Tumours

Biphasic Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT03228537P1active not recruitingAtezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Cancer of Unknown Primary Site (1)

NCTAcronymPhaseStatusTitle
NCT03498521CUPISCOP2completedA Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Stage III Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03566485P1/P2terminatedAtezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Non-small Cell Lung Cancer Stage IV (1)

NCTAcronymPhaseStatusTitle
NCT03526900ATEZO-BRAINP2completedAtezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis

HPV-Associated Cancers (1)

NCTAcronymPhaseStatusTitle
NCT03618953KingfisherP1terminatedThis is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers

HER2-positive Metastatic Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03417544P2active not recruitingAtezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Diffuse Large B Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03422523ARGOP2terminatedAtezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy

Non-Hodgkins Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03533283P1/P2active not recruitingAn Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Glioblastoma, Adult (1)

NCTAcronymPhaseStatusTitle
NCT03158389N²M²P1/P2completedNCT Neuro Master Match - N²M² (NOA-20)

Safety Issues (1)

NCTAcronymPhaseStatusTitle
NCT03620435P2unknownTrimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

Stage I Non-Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02599454P1completedAtezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Non-Small-Cell Lung (1)

NCTAcronymPhaseStatusTitle
NCT03456063P3completedA Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) (1)

NCTAcronymPhaseStatusTitle
NCT03452137IMvoke010P3terminatedA Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Stomach Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03448835PANDAP2active not recruitingNeoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers (1)

NCTAcronymPhaseStatusTitle
NCT03386721P2terminatedBasket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Gallbladder Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03201458P2completedAtezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Small Cell Lung Cancer Recurrent (1)

NCTAcronymPhaseStatusTitle
NCT03262454AtezolizumabP2unknownSequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC

Metastatic Colorectal Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02997228P3active not recruitingTesting the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Breast Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT03280563MORPHEUS HR+BCP1/P2completedA Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Advanced BRAFV600 Wild-type Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT03273153P3terminatedA Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

MSI (1)

NCTAcronymPhaseStatusTitle
NCT02982694P2terminatedStudy With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Advanced Ovarian Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03292172P1terminatedA Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03281369P1/P2completedA Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Cholangiocarcinoma Non-resectable (1)

NCTAcronymPhaseStatusTitle
NCT03267940CISP1terminatedStudy of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Recurrent Breast Inflammatory Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03202316P2active not recruitingAtezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Recurrent Non-Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02919449P1terminatedDose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

Invasive Breast Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02883062P2active not recruitingCarboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Metastatic Thyroid Gland Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03181100P2active not recruitingAtezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Advanced Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03014648NSCLCP2completedEvaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

Metastatic Colorectal Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02873195P2completedCapecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Pancreatic Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03193190P1/P2completedA Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Esophageal Cancer, Stage II (1)

NCTAcronymPhaseStatusTitle
NCT03087864PERFECTP2completedPDL-1 Targeting in Resectable Oesophageal Cancer

Fallopian Tube High Grade Serous Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02839707P2/P3active not recruitingPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

BRAF V600 Wild Type (1)

NCTAcronymPhaseStatusTitle
NCT03175432P2active not recruitingBevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Metastatic Kidney Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03050060P2terminatedImage Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

Cancer, Breast (1)

NCTAcronymPhaseStatusTitle
NCT03164993ALICEP2completedAtezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer

Advanced Gynecological Cancers (1)

NCTAcronymPhaseStatusTitle
NCT03073525P2completedA Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Hematopoietic and Lymphoid Cell Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT02862275P1active not recruitingAtezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Gynecologic Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT03101280P1completedA Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Metastatic Alveolar Soft Part Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03141684P2active not recruitingTesting Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03120676P2terminatedStudy of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Skin Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03108131P2completedCobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Recurrent Bladder Urothelial Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02844816P2completedAtezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Appendix Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03074513P2active not recruitingAtezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Asymptomatic Myeloma (1)

NCTAcronymPhaseStatusTitle
NCT02784483P1terminatedPilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Prostate Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT03024216P1completedClinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant (1)

NCTAcronymPhaseStatusTitle
NCT03016312IMbassador250P3completedA Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Ovarian Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT02659384P2completedAnti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

Nonsmall Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02994576PRINCEPSP2completedAtezolizumab as Induction Therapy in Non-small Cell Lung Cancer

Metastatic Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03115801P2terminatedA Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Urinary Tract Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02928406P3completedA Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma ) (1)

NCTAcronymPhaseStatusTitle
NCT02992912SABR-PDL1P2unknownAtezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours

Chronic Myelomonocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02935361P1/P2active not recruitingGuadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Refractory Diffuse Large B Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02926833ZUMA-6P1/P2completedStudy of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Castrate-Resistant Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02814669ATZP1completedSafety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Advanced Non-Clear Cell Kidney Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02724878P2completedStudy of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Advanced/Metastatic Tumors (1)

NCTAcronymPhaseStatusTitle
NCT02794571PKP1completedSafety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Breast Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02530489P2completedNab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Renal Cell Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02655822P1completedPhase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Lymphoma, Follicular (1)

NCTAcronymPhaseStatusTitle
NCT02631577P1/P2completedA Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

HER2-Positive Metastatic Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02605915P1completedSafety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Diffuse Large B-Cell Lymphoma, Lymphoma Follicular (1)

NCTAcronymPhaseStatusTitle
NCT02596971CHOPP1/P2completedA Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic (1)

NCTAcronymPhaseStatusTitle
NCT02594384LAM-002A/NHLP1completedA Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Myelodysplastic Syndromes (1)

NCTAcronymPhaseStatusTitle
NCT02508870P1completedA Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes

Lymphocytic Leukemia, Chronic (1)

NCTAcronymPhaseStatusTitle
NCT02500407NHLP1/P2completedA Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02409342MPDL3280AP3completedA Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Squamous Non-Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02367794NSCLCP3completedA Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Carcinoma, Non-Squamous Non-Small Cell Lung (1)

NCTAcronymPhaseStatusTitle
NCT02367781IMpower130P3completedA Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NSCLC (Non-small Cell Lung Carcinoma) (1)

NCTAcronymPhaseStatusTitle
NCT02298153P1terminatedA Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma

Non-Squamous Non-Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02008227OAKP3completedA Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT01810913P2/P3recruitingTesting Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Neoplasm Metastasis (1)

NCTAcronymPhaseStatusTitle
NCT00781612P2active not recruitingA Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Atezolizumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
MINUTENCT06031233P4recruitingOncology776
ANTELOPENCT05689671P4active not recruitingNon-Small Cell Lung Cancer Metastatic136PMID 32620471
BUDDYNCT04059887P4completedLung Neoplasm Malignant100PMID 30013197
TAILNCT03285763P4completedCarcinoma, Non-Small-Cell Lung619PMID 33737339
AstefaniaNCT04873362P3active not recruitingBreast Cancer1,188PMID 36382554
UmbrellaMAXNCT05862285P3recruitingCancer100
TIGOSNCT06646276P3recruitingExtensive-Stage Small Cell Lung Cancer530
IMAGINENCT04637594P3active not recruitingLocally Advanced Bladder Urothelial Carcinoma3
ARTEMIDE-HCC01NCT06921785P3recruitingHepatocellular Carcinoma1,220
AtezoMesoNCT04996017P3recruitingMesotheliomas Pleural162
AtezoTRIBE2NCT06733038P3recruitingColorectal Cancer238
MPDL3280ANCT03811002P3active not recruitingLimited Stage Lung Small Cell Carcinoma544PMID 36006678
MRD-GINCT05482516P3recruitingColon Adenocarcinoma20
STONE-001NCT06719336P3not yet recruitingExtensive-stage Small Cell Lung Cancer182
ALBANNCT03799835P3active not recruitingBladder Cancer517
COMETNCT06908993P3recruitingAdvanced Non Small Cell Lung Cancer133
IMbrella BNCT03768063P3active not recruitingCancer1,000
TALENTOPNCT04649489P3active not recruitingVenous Thrombosis501
LIMITLESSNCT05317858P3recruitingBrain Tumor30
MPDL3280ANCT02486718P3active not recruitingNon-Small Cell Lung Cancer1,280PMID 37903590
TACENCT04803994P3recruitingHepatocellular Carcinoma434
MK-7684ANCT05224141P3active not recruitingSmall Cell Lung Carcinoma460PMID 39230120
SKYSCRAPER-07NCT04543617P3active not recruitingEsophageal Squamous Cell Carcinoma760
APTneoNCT03595592P3active not recruitingInvasive Breast Cancer650
STELLAR-303NCT05425940P3active not recruitingColorectal Cancer901PMID 39041200
ELDERLYNCT03977194P3active not recruitingNon Small Cell Lung Cancer Metastatic510PMID 21831418
CONTACT-02NCT04446117P3active not recruitingMetastatic Prostate Cancer575PMID 40523369
IMvigor011NCT04660344P3active not recruitingMuscle-invasive Bladder Cancer761PMID 41124204
SKYSCRAPER-14NCT05904886P3active not recruitingHepatocellular Carcinoma687PMID 38861301
IMforteNCT05091567P3active not recruitingSmall-Cell Lung Cancer660PMID 40473449
COSMIC-312NCT03755791P3active not recruitingHepatocellular Carcinoma837PMID 38364832
IMbrave251NCT04770896P3active not recruitingUnresectable Hepatocellular Carcinoma557
SKYSCRAPER-02CNCT04665856P3active not recruitingSmall Cell Lung Carcinoma123
IMbrave050NCT04102098P3active not recruitingCarcinoma, Hepatocellular668PMID 41580093
AMBITIONNCT04732598P3completedBreast Cancer281
SKYSCRAPER-01NCT04294810P3completedNon-Small Cell Lung Cancer620
SKYSCRAPER-15NCT06267001P3terminatedNon-small Cell Lung Cancer (NSCLC)56
BEATccNCT03556839P3completedCarcinoma of the Cervix, Stage IVB410PMID 40968753
SKYSCRAPER-08NCT04540211P3completedEsophageal Cancer461PMID 41449151
SKYSCRAPER-03NCT04513925P3completedNon-small Cell Lung Cancer (NSCLC)829
SKYSCRAPER-02NCT04256421P3completedSmall Cell Lung Cancer490PMID 37976444
CONTACT-03NCT04338269P3terminatedCarcinoma, Renal Cell522PMID 35304832
AtTEndNCT03603184P3completedEndometrial Cancer549PMID 40590326
CONTACT-01NCT04471428P3completedCarcinoma, Non-Small-Cell Lung366PMID 38552197
EL1SSARNCT04148911P3completedTriple-Negative Breast Cancer184
BEAT-mesoNCT03762018P3completedPleural Mesothelioma Malignant Advanced400PMID 33358660
IMpassion132NCT03371017P3completedTriple Negative Breast Neoplasms595
AMETHISTANCT04487067P3completedCarcinoma, Hepatocellular152PMID 39874903
ANITANCT03598270P3completedRecurrent Ovarian Carcinoma417PMID 33318079
KATE3NCT04740918P3terminatedMetastatic Breast Cancer96
IMvoke010NCT03452137P3terminatedLocally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)406PMID 40079944
ATALANTENCT02891824P3completedOvarian Cancer614PMID 37643382
IMvigor130NCT02807636P3completedUrothelial Carcinoma1,213PMID 37954037
IPSOSNCT03191786P3completedNon-Small Cell Lung Cancer453PMID 37423228
IMpassion050NCT03726879P3completedBreast Cancer454PMID 35763704
IMpassion030NCT03498716P3terminatedTriple Negative Breast Cancer2,199PMID 39883436
MAURISNCT04028050P3completedSmall Cell Lung Carcinoma155PMID 38377176
IMpassion131NCT03125902P3completedTriple-Negative Breast Cancer653PMID 34219000
IMpower210NCT02813785P3completedCarcinoma, Non-Small-Cell Lung565
IMbassador250NCT03016312P3completedProstatic Neoplasms, Castration-Resistant759PMID 35013615
NSCLCNCT02657434P3completedNon-Small Cell Lung Cancer578PMID 35511917
IMmotion010NCT03024996P3terminatedRenal Cell Carcinoma778PMID 36099926
IMbrave150NCT03434379P3completedCarcinoma, Hepatocellular558PMID 40891895
IMpassion031NCT03197935P3completedTriple-negative Breast Cancer333PMID 32966830
IMagyn050NCT03038100P3completedOvarian Cancer1,301PMID 37625235
IMpower133NCT02763579P3completedSmall Cell Lung Carcinoma503PMID 31466854
IMvigor010NCT02450331P3terminatedCarcinoma, Transitional Cell809PMID 37601688
MPDL3280ANCT02409342P3completedNon-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer572PMID 39532375
IMmotion151NCT02420821P3completedRenal Cell Carcinoma915PMID 31079938
NSCLCNCT02367794P3completedSquamous Non-Small Cell Lung Cancer1,021
IMpower130NCT02367781P3completedCarcinoma, Non-Squamous Non-Small Cell Lung723PMID 31122901
IMpower150NCT02366143P3completedCarcinoma, Non-Small-Cell Lung1,202PMID 40379995
OAKNCT02008227P3completedNon-Squamous Non-Small Cell Lung Cancer1,225PMID 37004206
NSCLCNCT02409355P3terminatedNon-Small Cell Lung Cancer8
IMPRESS-NNCT04817956P2recruitingCancer Metastatic3,000PMID 35568909
ATHENEANCT07153445P2recruitingNon Small Cell Lung Cancer97
TAPISTRYNCT04589845P2active not recruitingSolid Tumors920PMID 40086048
SEZanneNCT07155174P2recruitingSmall Cell Lung Cancer180
PhotonABNCT06339424P2recruitingHepatocellular Carcinoma45
AB-LATE02NCT04727307P2recruitingHepatocellular Carcinoma202
StereosarcNCT03548428P2recruitingSarcoma103PMID 32967883
IMCODE003NCT05968326P2recruitingAdenocarcinoma, Pancreatic Ductal260
PhenixNCT07263438P2recruitingGlioblastoma59
COGNITION-GUIDENCT05332561P2recruitingEarly-stage Breast Cancer240
Triple-BNCT01898117P2active not recruitingBreast Cancer304PMID 33084020
ASPIRENCT07018947P2not yet recruitingResectable Hepatocellular Carcinoma90
ATTACHNCT07239245P2recruitingResectable Hepatocellular Carcinoma With High Risk of Recurrence30
TOMBOLANCT04138628P2active not recruitingBladder Cancer154
ProtonABNCT06133062P2recruitingHepatocellular Carcinoma Non-resectable45
NAUTIKA1NCT04302025P2recruitingNon-small Cell Lung Cancer99
ProTargetNCT04341181P2recruitingCancer300PMID 36814246
TONIC-3NCT06342037P2recruitingMetastatic Breast Cancer60
TERTIONCT05528952P2recruitingHepatocellular Carcinoma105PMID 37516867
SATURN-STSNCT07049848P2recruitingSoft Tissue Sarcoma50
SPRINGNCT06692491P2not yet recruitingRare Tumour200
IMperatorNCT06331598P2withdrawnSolid Tumors0
ECTOP-1030NCT06572722P2withdrawnLung Cancer0
VIRO-25NCT06463665P2recruitingAdvanced Non-squamous Non-small-cell Lung Cancer142
CARRY-ONNCT06663098P2recruitingExtensive Stage Small Cell Lung Cancer (ES-SCLC)142PMID 23890065
BladderSparNCT03697850P2active not recruitingBladder Cancer79
FASTIMMUNENCT05703997P2not yet recruitingSmall Cell Lung Carcinoma20PMID 34789537
LCNEC-ALPINENCT05470595P2active not recruitingLarge Cell Neuroendocrine Carcinoma of the Lung67
TAPURNCT02693535P2recruitingLymphoma, Non-Hodgkin4,200PMID 36753688
SMARTNCT06161532P2recruitingSmall Cell Carcinoma of the Bladder60PMID 40548513
MoST-TAPNCT06003621P2recruitingSolid Tumor, Adult96
Cabatezo-1NCT05859217P2not yet recruitingLung Cancer40
TIRANUSNCT05661188P2recruitingSquamous Cell Carcinoma of the Anal Canal45
BOUQUETNCT04931342P2active not recruitingOvarian Cancer176
FLORANCT05690048P2recruitingImmunotherapy48PMID 40930564
STRATUMNCT05377034P2recruitingLocally Advanced Hepatocellular Carcinoma100
(HCC)NCT06789757P2recruitingHepatocellular Carcinoma19PMID 31954490
MOABNCT06069726P2recruitingRecurrent Glioblastoma80
Young-PALETTANCT04819243P2recruitingPremenopausal HR+/HER2- Metastatic Breast Cancer178
AGADIRNCT03915678P2recruitingSolid Tumor, Adult247
DANTENCT03421288P2active not recruitingGastric Cancer677PMID 37963317
DRUPNCT02925234P2recruitingCancer1,550PMID 37424386
KirrosNCT06096779P2recruitingHepatocellular Carcinoma30
ASPRIANCT04434040P2recruitingBreast Cancer40
APOLONCT04776447P2active not recruitingLung Diseases38
GEJNCT05836584P2active not recruitingClinical Stage I Gastric Cancer AJCC v8240
ATEZOGISTNCT05152472P2recruitingUnresectable Gastrointestinal Stromal Tumor (GIST)110
CAPTIV-8NCT04273061P2recruitingBreast Cancer200PMID 31011208
TIRACANNCT05483400P2recruitingHead and Neck Neoplasms97
ATREZZONCT04759248P2active not recruitingBreast Cancer55
AMG757NCT06830694P2recruitingSmall Cell Carcinoma of Lung50
NEO-TIMNCT04722575P2active not recruitingMelanoma95
BEATNCT03896074P2active not recruitingNon-small-cell Lung Cancer Patients206
ANTONIONCT05118724P2active not recruitingColorectal Cancer80
ACHILESNCT03540420P2active not recruitingSmall-cell Lung Cancer212
EMPHASISNCT05516628P2recruitingHepatocellular Carcinoma30
AZALEANCT06690840P2recruitingTriple Negative Breast Cancer45
AtezoCabNCT05168618P2recruitingCastration-Resistant Prostate Carcinoma33
HO151DLBCLNCT03463057P2active not recruitingNHL109PMID 40249860
MOLTONCT04082897P2active not recruitingCLL Transformation28PMID 39270702
iRePNCT04865250P2recruitingNSCLC Stage II20
RT-ImmuneNCT03474094P2active not recruitingSarcoma,Soft Tissue62
BoBNCT03767075P2recruitingAdvanced Solid Tumor1,000
FINPROVENCT05159245P2recruitingAdvanced Cancer250
OCSCCNCT05681039P2active not recruitingSquamous Cell Carcinoma29
PANDANCT03448835P2active not recruitingStomach Cancer20PMID 38191613
INTEGRATENCT04563338P2active not recruitingHepatocellular Carcinoma36
BARBICANNCT05498896P2active not recruitingTriple Negative Breast Cancer146
ADAPTABLENCT05781308P2active not recruitingNon Small Cell Lung Cancer156
IMMUNOGASTNCT04739202P2completedGastric Adenocarcinoma54
ABACUS-2NCT04624399P2recruitingUrogenital Cancer58
DYNAMICNCT04954339P2completedHepatocellular Carcinoma40PMID 28130846
RANNCT05007769P2withdrawnNon-small Cell Lung Cancer0
GUNSNCT04812366P2recruitingProstate Cancer315
ALERT-HCCNCT05992220P2recruitingHepatocellular Carcinoma138
NSCLCNCT04367311P2active not recruitingLung Cancer100
EndoBARRNCT03694262P2completedEndometrial Cancer30PMID 28403786
CATHAYANCT04611776P2withdrawnCarcinoma, Non-Small Cell Lung0
ABATENCT04289779P2active not recruitingBladder Cancer46
SKYSCRAPER-11NCT05661578P2completedPD-L1-selected Solid Tumors64
EF-39 PANOVA-4NCT06390059P2completedMetastatic Pancreatic Ductal Adenocarcinoma84
NSCLCNCT05746481P2terminatedNon-small Cell Lung Cancer3
AB7NCT04829383P2active not recruitingUnresectable Hepatocellular Carcinoma50
BELLANCT04739670P2unknownMetastatic Triple Negative Breast Cancer31
INDIGONCT06713798P2withdrawnMetastatic Cancer Lung0
TARZANNCT04017455P2active not recruitingRectal Cancer38
SKYSCRAPER-09NCT04665843P2completedSquamous Cell Carcinoma of Head and Neck123
MSSNCT06603818P2withdrawnMicrosatellite Stable Metastatic Colorectal Cancer0
FLUORONCT04962126P2active not recruitingFollicular Lymphoma15PMID 41949430
ROMENCT04591431P2unknownBreast Cancer400PMID 41963505
BEACONNCT03363867P2unknownOvarian Cancer30
LOST-BNCT05537402P2terminatedHepatocellular Carcinoma1
ATEZOLACCNCT03612791P2completedLocally Advanced Cervical Cancer189
SPACENCT04221529P2completedSCLC, Extensive Stage70
GFPC 06-2018NCT04042558P2completedNSCLC Stage IIIB150PMID 36801605
DEMANDNCT04224636P2recruitingHepatocellular Carcinoma Non-resectable106PMID 35081747
ATELIERNCT03340558P2withdrawnMetastatic Colorectal Cancer0
SKYSCRAPER-04NCT04300647P2completedCervical Cancer172PMID 38858106
AURORANCT05038657P2unknownSquamous Cell Carcinoma36PMID 37726695
ATHENANCT03818061P2completedHead and Neck Neoplasms33
CRAFTNCT04551521P2completedMetastatic or Locally Advanced Malignancies72PMID 34808524
BIS-ProgramNCT05180006P2terminatedBreast Cancer33
CUPISCONCT03498521P2completedCancer of Unknown Primary Site529PMID 39096924
VolATILNCT03946358P2completedSquamous Cell Carcinoma of the Head and Neck47PMID 35928870
MEGALiTNCT04185831P2active not recruitingSolid Tumor167
SIRTCINCT04659382P2unknownMetastatic Colorectal Cancer52PMID 28781171
SABR-PDL1NCT02992912P2unknownPatients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )138PMID 38519913
TELMANCT03836066P2completedNon Small Cell Lung Cancer41PMID 36520426
neoMonoNCT04770272P2terminatedTriple-negative Breast Cancer442PMID 24562447
TREASURENCT04462276P2completedSmall Cell Lung Cancer Extensive Stage68PMID 36153496
AtezolizumabNCT03262454P2unknownSmall Cell Lung Cancer Recurrent35
ABC-lungNCT04245085P2completedEGFRmutant Stage IIIB/C or IV Non-squamous NSCLC95PMID 40023017
MatchNCT04622228P2completedCarcinoma, Small Cell Lung56
CeLEBrATENCT04730999P2completedSmall Cell Lung Cancer54PMID 19934295
RamAtezo-1NCT03689855P2completedNon-small Cell Lung Cancer21PMID 34409776
ORIGINNCT04480372P2completedMalignant Pleural Mesothelioma68
ImmunoCobiVemNCT02902029P2completedMalignant Melanoma186
PIONEERNCT04939480P2completedSquamous Cell Carcinoma of Head and Neck20
ABE-LIVERNCT05448677P2terminatedHepatocellular Carcinoma3
MyTACTICNCT04632992P2completedAdvanced Unresectable or Metastatic Solid Malignancy252PMID 41392942
CHANCENCT03976518P2completedNon-Small Cell Lung Cancer43PMID 28840008
AUREANCT04602078P2completedLocally Advanced or Metastatic Urothelial Carcinoma82
CHEERSNCT03511391P2completedUrothelial Carcinoma99PMID 37410476
SKYROCKETNCT05034055P2unknownNon-small Cell Lung Cancer45
ARIANESNCT04276376P2terminatedSolid Tumor130
ATRACTIBNCT04408118P2completedMetastatic Breast Cancer100PMID 40467896
GEJNCT04933227P2terminatedStomach Neoplasms29
MiSTNCT03654833P2unknownMesothelioma, Malignant186PMID 35157829
CLIMBNCT03698461P2completedColorectal Neoplasms20
ALICENCT03164993P2completedCancer, Breast68PMID 36482103
PERICLESNCT03686332P2completedPenile Cancer32PMID 37487169
NSCLCNCT02927301P2completedNon-Small Cell Lung Cancer181PMID 36097216
MARIO-3NCT03961698P2unknownBreast Cancer91
AtezoTRIBENCT03721653P2completedMetastatic Colorectal Cancer218PMID 38865678
ECLIPSENCT03395899P2completedBreast Cancer71
HCCNCT04541173P2terminatedHepatocellular Carcinoma6
AZTECNCT03464942P2completedBreast Cancer54
PRINCEPSNCT02994576P2completedNonsmall Cell Lung Cancer60
TARANCT04690855P2terminatedBreast Cancer1
SCLCNCT04610684P2terminatedSmall-cell Lung Cancer3
ATEZO-BRAINNCT03526900P2completedNon-small Cell Lung Cancer Stage IV40PMID 37603816
PARCTNCT03357224P2terminatedLymphoma, T-Cell, Cutaneous26
GELATONCT03147040P2terminatedBreast Cancer23PMID 37038006
DYNAMICNCT03818997P2withdrawnEsophageal Cancer0
NSCLCNCT03014648P2completedAdvanced Non-small Cell Lung Cancer28
VinMetAtezoNCT03801304P2completedNon-small Cell Lung Cancer80PMID 31894704
ARGONCT03422523P2terminatedDiffuse Large B Cell Lymphoma53
PREDIXIIHER2NCT03894007P2terminatedEarly-stage Breast Cancer6
CONTESSA TRIONCT03952325P2terminatedBreast Cancer294
MODULNCT02291289P2completedColorectal Cancer1,044PMID 36921494
COM-IT-1NCT03644823P2terminatedNon-small Cell Lung Cancer21
G1T28NCT03041311P2completedSmall Cell Lung Cancer107PMID 34777341
NEO-VCNCT02303951P2terminatedMalignant Melanoma47PMID 36648215
KATE2NCT02924883P2completedMetastatic Breast Cancer202PMID 33002436
NEOiPANCNCT03979066P2terminatedPancreatic Ductal Adenocarcinoma1
PERFECTNCT03087864P2completedEsophageal Cancer, Stage II40PMID 30902915
B-F1RSTNCT02848651P2completedNon-Small Cell Lung Cancer153PMID 35422531
BIRCHNCT02031458P2completedNon-Small Cell Lung Cancer667PMID 38367405
IMmotion150NCT01984242P2completedRenal Cell Carcinoma305PMID 32233107
PD-L1NCT01846416P2completedNon-Small Cell Lung Cancer138

Terminated and withdrawn Atezolizumab trials (144)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

All Atezolizumab trials (746)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT04817956IMPRESS-NImproving Public Cancer Care by Implementing Precision Medicine in NorwayP2recruiting3,000Oslo University HospitalApr 2021
NCT05620771Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-riskP2recruiting200Northwestern UniversityNov 2022
NCT05468359Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsP1/P2recruiting64St. Jude Children's Research HospitalNov 2022
NCT07195695Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsP3recruiting400Boehringer IngelheimJan 2026
NCT07153445ATHENEANeoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)P2recruiting97Fundación GECPJul 2025
NCT07293468BIIRTHComparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)P2/P3recruiting106Tuen Mun HospitalApr 2024
NCT04873362AstefaniaA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyP3active not recruiting1,188Hoffmann-La RocheMay 2021
NCT06725121MacroTransUsing Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before TransplantP1/P2recruiting48University Health Network, TorontoDec 2024
NCT07226999Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerP2/P3recruiting550PfizerDec 2025
NCT05538091Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal CancerP2recruiting48Ronald BuckanovichMay 2023
NCT05862285UmbrellaMAXA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyP3recruiting100Hoffmann-La RocheJun 2023
NCT06043674Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationP2recruiting70Christine RyanJan 2024
NCT04589845TAPISTRYTumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyP2active not recruiting920Hoffmann-La RocheJan 2021
NCT05096715Atezolizumab+Bevacizumab+SBRT in Unresectable HCCP1recruiting20Massachusetts General HospitalAug 2022
NCT07322341SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung CancerP2not yet recruiting32University of WashingtonSep 2026
NCT07291076HCCA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)P1/P2recruiting198Bristol-Myers SquibbMar 2026
NCT07155174SEZanneA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerP2recruiting180AbbVieNov 2025
NCT06646276TIGOSA Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).P3recruiting530Bristol-Myers SquibbFeb 2025
NCT06898957(DeLLphi-310)Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)P1active not recruiting29AmgenMay 2025
NCT04989283Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung CancerP2withdrawn0National Cancer Institute (NCI)Sep 2021
NCT06339424PhotonABAtezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular CarcinomaP2recruiting45Chang Gung Memorial HospitalMar 2024
NCT04727307AB-LATE02Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II TrialP2recruiting202University Hospital, MontpellierFeb 2021
NCT03548428StereosarcStereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)P2recruiting103Centre Antoine LacassagneJun 2020
NCT05968326IMCODE003A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACP2recruiting260Genentech, Inc.Oct 2023
NCT07170592A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor PatientsP1not yet recruiting24Bionoxx Inc.Jan 2027
NCT07190833A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)P1recruiting27Bionoxx Inc.Mar 2026
NCT07263438PhenixEfficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 TrialP2recruiting59Centre Hospitalier Universitaire VaudoisNov 2025
NCT06618664A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular CarcinomaP3recruiting590Suzhou Suncadia Biopharmaceuticals Co., Ltd.Oct 2024
NCT05332561COGNITION-GUIDEGenomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)P2recruiting240German Cancer Research CenterJun 2023
NCT03228667QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsP2active not recruiting40ImmunityBio, Inc.Dec 2018
NCT01898117Triple-BTriple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast CancerP2active not recruiting304The Netherlands Cancer InstituteJul 2013
NCT07227597MK-6070A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)P1/P2recruiting170Merck Sharp & Dohme LLCJan 2026
NCT07317414β-alanine in the Treatment of Advanced Hepatocellular CarcinomaP2recruiting158Peking Union Medical College HospitalDec 2025
NCT07018947ASPIREStudy to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCCP2not yet recruiting90Fundacion Clinic per a la Recerca BiomédicaNov 2025
NCT07239245ATTACHStudy to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular CarcinamoP2recruiting30Cancer Institute and Hospital, Chinese Academy of Medical SciencesNov 2025
NCT04138628TOMBOLATreatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical CystectomyP2active not recruiting154Jørgen Bjerggaard JensenMar 2020
NCT06109272LIVIGNO-2A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)P2/P3recruiting660AbbVieJan 2024
NCT06133062ProtonABAtezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular CarcinomaP2recruiting45Chang Gung Memorial HospitalNov 2023
NCT04637594IMAGINETrying to Find the Correct Length of Treatment With Immune Checkpoint TherapyP3active not recruiting3Alliance for Clinical Trials in OncologyMay 2022
NCT03424005Morpheus-panBCA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerP1/P2recruiting792Hoffmann-La RocheMar 2018
NCT06760481TIGERPhase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)P1active not recruiting7M.D. Anderson Cancer CenterApr 2025
NCT04929223INTRINSICA Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)P1recruiting542Hoffmann-La RocheOct 2021
NCT06680258A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyP3not yet recruiting740Tempest TherapeuticsDec 2025
NCT04630730Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBCP2active not recruiting46Swiss Cancer InstituteJun 2022
NCT04302025NAUTIKA1A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)P2recruiting99Genentech, Inc.Nov 2020
NCT06632327Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerP3recruiting1,100Alliance for Clinical Trials in OncologyDec 2024
NCT04341181ProTargetProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingP2recruiting300Ulrik LassenAug 2020
NCT00781612A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesP2active not recruiting720Genentech, Inc.Oct 2008
NCT05300282FIL_A-BEGEVStudy of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma PatientsP1/P2recruiting122Fondazione Italiana Linfomi - ETSFeb 2023
NCT06342037TONIC-3NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialP2recruiting60The Netherlands Cancer InstituteJun 2024
NCT05286801Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsP1/P2active not recruiting86National Cancer Institute (NCI)Nov 2022
NCT06921785ARTEMIDE-HCC01Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaP3recruiting1,220AstraZenecaMay 2025
NCT03148418A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)P3active not recruiting382Hoffmann-La RocheSep 2017
NCT05528952TERTIOEvaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular CarcinomaP2recruiting105Centre Hospitalier Universitaire de BesanconSep 2022
NCT06439485Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 FusionP1/P2recruiting25M.D. Anderson Cancer CenterNov 2024
NCT07545954DSP-0390 in Combination With Atezolizumab for Small Cell Lung CancerP1not yet recruiting20Washington University School of MedicineJul 2026
NCT07113691TIARAIadademstat + SBRT With Atezo in ES-SCLCP1recruiting15Yale UniversityJan 2026
NCT07049848SATURN-STSSATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue SarcomaP2recruiting50M.D. Anderson Cancer CenterSep 2025
NCT07461675Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver ResectionP3not yet recruiting30University of Geneva, SwitzerlandMar 2026
NCT07281664Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular CarcinomaN/Anot yet recruiting30Third Affiliated Hospital, Sun Yat-Sen UniversityJan 2026
NCT06692491SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGSP2not yet recruiting200Peking University Shenzhen HospitalJan 2025
NCT07339059Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerP2recruiting35Bindu R PotugariJun 2026
NCT05770102DETERMINEDETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) DispositionP2/P3recruiting30Cancer Research UKOct 2023
NCT05722886DETERMINEDETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolP2/P3recruiting825Cancer Research UKMar 2023
NCT05312671Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder CancerP2recruiting63Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJun 2022
NCT07388524Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialP3not yet recruiting336National Cancer Institute (NCI)Jun 2026
NCT06331598IMperatorA Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)P2withdrawn0Hoffmann-La RocheNov 2024
NCT06572722ECTOP-1030Perioperative Immunotherapy for NSCLC (ECTOP-1030)P2withdrawn0Fudan UniversitySep 2024
NCT07543510Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular CarcinomaN/Anot yet recruiting38Third Affiliated Hospital, Sun Yat-Sen UniversityMay 2026
NCT05423210Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma MultiformeEarly P1recruiting12Stony Brook UniversityOct 2022
NCT03942328Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerP1/P2recruiting85Mayo ClinicSep 2019
NCT05984511TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTTN/Arecruiting234Third Affiliated Hospital, Sun Yat-Sen UniversityAug 2023
NCT06463665VIRO-25Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerP2recruiting142Genelux CorporationSep 2024
NCT07472517DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemotherapyP3recruiting670Boehringer IngelheimApr 2026
NCT06287775Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerP1/P2recruiting45National Cancer Institute (NCI)Apr 2025
NCT06754501A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown PrimaryP2active not recruiting4M.D. Anderson Cancer CenterApr 2025
NCT04996017AtezoMesoAtezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)P3recruiting162Gruppo Oncologico Italiano di Ricerca ClinicaDec 2021
NCT06551142PanTumor-101A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)P1recruiting845GlaxoSmithKlineSep 2024
NCT06663098CARRY-ONAtezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).P2recruiting142Gruppo Oncologico Italiano di Ricerca ClinicaJan 2025
NCT04802759A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerP1/P2recruiting316Hoffmann-La RocheJun 2021
NCT06733038AtezoTRIBE2FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.P3recruiting238Gruppo Oncologico del Nord-OvestNov 2024
NCT06712355Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerP3recruiting621BioNTech SEFeb 2025
NCT05142696A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabP1/P2active not recruiting24Novartis PharmaceuticalsJul 2022
NCT05546879Liver-NET1Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCCP1active not recruiting43University Hospital, GrenobleMar 2023
NCT07166406Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialP3recruiting226NRG OncologyFeb 2026
NCT07407933A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid TumorsP1/P2recruiting118MediLink Therapeutics (Suzhou) Co., Ltd.Mar 2026
NCT03811002MPDL3280ATesting the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)P3active not recruiting544National Cancer Institute (NCI)Jul 2019
NCT03697850BladderSparAtezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical CystectomyP2active not recruiting79UNICANCERDec 2018
NCT04712643A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaP3active not recruiting342Hoffmann-La RocheMar 2021
NCT05703997FASTIMMUNEFASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy InductionP2not yet recruiting20Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoJan 2023
NCT05470595LCNEC-ALPINEA Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the LungP2active not recruiting67Technische Universität DresdenJan 2022
NCT07276100Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and BevacizumabP2recruiting15IRCCS Azienda Ospedaliero-Universitaria di BolognaJan 2026
NCT06771622Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid TumorsP1/P2active not recruiting500FBD Biologics LimitedMar 2025
NCT07172412Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerP2not yet recruiting165Tianjin Medical University Cancer Institute and HospitalNov 2025
NCT07284121A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practicerecruiting700Hoffmann-La RocheJul 2025
NCT06031233MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieP4recruiting776IsalaSep 2023
NCT05482516MRD-GIEvaluating Novel Therapies in ctDNA Positive GI CancersP3recruiting20Georgetown UniversityMar 2023
NCT05394337Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial CarcinomaP1/P2recruiting10M.D. Anderson Cancer CenterFeb 2023
NCT05109052Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular CarcinomaP1/P2withdrawn0University of RochesterSep 2022
NCT07280377GOBLETA Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and AtezolizumabP1/P2active not recruiting122Oncolytics BiotechOct 2021
NCT02693535TAPURTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerP2recruiting4,200American Society of Clinical OncologyMar 2016
NCT04919382Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung CancerP2recruiting56Dwight OwenJan 2022
NCT06719336STONE-001Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)P3not yet recruiting182Anhui Shi, MDDec 2024
NCT06717243STRATUSGenomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)recruiting111Oncology Center of Biochemical Education And ResearchFeb 2025
NCT06161532SMARTSacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...P2recruiting60National Cancer Institute (NCI)Aug 2024
NCT06003621MoST-TAPTiragolumab and Atezolizumab in Advanced Pan-cancer PatientsP2recruiting96OmicoDec 2023
NCT03614949SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical CancerP2active not recruiting21H. Lee Moffitt Cancer Center and Research InstituteJan 2019
NCT03799835ALBANAtezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer PatientsP3active not recruiting517UNICANCERJan 2019
NCT05999812Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal CancerP2active not recruiting22University of Texas Southwestern Medical CenterDec 2023
NCT05058651Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the LungP2/P3recruiting189National Cancer Institute (NCI)Jun 2022
NCT05652686PT217A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)P1/P2recruiting203Phanes TherapeuticsSep 2023
NCT06294548A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCCP1/P2recruiting45University of Alabama at BirminghamJul 2025
NCT05361395ES-SCLCFirst-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)P1active not recruiting184AmgenAug 2022
NCT07059494Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver TransplantP4recruiting40Icahn School of Medicine at Mount SinaiJun 2026
NCT06823375SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein ThrombosisP2recruiting40Chinese University of Hong KongJul 2025
NCT05935774OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung CancerP2withdrawn0University of WashingtonDec 2023
NCT05542407ONC201 and Atezolizumab in Obesity-Driven Endometrial CancerP1recruiting58UNC Lineberger Comprehensive Cancer CenterOct 2023
NCT05581004A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsP1recruiting450Genentech, Inc.Oct 2022
NCT06908993COMETTepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedP3recruiting133Intergroupe Francophone de Cancerologie ThoraciqueDec 2025
NCT03768063IMbrella BA Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyP3active not recruiting1,000Hoffmann-La RocheFeb 2019
NCT05733598Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCP2recruiting60Replimune, Inc.Aug 2024
NCT04423185PLATFORM Study of Precision Medicine for Rare TumorsP2recruiting770Cancer Institute and Hospital, Chinese Academy of Medical SciencesAug 2020
NCT07093762Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLCnot yet recruiting35Fuzhou General HospitalAug 2025
NCT05859217Cabatezo-1A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)P2not yet recruiting40Jun Zhang, MD, PhDDec 2024
NCT06110572TESSERACTPhase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body IrradiationP1/P2recruiting18Vanderbilt-Ingram Cancer CenterApr 2024
NCT05661188TIRANUSTiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)P2recruiting45Grupo Espanol Multidisciplinario del Cancer DigestivoFeb 2023
NCT03708224Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckP2recruiting55Alain AlgaziMar 2019
NCT06784947Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal CancerP2active not recruiting13University of Colorado, DenverMar 2025
NCT06478693A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCCP1recruiting70Myeloid TherapeuticsJul 2024
NCT06099418Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.P2withdrawn0Nykode Therapeutics ASAApr 2024
NCT04931342BOUQUETA Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsP2active not recruiting176Hoffmann-La RocheOct 2021
NCT05690048FLORAFecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)P2recruiting48Michael DillJul 2025
NCT06332755LB-LR1109Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLCP1recruiting76LG ChemJun 2024
NCT04649489TALENTOPA Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevP3active not recruiting501Jia FanApr 2021
NCT06066138A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingP1recruiting30National Cancer Institute (NCI)Nov 2025
NCT05377034STRATUMMultinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC PatientsP2recruiting100National Cancer Centre, SingaporeOct 2022
NCT04471727A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)P1/P2active not recruiting232Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Dec 2020
NCT06789757(HCC)The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)P2recruiting19Inova Health Care ServicesFeb 2025
NCT06731270Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent ImmunotherapyP2recruiting20Emory UniversityApr 2025
NCT06069726MOABA Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB TrialP2recruiting80Duke UniversityMar 2024
NCT06584071A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCP1/P2not yet recruiting140Biotheus Inc.Dec 2024
NCT06444815STEALTH-001A Study of VET3-TGI in Patients With Solid TumorsP1recruiting60KaliVir ImmunotherapeuticsSep 2024
NCT06031441A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsP1recruiting250Genentech, Inc.Nov 2023
NCT05019703Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyP2recruiting40M.D. Anderson Cancer CenterApr 2023
NCT05340309Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung CancerP2active not recruiting5University of Southern CaliforniaDec 2022
NCT05468489To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCP3active not recruiting200Shanghai Henlius BiotechNov 2022
NCT05039281Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaP1/P2recruiting6M.D. Anderson Cancer CenterSep 2022
NCT04981509Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerP2recruiting65National Cancer Institute (NCI)Jun 2022
NCT04819243Young-PALETTAPALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo StudyP2recruiting178Samsung Medical CenterAug 2021
NCT03915678AGADIRAtezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid TumorsP2recruiting247Institut BergoniéMar 2021
NCT04721132Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver CancerP2active not recruiting16M.D. Anderson Cancer CenterFeb 2021
NCT04449874A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationP1active not recruiting498Genentech, Inc.Jul 2020
NCT04160494D2C7-IT With Atezolizumab for Recurrent GliomasP1active not recruiting18Darell BignerFeb 2020
NCT03756298Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast CancerP2active not recruiting284National Cancer Center, KoreaJan 2019
NCT03421288DANTEStudy of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune ResponsivenessP2active not recruiting677Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestSep 2018
NCT03202316Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast CancerP2active not recruiting37M.D. Anderson Cancer CenterAug 2017
NCT03125928Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast CancerP2active not recruiting16Fox Chase Cancer CenterJun 2017
NCT02935361Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedP1/P2active not recruiting33University of Southern CaliforniaNov 2016
NCT02925234DRUPThe Drug Rediscovery Protocol (DRUP Trial)P2recruiting1,550The Netherlands Cancer InstituteAug 2016
NCT06096779KirrosA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisP2recruiting30Genentech, Inc.Jul 2024
NCT04434040ASPRIAAtezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)P2recruiting40Dana-Farber Cancer InstituteJul 2020
NCT05063552Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersP2/P3active not recruiting430National Cancer Institute (NCI)Mar 2023
NCT04185883Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)P1active not recruiting610AmgenDec 2019
NCT05327738Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular CarcinomaP2withdrawn0OHSU Knight Cancer InstituteDec 2022
NCT06616623Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerP1recruiting24Dwight OwenDec 2024
NCT05317858LIMITLESSBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsP3recruiting30InSightecAug 2022
NCT03281954Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboP3active not recruiting1,550NSABP Foundation IncDec 2017
NCT04776447APOLOAtezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)P2active not recruiting38Fundación GECPJun 2021
NCT05836584GEJTesting Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) CancerP2active not recruiting240National Cancer Institute (NCI)Dec 2023
NCT05765084Immuno-MESODECIntegration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural MesotheliomaP1/P2recruiting15University Hospital, AntwerpFeb 2023
NCT05185505Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan CriteriaP4recruiting24The Methodist Hospital Research InstituteJan 2023
NCT05152472ATEZOGISTA Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard TreatmentsP2recruiting110Centre Leon BerardJan 2022
NCT04486352EndoMAPA Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerP1/P2recruiting148Alliance Foundation Trials, LLC.Oct 2021
NCT04273061CAPTIV-8Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible SensitivityP2recruiting200British Columbia Cancer AgencyJun 2020
NCT05434234A Study of YL201 in Patients With Advanced Solid TumorsP1/P2recruiting312MediLink Therapeutics (Suzhou) Co., Ltd.May 2022
NCT05483400TIRACANOpen Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid TumorsP2recruiting97University Medical Center GroningenOct 2023
NCT04691817Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based TherapyP1/P2recruiting28Abramson Cancer Center at Penn MedicineJul 2023
NCT04524871MORPHEUS-LIVERA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)P1/P2recruiting518Hoffmann-La RocheNov 2020
NCT03170960Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsP1active not recruiting914ExelixisSep 2017
NCT03074513Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsP2active not recruiting133M.D. Anderson Cancer CenterMar 2017
NCT05085496Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCCP1recruiting12City of Hope Medical CenterApr 2022
NCT05703971Acclaim-3Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC PatientsP1/P2recruiting62Genprex, Inc.May 2024
NCT04467723Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLCP1/P2recruiting25University of Kansas Medical CenterMay 2022
NCT02486718MPDL3280AStudy to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]P3active not recruiting1,280Hoffmann-La RocheOct 2015
NCT05047250A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung CancerP3active not recruiting60Hoffmann-La RocheJun 2022
NCT04387084Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyP1active not recruiting10University of Southern CaliforniaAug 2020
NCT06537310A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid TumorsP1active not recruiting34Hoffmann-La RocheSep 2024
NCT06179069A Study of ZL-1310 in Subjects With Small Cell Lung CancerP1recruiting339Zai Lab (Shanghai) Co., Ltd.Jan 2024
NCT05595460Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLCP1active not recruiting21RayzeBio, Inc.Oct 2022
NCT04803994TACEThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular CarcinomaP3recruiting434Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestJul 2021
NCT03181100Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid CancerP2active not recruiting50M.D. Anderson Cancer CenterJul 2017
NCT05878691A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.P1active not recruiting320Glenmark Specialty S.A.Jun 2022
NCT06496568A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated CancersP1active not recruiting30Hoffmann-La RocheDec 2023
NCT05411081Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialP2active not recruiting200National Cancer Institute (NCI)Mar 2023
NCT04696575Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung CancerP2recruiting28Roswell Park Cancer InstituteJul 2021
NCT04759248ATREZZOStudy With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast CancerP2active not recruiting55SOLTI Breast Cancer Research GroupMar 2021
NCT06492954AflacST2301Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaP1recruiting12Emory UniversityJul 2026
NCT06830694AMG757Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI TreatmentP2recruiting50Se-Hoon LeeMay 2025
NCT07157969ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCCP2recruiting300Peking Union Medical College HospitalFeb 2025
NCT05944237HTL0039732 in Participants With Advanced Solid TumoursP1/P2recruiting150Cancer Research UKJul 2023
NCT05797493PICASSOPanomic Approach to Immune-Connected Assays in Small Cell Lung Cancerrecruiting100Fondazione Policlinico Universitario Agostino Gemelli IRCCSOct 2022
NCT05000294Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesP1/P2recruiting29University of FloridaDec 2021
NCT05112965An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)P3active not recruiting49Hoffmann-La RocheDec 2021
NCT04722575NEO-TIMCombination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable MelanomaP2active not recruiting95Fondazione Melanoma OnlusOct 2020
NCT03321643Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell LymphomaP1active not recruiting24National Cancer Institute (NCI)Sep 2018
NCT03237780Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerP2active not recruiting72National Cancer Institute (NCI)Jul 2018
NCT04214262Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung CancerP3active not recruiting415National Cancer Institute (NCI)Aug 2020
NCT05224141MK-7684APembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)P3active not recruiting460Merck Sharp & Dohme LLCMar 2022
NCT05825625NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKingP2active not recruiting35Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestMay 2023
NCT03775265Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerP3active not recruiting475National Cancer Institute (NCI)Jun 2019
NCT02997228Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT StudyP3active not recruiting120National Cancer Institute (NCI)Jan 2018
NCT03896074BEATAtezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)P2active not recruiting206Fondazione Ricerca TraslazionaleMar 2020
NCT04186013Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncerP2active not recruiting39Spanish Oncology Genito-Urinary GroupSep 2019
NCT03845166STELLAR-001A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsP1active not recruiting325ExelixisMar 2019
NCT02839707Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerP2/P3active not recruiting444National Cancer Institute (NCI)Jun 2017
NCT05333458Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM TrialP2recruiting27National Cancer Institute (NCI)Aug 2022
NCT07235293A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.P2recruiting90Kahr Bio Australia Pty LtdJan 2026
NCT05515627Atezolizumab for Idiopathic Pulmonary FibrosisP1active not recruiting24Cedars-Sinai Medical CenterFeb 2023
NCT05118724ANTONIOAtezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for OxaliplatinP2active not recruiting80AIO-Studien-gGmbHDec 2021
NCT05097911Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.P1active not recruiting33National University Hospital, SingaporeAug 2021
NCT04402788Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR TrialP2/P3recruiting138National Cancer Institute (NCI)Jan 2021
NCT03821246Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical ProstatectomyP2recruiting68David OhOct 2019
NCT04857684SBRT + Atezolizumab + Bevacizumab in Resectable HCCEarly P1active not recruiting20Massachusetts General HospitalJun 2021
NCT06077500DAREONᵀᴹ-8DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung CancerP1active not recruiting46Boehringer IngelheimFeb 2024
NCT03540420ACHILESAtezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung CancerP2active not recruiting212Norwegian University of Science and TechnologyJul 2018
NCT05516628EMPHASISDeep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular CarcinomaP2recruiting30National Cancer Centre, SingaporeFeb 2023
NCT05525858KOSMOSIIKPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors IIrecruiting1,000Seoul National University Bundang HospitalSep 2022
NCT05141721A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerP2/P3active not recruiting700Seattle Project CorporationFeb 2022
NCT04543617SKYSCRAPER-07A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyP3active not recruiting760Hoffmann-La RocheSep 2020
NCT03093922A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder CancerP2active not recruiting32Memorial Sloan Kettering Cancer CenterMar 2017
NCT06302426Trial of INI-4001 in Patients With Advanced Solid TumoursP1recruiting50Inimmune CorporationJul 2024
NCT06157827A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaP1/P2recruiting178Nanjing Leads Biolabs Co.,LtdDec 2023
NCT03595592APTneoNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast CancerP3active not recruiting650Fondazione MichelangeloSep 2018
NCT05440708A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaP1/P2recruiting193Tvardi Therapeutics, IncorporatedMar 2023
NCT07192185Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & BevacizumabP2recruiting30Sun Yat-sen UniversitySep 2025
NCT06867432Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular CarcinomaP2not yet recruiting20Tianjin Medical University Cancer Institute and HospitalMar 2025
NCT07538128Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent GlioblastomaEarly P1recruiting10Huashan HospitalJan 2025
NCT02846623Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter SyndromeP2active not recruiting50M.D. Anderson Cancer CenterJan 2017
NCT06690840AZALEAAtezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer PatientsP2recruiting45European Institute of OncologyMar 2025
NCT05501665Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerP1/P2recruiting25Vanderbilt-Ingram Cancer CenterMay 2023
NCT06807632A Study of Valemetostat in Combination With Atezolizumab in People With Lung CancerP1recruiting24Memorial Sloan Kettering Cancer CenterJan 2025
NCT04796012VITASVITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid TumorsP1/P2recruiting23University of Texas Southwestern Medical CenterApr 2023
NCT05425940STELLAR-303Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerP3active not recruiting901ExelixisSep 2022
NCT05168618AtezoCabCabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerP2recruiting33University of UtahMar 2022
NCT04820179Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic CancerP2active not recruiting30University of ArizonaOct 2021
NCT03463057HO151DLBCLThe Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCLP2active not recruiting109Stichting Hemato-Oncologie voor Volwassenen NederlandAug 2018
NCT04560972LB-100LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung CancerP1active not recruiting3City of Hope Medical CenterMay 2021
NCT04334941Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerP2active not recruiting103National Cancer Institute (NCI)Jul 2020
NCT03830918Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line ChemotherapyP1/P2active not recruiting59Jonsson Comprehensive Cancer CenterMar 2019
NCT01810913Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerP2/P3recruiting613National Cancer Institute (NCI)Mar 2013
NCT05907980A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid TumorsP1recruiting219Chugai PharmaceuticalMay 2023
NCT05645692A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerP2active not recruiting204Hoffmann-La RocheApr 2023
NCT05488522SBRT With Atezo/Bev for HCCP1recruiting18Abramson Cancer Center at Penn MedicineSep 2022
NCT05168163Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerP2recruiting122Academic and Community Cancer Research UnitedMay 2022
NCT04958811Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLCP2active not recruiting29Georgetown UniversityDec 2021
NCT04919369ATRAAll-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerP1active not recruiting18Dwight OwenOct 2021
NCT04180072Atezolizumab Plus Bevacizumab With HCC and HBV InfectionN/Aactive not recruiting51National Health Research Institutes, TaiwanMar 2020
NCT04082897MOLTOObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmationP2active not recruiting28Niguarda HospitalOct 2019
NCT0400652289Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell CarcinomaP2active not recruiting46James BrugarolasOct 2019
NCT03977194ELDERLYAtezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel ChemotherapyP3active not recruiting510Intergroupe Francophone de Cancerologie ThoraciqueJul 2019
NCT03784326Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal AdenocarcinomaP2active not recruiting43M.D. Anderson Cancer CenterFeb 2019
NCT02989584A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder CancerP1/P2active not recruiting54Memorial Sloan Kettering Cancer CenterDec 2016
NCT06362252A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)P1/P2recruiting123Daiichi SankyoJul 2024
NCT04865250iRePPredicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLCP2recruiting20University Hospital HeidelbergJan 2021
NCT03474094RT-ImmuneClinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With RadiotherapyP2active not recruiting62Centre Leon BerardAug 2018
NCT02912559Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairP3active not recruiting712National Cancer Institute (NCI)Oct 2017
NCT04458922Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced ChondrosarcomaP2active not recruiting27National Cancer Institute (NCI)Oct 2020
NCT06254911Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal CarcinomaP2suspended20Emory UniversityOct 2023
NCT06771518Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With AtezolizumabP2recruiting37Regina Elena Cancer InstituteDec 2021
NCT06117891REFINE-IOAn Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgeryactive not recruiting300BayerNov 2023
NCT05798663Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLCP2active not recruiting178Alliance Foundation Trials, LLC.Dec 2023
NCT03767075BoBA Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)P2recruiting1,000Vall d'Hebron Institute of OncologyDec 2018
NCT05159245FINPROVEThe Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsP2recruiting250Helsinki University Central HospitalDec 2021
NCT05715281Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 TrialP2active not recruiting12National Cancer Institute (NCI)Sep 2023
NCT02862275Atezolizumab in Treating Patients With Cancer Following Adoptive Cell TransferP1active not recruiting40National Cancer Institute (NCI)May 2017
NCT04161755Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With SurgeryP1active not recruiting29Memorial Sloan Kettering Cancer CenterDec 2019
NCT05009069A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal CancerP2active not recruiting58Hoffmann-La RocheMar 2022
NCT05681039OCSCCPhase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).P2active not recruiting29M.D. Anderson Cancer CenterJun 2023
NCT05689671ANTELOPEPemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung AdenocarcinomaP4active not recruiting136Nikolaj Frost MDDec 2023
NCT03693014A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsP2active not recruiting69Memorial Sloan Kettering Cancer CenterOct 2018
NCT03448835PANDANeoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)P2active not recruiting20The Netherlands Cancer InstituteMar 2018
NCT03178552B-FASTA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)P2/P3active not recruiting1,000Hoffmann-La RocheSep 2017
NCT03141684Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part SarcomaP2active not recruiting63National Cancer Institute (NCI)Apr 2017
NCT04446117CONTACT-02Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCP3active not recruiting575ExelixisOct 2020
NCT03533283An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaP1/P2active not recruiting211Hoffmann-La RocheMay 2018
NCT03600701Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerP2active not recruiting51National Cancer Institute (NCI)Nov 2018
NCT04660344IMvigor011A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following CystectomyP3active not recruiting761Hoffmann-La RocheMay 2021
NCT04020809Neoadjuvant Atezolizumab in Cutaneous MelanomaP1active not recruiting20The Methodist Hospital Research InstituteSep 2020
NCT04262154Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate CancerP2active not recruiting28Memorial Sloan Kettering Cancer CenterMar 2020
NCT03526432Phase II Study of Atezolizumab + Bevacizumab in Endometrial CancerP2active not recruiting110University of OklahomaAug 2018
NCT03228537Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant MesotheliomaP1active not recruiting28National Cancer Institute (NCI)Jul 2018
NCT02883062Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast CancerP2active not recruiting67National Cancer Institute (NCI)Aug 2017
NCT04729959Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaP2active not recruiting59National Cancer Institute (NCI)Mar 2022
NCT05904886SKYSCRAPER-14A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)P3active not recruiting687Hoffmann-La RocheSep 2023
NCT05092373TTFPhase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxP1recruiting43M.D. Anderson Cancer CenterApr 2022
NCT04310020Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer PatientsP2active not recruiting47National Cancer Institute (NCI)Jan 2021
NCT04356729A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic MelanomaP2active not recruiting30Elizabeth Buchbinder, MDAug 2020
NCT05174650Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/RearrangementsP2active not recruiting27Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestApr 2022
NCT04563338INTEGRATEAn Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)P2active not recruiting36University Health Network, TorontoJun 2021
NCT05498896BARBICANInvestigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCP2active not recruiting146Queen Mary University of LondonDec 2018
NCT02849496Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast CancerP2active not recruiting81National Cancer Institute (NCI)Mar 2017
NCT07285850ABATE-MASLDThe Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLDP2/P3recruiting20Eastern Hepatobiliary Surgery HospitalOct 2025
NCT05001880Chemotherapy With or Without Immunotherapy for Peritoneal MesotheliomaP2recruiting66National Cancer Institute (NCI)Mar 2022
NCT05091567IMforteA Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung CancerP3active not recruiting660Hoffmann-La RocheNov 2021
NCT06012734CoLBAtLB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer PatientsP1recruiting37The Netherlands Cancer InstituteJun 2024
NCT03782207IMrealA Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practiceactive not recruiting2,756Hoffmann-La RocheFeb 2019
NCT03755791COSMIC-312Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyP3active not recruiting837ExelixisJun 2018
NCT04661150A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionP2active not recruiting42Hoffmann-La RocheMar 2021
NCT06971237IMSIRTSIRT and Peri-immunotherapy : a New Conceptnot yet recruiting60Assistance Publique - Hôpitaux de ParisJun 2025
NCT06097962Safety and Efficacy of NK510 to Treat NSCLCEarly P1recruiting12Base Therapeutics (Shanghai) Co., Ltd.Jul 2023
NCT05867121A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010P1active not recruiting102Genentech, Inc.Oct 2023
NCT05781308ADAPTABLECombination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & ChemotherapyP2active not recruiting156Intergroupe Francophone de Cancerologie ThoraciqueApr 2023
NCT05211323A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver CancerP2active not recruiting88National Cancer Institute (NCI)Dec 2022
NCT04770896IMbrave251A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabP3active not recruiting557Hoffmann-La RocheApr 2021
NCT04665856SKYSCRAPER-02CStudy of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerP3active not recruiting123Hoffmann-La RocheDec 2020
NCT04158258A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin Americaactive not recruiting2,907Hoffmann-La RocheFeb 2020
NCT03175432Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain MetastasesP2active not recruiting29M.D. Anderson Cancer CenterJun 2017
NCT04250155An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsP1active not recruiting195Genentech, Inc.Mar 2020
NCT05334329NKGenetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint InhibitorsP1active not recruiting6University of California, IrvineJul 2022
NCT04896697XTX101Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid TumorsP1/P2active not recruiting136Xilio Development, Inc.Sep 2021
NCT04739202IMMUNOGASTPersonalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)P2completed54Hospices Civils de LyonMar 2021
NCT05243862Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.P2active not recruiting18Treos Bio LimitedJun 2022
NCT05238831ACTSMMART Adaptive Clinical Treatment (ACT) TrialEarly P1withdrawn0OHSU Knight Cancer InstituteJan 2023
NCT03417544Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BCP2active not recruiting19Nancy Lin, MDMay 2018
NCT04624399ABACUS-2Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial CancerP2recruiting58Queen Mary University of LondonJun 2021
NCT04954339DYNAMICDYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumabP2completed40Tae Won KimOct 2021
NCT04102098IMbrave050A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationP3active not recruiting668Hoffmann-La RocheDec 2019
NCT05007769RANRamucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLCP2withdrawn0Washington University School of MedicineOct 2021
NCT04751929Abemaciclib With or Without Atezolizumab for mCRPCP2active not recruiting19Dana-Farber Cancer InstituteAug 2021
NCT04941287Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract CancerP2active not recruiting57National Cancer Institute (NCI)Dec 2021
NCT04812366GUNSGenomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerP2recruiting315University of British ColumbiaSep 2021
NCT05992220ALERT-HCCAtezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular InvasionP2recruiting138Asan Medical CenterOct 2022
NCT04367311NSCLCAdjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)P2active not recruiting100Nasser HannaMay 2020
NCT03673787IceCAPA Trial of Ipatasertib in Combination With AtezolizumabP1/P2active not recruiting87Institute of Cancer Research, United KingdomAug 2018
NCT04732598AMBITIONA Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast CancerP3completed281Japanese Foundation for Cancer ResearchJan 2021
NCT03694262EndoBARRThe EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)P2completed30Medical College of WisconsinJul 2019
NCT04147351A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.P2completed22National Taiwan University HospitalApr 2020
NCT04611776CATHAYAA Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung CancerP2withdrawn0Hoffmann-La RocheJul 2021
NCT06939036SANTANA-225Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )P1/P2terminated2Ariceum Therapeutics GmbHJul 2025
NCT05022927A Phase I Study of ERY974 in Patients With Hepatocellular CarcinomaP1active not recruiting179Chugai PharmaceuticalJun 2021
NCT04289779ABATEStudy of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr CancerP2active not recruiting46Deepak KilariMay 2020
NCT04166721WaKING: Wnt and checKpoint INhibition in Gastric CancerP1/P2active not recruiting52Royal Marsden NHS Foundation TrustFeb 2020
NCT03456063A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)P3completed453Hoffmann-La RocheApr 2018
NCT05751343Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical TrialP2recruiting55Sun Yat-sen UniversityMar 2023
NCT06323382Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinomarecruiting240Sun Yat-sen UniversityJan 2021
NCT05713994CCGLC-001Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinomarecruiting300Ze-yang Ding, MDMay 2020
NCT04294810SKYSCRAPER-01A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerP3completed620Hoffmann-La RocheMar 2020
NCT05661578SKYSCRAPER-11A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid TumorsP2completed64Hoffmann-La RocheMay 2023
NCT05450562Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid TumorsP1/P2terminated33SanofiSep 2022
NCT03869190MORPHEUS-UCStudy Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)P1/P2completed272Hoffmann-La RocheJun 2019
NCT06267001SKYSCRAPER-15A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based ChemotherapyP3terminated56Hoffmann-La RocheMar 2024
NCT03337698Morpheus LungA Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)P1/P2terminated314Hoffmann-La RocheDec 2017
NCT04619797SKYSCRAPER-06A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung CancerP2/P3completed542Hoffmann-La RocheDec 2020
NCT06390059EF-39 PANOVA-4EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaP2completed84NovoCure Ltd.Aug 2023
NCT02705196LOAd703 Oncolytic Virus Therapy for Pancreatic CancerP1/P2completed51Lokon Pharma ABNov 2016
NCT03563716A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerP2completed135Genentech, Inc.Aug 2018
NCT05908786A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular CarcinomaP1/P2completed62Hoffmann-La RocheDec 2023
NCT03483012Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain MetastasisP2completed6Dana-Farber Cancer InstituteMay 2018
NCT07272265The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective StudyN/Acompleted300Sun Yat-sen UniversityOct 2020
NCT05746481NSCLCTiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain MetastasesP2terminated3Liza Villaruz, MDAug 2023
NCT06488716A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid TumorsP1terminated12Genentech, Inc.Dec 2024
NCT05240131NSCLCA Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).P1/P2unknown88Galecto Biotech ABMar 2022
NCT04829383AB7A Study of Atezolizumab and Bevacizumab in Hepatocellular CarcinomaP2active not recruiting50Howard S HochsterMar 2021
NCT03520686Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerP3terminated102ImmunityBio, Inc.May 2018
NCT03281369A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)P1/P2completed214Hoffmann-La RocheOct 2017
NCT04303858RO7284755A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid TumorsP1terminated189Hoffmann-La RocheMay 2020
NCT06780826A Study on the Efficacy of Atezolizumab Combined with Chemotherapyrecruiting1,430Shanghai Pulmonary Hospital, Shanghai, ChinaAug 2024
NCT04267237A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung CancerP2withdrawn0Hoffmann-La RocheMar 2021
NCT04739670BELLAEvaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast CancerP2unknown31Peter MacCallum Cancer Centre, AustraliaMar 2021
NCT04440735A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid TumorsP1/P2active not recruiting125Kahr MedicalOct 2020
NCT03340376Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical CancerP2active not recruiting48Universitaire Ziekenhuizen KU LeuvenAug 2017
NCT03174197Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaP1/P2completed60M.D. Anderson Cancer CenterJun 2017
NCT06713798INDIGOTargeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid StructuresP2withdrawn0Gustave Roussy, Cancer Campus, Grand ParisJan 2025
NCT03738228Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical CancerP1completed40National Cancer Institute (NCI)Jan 2019
NCT04487756VENEZO-LUNGCombination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung CancerP1/P2completed20Instituto Oncológico Dr RosellMar 2021
NCT05251948An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction CarcinomaP1/P2terminated40Hoffmann-La RocheMar 2022
NCT05276284TEMPLEThiopurine Enhanced Mutations for PD-1/Ligand-1 EfficacyP1/P2completed18Kristoffer RohrbergSep 2022
NCT02500407NHLA Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)P1/P2completed713Genentech, Inc.Sep 2015
NCT04017455TARZANNeoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)P2active not recruiting38The Netherlands Cancer InstituteOct 2019
NCT03556839BEATccPlatinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the CervixP3completed410Grupo Español de Investigación en Cáncer de OvarioSep 2018
NCT04540211SKYSCRAPER-08A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaP3completed461Hoffmann-La RocheOct 2020
NCT04665843SKYSCRAPER-09A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and NeckP2completed123Hoffmann-La RocheMar 2021
NCT05733611RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCP2terminated5Replimune, Inc.Jun 2023
NCT06603818MSSImmunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)P2withdrawn0National Cancer Institute (NCI)Aug 2025
NCT04373369Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerP2terminated11Washington University School of MedicineOct 2020
NCT06762808Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCCP2withdrawn0M.D. Anderson Cancer CenterMay 2025
NCT04962126FLUOROFrontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapyP2active not recruiting15Olivia Newton-John Cancer Research InstituteAug 2021
NCT04513925SKYSCRAPER-03A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)P3completed829Hoffmann-La RocheAug 2020
NCT04256421SKYSCRAPER-02A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung CancerP3completed490Hoffmann-La RocheFeb 2020
NCT05359861Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular CarcinomaP2completed30Coherus Oncology, Inc.Apr 2022
NCT04107168Microbiome Immunotherapy Toxicity and Response Evaluationunknown1,800CCTU- Cancer ThemeJul 2020
NCT03568656Study to Evaluate CCS1477 in Advanced TumoursP1/P2completed220CellCentric Ltd.Jul 2018
NCT06328036Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent GlioblastomaP2withdrawn0National Cancer Institute (NCI)Apr 2025
NCT05295212Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIBP2recruiting120Hunan Province Tumor HospitalFeb 2023
NCT03289962RO7198457A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsP1completed273Genentech, Inc.Dec 2017
NCT04591431ROMEThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyP2unknown400Fondazione per la Medicina PersonalizzataOct 2020
NCT03363867BEACONBEACON - ABC in Recurrent Platinum Resistant HGSOCP2unknown30Peter MacCallum Cancer Centre, AustraliaJul 2018
NCT05487235A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsP1completed57Genentech, Inc.Aug 2022
NCT05109442Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing CancersP1/P2terminated112Affimed GmbHNov 2021
NCT05537402LOST-BLOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCCP2terminated1University of Texas Southwestern Medical CenterSep 2023
NCT04549428Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLCP2terminated12Oncology Institute of Southern SwitzerlandOct 2020
NCT04253145Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.P1/P2unknown184Fundacion OncosurDec 2019
NCT02530489Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast CancerP2completed37M.D. Anderson Cancer CenterFeb 2016
NCT06719973Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)P1withdrawn0EMD Serono Research & Development Institute, Inc.May 2025
NCT03612791ATEZOLACCTrial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint AtezolizumabP2completed189Gustave Roussy, Cancer Campus, Grand ParisAug 2018
NCT05665348TRIPLETStudy Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic TherapyP2/P3completed229Federation Francophone de Cancerologie DigestiveMar 2023
NCT03502785INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial CarcinomaP1/P2completed35Inovio PharmaceuticalsMay 2018
NCT06067061neoBREASTIM"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast CancerP1/P2terminated2Institut CurieApr 2024
NCT03554083Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III MelanomaP2completed64Mayo ClinicOct 2018
NCT04477759DEHARTDose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck CancerP1completed18Medical College of WisconsinJan 2021
NCT04221529SPACEPatients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-EtoposideP2completed70AIO-Studien-gGmbHJan 2020
NCT04042558GFPC 06-2018A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted TherapiesP2completed150Centre Francois BaclesseSep 2019
NCT03199885Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerP3terminated190National Cancer Institute (NCI)Apr 2019
NCT05833126Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver TransplantationP2unknown25Shuhong YiDec 2023
NCT04911166Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without ChemotherapyP1terminated13The Methodist Hospital Research InstituteOct 2021
NCT04338269CONTACT-03A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor TreatmentP3terminated522Hoffmann-La RocheJul 2020
NCT03802604PROMETEOCombination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerEarly P1completed28SOLTI Breast Cancer Research GroupDec 2018
NCT05750030FMT in IT-refractory HCC - FAB-HCC Pilot StudyP2completed12Medical University of ViennaMay 2023
NCT04216953COTESARCMEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue SarcomaP1/P2completed229Centre Leon BerardFeb 2020
NCT03353831Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian CancerP3completed574AGO Research GmbHSep 2018
NCT04832854A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung CancerP2terminated50Hoffmann-La RocheApr 2021
NCT04224636DEMANDAtezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/BevacizumabP2recruiting106Ludwig-Maximilians - University of MunichJun 2020
NCT03340558ATELIERAtezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal CancerP2withdrawn0Niharika MettuMay 2018
NCT04902040Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesP1/P2terminated19M.D. Anderson Cancer CenterApr 2021
NCT03193190A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)P1/P2completed341Hoffmann-La RocheJul 2017
NCT04300647SKYSCRAPER-04A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical CancerP2completed172Hoffmann-La RocheJun 2020
NCT05038657AURORAAtezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).P2unknown36University Hospital Southampton NHS Foundation TrustMay 2022
NCT04630210AteBrOInvestigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsityEarly P1withdrawn0Universitaire Ziekenhuizen KU LeuvenFeb 2021
NCT04975958Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid TumorsP1completed47Adlai Nortye Biopharma Co., Ltd.Sep 2021
NCT03603184AtTEndAtezolizumab Trial in Endometrial Cancer - AtTEndP3completed549Mario Negri Institute for Pharmacological ResearchOct 2018
NCT04471428CONTACT-01Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing ChemotherapyP3completed366Hoffmann-La RocheOct 2020
NCT03818061ATHENAAtezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and NeckP2completed33Centre Leon BerardMar 2019
NCT05717738CCGLC-008Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinomarecruiting300Tongji HospitalJan 2022
NCT05173298HCCPredictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumabunknown100CHA UniversityAug 2021
NCT02724878Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaP2completed65Dana-Farber Cancer InstituteJul 2016
NCT04551521CRAFTCRAFT: The NCT-PMO-1602 Phase II TrialP2completed72German Cancer Research CenterOct 2021
NCT04109456IN10018 Monotherapy and Combination Therapy for Metastatic MelanomaP1completed51InxMed (Shanghai) Co., Ltd.Mar 2020
NCT05180006BIS-ProgramImpact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyP2terminated33Gustave Roussy, Cancer Campus, Grand ParisFeb 2022
NCT04148911EL1SSARA Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast CancerP3completed184Hoffmann-La RocheDec 2019
NCT05776875Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCCP2terminated3Yale UniversityJun 2023
NCT05259319IMMUNOs-SBRTStudy Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)P1unknown92Centre Georges Francois LeclercDec 2022
NCT05886465HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 TrialP2unknown40Sun Yat-sen UniversityMay 2023
NCT05007613Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaP2completed24National Taiwan University HospitalJun 2021
NCT06503250A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolizationcompleted113Hoffmann-La RocheJul 2024
NCT03762018BEAT-mesoBEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural MesotheliomaP3completed400ETOP IBCSG Partners FoundationApr 2019
NCT02794571PKSafety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic TumorsP1completed518Genentech, Inc.May 2016
NCT03735121A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung CancerP3completed438Hoffmann-La RocheDec 2018
NCT04432207A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung CancerP1terminated24Imugene LimitedNov 2020
NCT03498521CUPISCOA Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteP2completed529Hoffmann-La RocheJul 2018
NCT06098898Safety and Efficacy of NK510 to Treat Gastric CancerEarly P1unknown9Base Therapeutics (Shanghai) Co., Ltd.Nov 2023
NCT03946358VolATILCombination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)P2completed47Centre Hospitalier Universitaire de BesanconFeb 2020
NCT04185831MEGALiTA MolEcularly Guided Anti-Cancer Drug Off-Label TrialP2active not recruiting167Uppsala University HospitalOct 2020
NCT04659382SIRTCIStudy to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal CancerP2unknown52Federation Francophone de Cancerologie DigestiveOct 2020
NCT02992912SABR-PDL1Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic TumoursP2unknown138Gustave Roussy, Cancer Campus, Grand ParisNov 2016
NCT05171777A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung CancerP2completed179Hoffmann-La RocheApr 2022
NCT03371017IMpassion132A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast CancerP3completed595Hoffmann-La RocheJan 2018
NCT03836066TELMAAtezolizumab Plus Bevacizumab in First Line NSCLC PatientsP2completed41Fundación GECPMay 2019
NCT03127007R-IMMUNESafety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal CancerP1/P2completed45Grand Hôpital de CharleroiApr 2017
NCT03829501KY1044A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesP1/P2terminated222Kymab LimitedJan 2019
NCT04770272neoMonoStudy to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX TherapyP2terminated442Palleos Healthcare GmbHMar 2021
NCT04134000BladderGATEAtezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)P1unknown40Fundacion OncosurFeb 2020
NCT03280563MORPHEUS HR+BCA Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerP1/P2completed144Hoffmann-La RocheDec 2017
NCT04984811NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLCP2terminated33NeoImmuneTechNov 2021
NCT05052099COMBATBILPhase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract CancerP1/P2completed20University Hospital, EssenOct 2021
NCT04462276TREASUREThoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive DiseaseP2completed68Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestJul 2020
NCT05253053To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsP1/P2completed84TransThera Sciences (Nanjing), Inc.Apr 2022
NCT05717400Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyP4terminated2M.D. Anderson Cancer CenterMar 2023
NCT05459129A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)P1/P2completed12Hoffmann-La RocheApr 2023
NCT04196530EIK1001BDB001-102: Open Label Dose Escalation of BDB001 in Combination w AtezolizumabP1completed40Eikon TherapeuticsNov 2019
NCT04487067AMETHISTAA Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-AmethistaP3completed152Hoffmann-La RocheAug 2020
NCT03977467Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 InhibitorP2completed46SCRI Development Innovations, LLCAug 2019
NCT03598270ANITAPlatinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian CancerP3completed417Grupo Español de Investigación en Cáncer de OvarioNov 2018
NCT03262454AtezolizumabSequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLCP2unknown35National Cancer Center, KoreaJan 2018
NCT04245085ABC-lungABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung CarcinomaP2completed95ETOP IBCSG Partners FoundationSep 2020
NCT04512430Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated PatientsP2terminated4Fundación GECPDec 2020
NCT04096638Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid TumorsP1completed61invoX Pharma LimitedSep 2019
NCT06416436Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer PatientsP1withdrawn0University of Kansas Medical CenterJul 2024
NCT03473756FORT-2Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial CarcinomaP1completed37BayerMay 2018
NCT05266937Atezolizumab Plus CArboplatin Plus Nab-paclitaxelP2unknown49Consorzio OncotechJul 2020
NCT02908672A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced MelanomaP3completed514Hoffmann-La RocheJan 2017
NCT05694013ORIGAMAClinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical PracticeP2/P3terminated49Hoffmann-La RocheFeb 2023
NCT04622228MatchStudy of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung CancerP2completed56Hoffmann-La RocheDec 2020
NCT04194203A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)P3completed305Hoffmann-La RocheApr 2020
NCT02844816Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder CancerP2completed172National Cancer Institute (NCI)Mar 2017
NCT03024437Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell CarcinomaP1/P2terminated31Roberto PiliJun 2017
NCT05053737Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCCP1completed11University of Colorado, DenverNov 2021
NCT04740918KATE3A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)P3terminated96Hoffmann-La RocheJun 2021
NCT04730999CeLEBrATEEfficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung CancerP2completed54Gruppo Oncologico Italiano di Ricerca ClinicaJul 2020
NCT04321330A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic CarcinomaP2completed34Hoffmann-La RocheAug 2020
NCT05116202A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)P1/P2completed110Hoffmann-La RocheFeb 2022
NCT04101357Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411P1/P2terminated54BioNTech SEJun 2020
NCT04081688Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLCP1terminated16Rutgers, The State University of New JerseySep 2019
NCT04732286A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic TherapyP3terminated100Hoffmann-La RocheMay 2021
NCT03689855RamAtezo-1Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLCP2completed21Washington University School of MedicineJun 2019
NCT05191797Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung CancerP1/P2terminated3University of WashingtonApr 2022
NCT04480372ORIGINSAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph IIP2completed68Swiss Cancer InstituteMar 2021
NCT03108131Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare TumorsP2completed49M.D. Anderson Cancer CenterApr 2017
NCT03513952Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaP2completed47National Cancer Institute (NCI)Jun 2019
NCT02902029ImmunoCobiVemEvaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaP2completed186University Hospital, EssenNov 2016
NCT04939480PIONEERWindow of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHNP2completed20University Hospital, EssenOct 2021
NCT03866239A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal AdenocarcinomaP1terminated47Hoffmann-La RocheMay 2019
NCT03991403Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLCP3unknown228Samsung Medical CenterAug 2019
NCT05448677ABE-LIVEREzurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular CarcinomaP2terminated3University Hospital, GrenobleDec 2022
NCT03452137IMvoke010A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and NeckP3terminated406Hoffmann-La RocheApr 2018
NCT04632992MyTACTICA Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseP2completed252Genentech, Inc.Jan 2021
NCT02891824ATALANTEATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+BevacizumabP3completed614ARCAGY/ GINECO GROUPSep 2016
NCT02599454Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung CancerP1completed20Megan Daly, MDApr 2018
NCT03201458Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder CancerP2completed86National Cancer Institute (NCI)Feb 2018
NCT04710498Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell CarcinomaP2completed20Stanford UniversityJun 2021
NCT03976518CHANCEAtezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)P2completed43Gruppo Oncologico Italiano di Ricerca ClinicaMay 2019
NCT02807636IMvigor130Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial CarcinomaP3completed1,213Hoffmann-La RocheJun 2016
NCT04602078AUREAStudy of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial CarcinomaP2completed82Spanish Oncology Genito-Urinary GroupDec 2020
NCT03973879Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant GliomaP1/P2withdrawn0Darell BignerFeb 2020
NCT03693573A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell CarcinomaP3withdrawn0Hoffmann-La RocheJan 2019
NCT05834348DELINORA Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.completed5,279PfizerJun 2023
NCT03511391CHEERSCHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid TumorsP2completed99University Hospital, GhentMar 2018
NCT04857138A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid TumorsP1completed80Hoffmann-La RocheMay 2021
NCT04642365A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.P1terminated49Hoffmann-La RocheJan 2021
NCT05564416Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA TrialP2withdrawn0National Cancer Institute (NCI)Oct 2023
NCT05396937Efficacy and Safety of T+A+RAD in HCCP2unknown42Fudan UniversityJan 2022
NCT05034055SKYROCKETStudy of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung CancerP2unknown45Yonsei UniversityDec 2021
NCT05197504HCCPredictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapycompleted166CHA UniversityDec 2021
NCT04923776Liver Directed RT + Chemo-immunotherapy for ES-SCLCP2terminated2Brian Henick, MDSep 2021
NCT04276376ARIANESEfficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsP2terminated130Gustave Roussy, Cancer Campus, Grand ParisApr 2019
NCT04408118ATRACTIBFirst Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBCP2completed100MedSIROct 2020
NCT02873195Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal CancerP2completed133Academic and Community Cancer Research UnitedJul 2017
NCT05060003Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following ResectionP2terminated7Washington University School of MedicineNov 2022
NCT04405349Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical CancerP2completed52Nykode Therapeutics ASAJul 2020
NCT04933227GEJA Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)P2terminated29Hoffmann-La RocheAug 2021
NCT06006286A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular CarcinomaP1/P2withdrawn0M.D. Anderson Cancer CenterAug 2023
NCT04696939Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer PatientsP2unknown100Shanghai Pulmonary Hospital, Shanghai, ChinaJan 2021
NCT03654833MiSTMesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaP2unknown186University of LeicesterJan 2019
NCT03191786IPSOSA Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet ChemotherapyP3completed453Hoffmann-La RocheSep 2017
NCT03698461CLIMBTreatment of Colorectal Liver Metastases With Immunotherapy and BevacizumabP2completed20Asan Medical CenterMay 2019
NCT03206203Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast CancerP2completed106Vanderbilt-Ingram Cancer CenterAug 2017
NCT03164993ALICEAtezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast CancerP2completed68Oslo University HospitalJun 2017
NCT03973333Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With AtezolizumabP1/P2withdrawn0Immunocore LtdMay 2019
NCT03853707Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast CancerP1/P2completed28City of Hope Medical CenterMar 2019
NCT03686332PERICLESPEnile Cancer Radio- and Immunotherapy CLinical Exploration StudyP2completed32The Netherlands Cancer InstituteSep 2018
NCT02927301NSCLCA Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)P2completed181Genentech, Inc.Apr 2017
NCT04091217Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal MelanomaP2completed43Hoffmann-La RocheNov 2019
NCT03961698MARIO-3Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell CarcinomaP2unknown91Infinity Pharmaceuticals, Inc.Dec 2019
NCT03721653AtezoTRIBEFOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer PatientsP2completed218Gruppo Oncologico del Nord-OvestNov 2018
NCT04677504A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract CancerP2completed162Hoffmann-La RocheFeb 2021
NCT03726879IMpassion050A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerP3completed454Hoffmann-La RocheJan 2019
NCT03559647The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapycompleted358Hoffmann-La RocheMay 2018
NCT03395899ECLIPSEPre-operative Immunotherapy Combination Strategies in Breast CancerP2completed71Queen Mary University of LondonDec 2017
NCT03901573High-Risk Skin Cancers With Atezolizumab Plus NT-I7P1/P2terminated31NeoImmuneTechDec 2019
NCT03498716IMpassion030A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerP3terminated2,199Hoffmann-La RocheAug 2018
NCT05395052FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsP1terminated5Fate TherapeuticsMay 2022
NCT05510427Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/AmplificationP1withdrawn0M.D. Anderson Cancer CenterAug 2023
NCT04123470A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant MelanomaP1/P2completed24Lokon Pharma ABJan 2020
NCT04308785A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung CancerP2terminated24Hoffmann-La RocheDec 2021
NCT06199297Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinomacompleted188Sun Yat-sen UniversityMar 2021
NCT05315713An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin LymphomaP1/P2terminated8Hoffmann-La RocheMay 2022
NCT04028050MAURISA Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung CancerP3completed155Hoffmann-La RocheAug 2019
NCT03695380A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian CancerP1completed77Hoffmann-La RocheJan 2019
NCT04631029Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has SpreadP1completed3National Cancer Institute (NCI)Apr 2021
NCT04541173HCCStudy of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)P2terminated6Aiwu Ruth He, MDNov 2020
NCT03464942AZTECStereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast CancerP2completed54Peter MacCallum Cancer Centre, AustraliaAug 2018
NCT04099836Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving OsimertinibP2terminated7Duke UniversityJul 2020
NCT06090318Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A LossP1/P2withdrawn0Rain Oncology IncMay 2023
NCT02091141My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsP2completed673Genentech, Inc.Apr 2014
NCT06049966LANCEAtezolizumab in Large Cell Neuroendocrine CarcinomaP1completed22Oncology Center of Biochemical Education And ResearchMar 2018
NCT04713891A Study of KF-0210 in Advanced Solid Tumors PatientsP1completed14Keythera Pharmaceuticals (Australia) Pty LtdMar 2021
NCT05110781Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary SiteP2terminated1University of California, DavisDec 2021
NCT04322643Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaP2terminated4Case Comprehensive Cancer CenterMar 2020
NCT03625141A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System MetastasesP2completed80Hoffmann-La RocheDec 2018
NCT02994576PRINCEPSAtezolizumab as Induction Therapy in Non-small Cell Lung CancerP2completed60Gustave Roussy, Cancer Campus, Grand ParisDec 2016
NCT02451423Neoadjuvant Atezolizumab in Localized Bladder CancerP2completed23Lawrence FongMar 2016
NCT02594384LAM-002A/NHLA Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's LymphomaP1completed62OrphAI TherapeuticsOct 2015
NCT04471415Study to Investigate DRP-104 in Adults With Advanced Solid TumorsP1/P2terminated61Dracen Pharmaceuticals, Inc.Aug 2020
NCT04045028PKA Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaP1terminated41Genentech, Inc.Jul 2019
NCT04862949Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCCcompleted131CHA UniversityMay 2021
NCT04584112A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast CancerP1completed83Hoffmann-La RocheSep 2020
NCT04177108A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerP3completed242Hoffmann-La RocheNov 2019
NCT02108652A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)P2completed310Hoffmann-La RocheMay 2014
NCT02951767A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)P2completed119Hoffmann-La RocheMay 2014
NCT04510584Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian CancerP2withdrawn0University Health Network, TorontoJul 2021
NCT03158389N²M²NCT Neuro Master Match - N²M² (NOA-20)P1/P2completed228University Hospital HeidelbergMay 2018
NCT04426825A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung CancerP2completed23Hoffmann-La RocheSep 2020
NCT04084951Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsP1completed30SQZ BiotechnologiesJan 2020
NCT03125902IMpassion131A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)P3completed653Hoffmann-La RocheAug 2017
NCT02926833ZUMA-6Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2completed37Kite, A Gilead CompanySep 2016
NCT04801966TAILORSafety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyN/Aterminated3Peter MacCallum Cancer Centre, AustraliaSep 2021
NCT02813785IMpower210A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyP3completed565Hoffmann-La RocheJul 2016
NCT04690855TARAA Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast CancerP2terminated1Mylin A. Torres, MDOct 2021
NCT03016312IMbassador250A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane RegimenP3completed759Hoffmann-La RocheJan 2017
NCT02657434NSCLCA Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)P3completed578Hoffmann-La RocheApr 2016
NCT02928406A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary TractP3completed1,004Hoffmann-La RocheNov 2016
NCT03024996IMmotion010A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following NephrectomyP3terminated778Hoffmann-La RocheJan 2017
NCT03434379IMbrave150A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaP3completed558Hoffmann-La RocheMar 2018
NCT03841110FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsP1completed37Fate TherapeuticsFeb 2019
NCT02825940IMYO29233A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid TumorsP1completed120Hoffmann-La RocheAug 2016
NCT04272645Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate CancerP2withdrawn0University of Michigan Rogel Cancer CenterOct 2020
NCT04404140A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).P1terminated6Hoffmann-La RocheJul 2020
NCT05093608SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular CarcinomaP1terminated2H. Lee Moffitt Cancer Center and Research InstituteNov 2021
NCT04045613FIDES-02Derazantinib and Atezolizumab in Patients With Urothelial CancerP1/P2completed95Basilea PharmaceuticaAug 2019
NCT03102242Atezolizumab Immunotherapy in Patients With Advanced NSCLCP2completed64Alliance Foundation Trials, LLC.Nov 2017
NCT03197935IMpassion031A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast CancerP3completed333Hoffmann-La RocheJul 2017
NCT03555149A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)P1/P2terminated96Hoffmann-La RocheSep 2018
NCT04610684SCLCChemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain MetastasesP2terminated3Jeffrey ClarkeJan 2021
NCT03526900ATEZO-BRAINAtezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain MetastasisP2completed40Spanish Lung Cancer GroupJul 2018
NCT05456165Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon CancerP2withdrawn0Gritstone bio, Inc.May 2022
NCT03276468Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory LymphomasP2completed136The Lymphoma Academic Research OrganisationFeb 2018
NCT03138889PROPELBempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid TumorsP1/P2terminated162Nektar TherapeuticsJun 2017
NCT03357224PARCTPARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)P2terminated26European Organisation for Research and Treatment of Cancer - EORTCSep 2018
NCT04639245Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung CancerP1/P2terminated1Fred Hutchinson Cancer CenterJul 2021
NCT03232593MFDSA Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)completed1,758Hoffmann-La RocheNov 2017
NCT03038100IMagyn050A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerP3completed1,301Hoffmann-La RocheMar 2017
NCT03922997A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerP3completed101Hoffmann-La RocheJul 2019
NCT03650348PRS-343 in Combination With Atezolizumab in HER2-Positive Solid TumorsP1completed41Pieris Pharmaceuticals, Inc.Aug 2018
NCT03179943Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial CarcinomaP2active not recruiting21Fox Chase Cancer CenterNov 2017
NCT02763579IMpower133A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)P3completed503Hoffmann-La RocheJun 2016
NCT04214418MEKiAUTOStudy of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced MalignanciesP1/P2terminated27Columbia UniversityFeb 2020
NCT03147040GELATOAssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast CancerP2terminated23The Netherlands Cancer InstituteNov 2017
NCT04059887BUDDYEvaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]P4completed100Chonnam National University HospitalDec 2019
NCT03835949Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic CancerP1unknown36Tracon Pharmaceuticals Inc.Jul 2019
NCT02450331IMvigor010A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical ResectionP3terminated809Hoffmann-La RocheOct 2015
NCT05609903AnastaseAtezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancercompleted52Fondazione Policlinico Universitario Agostino Gemelli IRCCSNov 2019
NCT03577132The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder CancerN/Aunknown20Seoul National University HospitalAug 2018
NCT03737123Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial CarcinomaP2terminated6Nabil AdraDec 2018
NCT03073525A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological CancersP2completed25Gradalis, Inc.May 2017
NCT03637764SAR650984Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced MalignanciesP1/P2terminated107SanofiAug 2018
NCT03818997DYNAMICCombination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric CancerP2withdrawn0European Organisation for Research and Treatment of Cancer - EORTCDec 2019
NCT04102618AWARE-1A Window-of-opportunity Study of Pelareorep in Early Breast CancerEarly P1terminated26Oncolytics BiotechMar 2019
NCT03285763TAILA Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)P4completed619Hoffmann-La RocheOct 2017
NCT03014648NSCLCEvaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)P2completed28Liza Villaruz, MDJul 2017
NCT02659384Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian CancerP2completed122European Organisation for Research and Treatment of Cancer - EORTCDec 2016
NCT03272217Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial CancerP2terminated16Arjun Balar, MDSep 2017
NCT03800836A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerP1completed139Hoffmann-La RocheFeb 2018
NCT02409342MPDL3280AA Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]P3completed572Hoffmann-La RocheJul 2015
NCT03801304VinMetAtezoTrial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung CancerP2completed80University Hospital, BrestJan 2019
NCT03498222iTRAPStudy in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and CarboplatinP1withdrawn0Queen Mary University of LondonJun 2018
NCT03386721Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid TumorsP2terminated256Hoffmann-La RocheFeb 2018
NCT03713944Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung CancerP2terminated30Nasser HannaNov 2018
NCT02420821IMmotion151A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)P3completed915Hoffmann-La RocheMay 2015
NCT04167137Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult ParticipantsP1terminated32SynlogicDec 2019
NCT03256344Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesP1completed36AmgenMar 2018
NCT03422523ARGOAtezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose TherapyP2terminated53University Hospital Southampton NHS Foundation TrustMay 2018
NCT04249167Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerEarly P1withdrawn0Mayo ClinicJan 2020
NCT02914470PROLOGCarboplatin-cyclophosphamide Combined With AtezolizumabP1completed12The Netherlands Cancer InstituteJan 2017
NCT03359239Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial CancerP1completed10Matthew GalskyMay 2019
NCT04793399Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult PatientsP1/P2terminated9Fundacion Espanola para la Curacion de la Leucemia Mieloide CronicaFeb 2021
NCT02876510ACTologACTolog in Patients With Solid CancersP1completed38Immatics US, Inc.Jun 2017
NCT02322814A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has SpreadP2terminated169Hoffmann-La RocheMar 2015
NCT05055947Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancercompleted60Hunan Province Tumor HospitalApr 2019
NCT05055999Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancercompleted60Hunan Province Tumor HospitalApr 2019
NCT02425891A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)P3completed902Hoffmann-La RocheJun 2015
NCT02655822Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersP1completed502Corvus Pharmaceuticals, Inc.Jan 2016
NCT03894007PREDIXIIHER2Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast CancerP2terminated6Renske AltenaMay 2019
NCT03952325CONTESSA TRIOTesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBCP2terminated294Odonate Therapeutics, Inc.Jul 2019
NCT03730012FLT3A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)P1/P2completed11Astellas Pharma Global Development, Inc.Jun 2019
NCT03063762RCCStudy to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)P1completed69Hoffmann-La RocheMar 2017
NCT02715531A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid TumorsP1completed243Hoffmann-La RocheApr 2016
NCT03312530A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaP1/P2completed49Hoffmann-La RocheNov 2017
NCT04869501Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancerno longer available0I-Mab Biopharma US Limited
NCT03892525Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell LymphomaP1terminated4The Lymphoma Academic Research OrganisationJul 2019
NCT02708680Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead InP1/P2completed89Syndax PharmaceuticalsMay 2016
NCT02291289MODULA Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)P2completed1,044Hoffmann-La RocheApr 2015
NCT02431208MMA Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)P1completed85Hoffmann-La RocheJul 2015
NCT03618953KingfisherThis is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated CancersP1terminated8Turnstone Biologics, Corp.Jun 2018
NCT03273153A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type MelanomaP3terminated446Hoffmann-La RocheDec 2017
NCT02367794NSCLCA Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]P3completed1,021Hoffmann-La RocheJun 2015
NCT03628716CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder CancerP2completed43Bavarian NordicSep 2018
NCT03721679Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1P1/P2terminated7Oncovir, Inc.Sep 2018
NCT02367781IMpower130A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)P3completed723Hoffmann-La RocheApr 2015
NCT02921269Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical CancerP2completed11National Cancer Institute (NCI)Mar 2017
NCT03644823COM-IT-1Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLCP2terminated21Oslo University HospitalAug 2018
NCT03024216Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate CancerP1completed37University of HawaiiFeb 2017
NCT03620435Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder CancerP2unknown25McGill University Health Centre/Research Institute of the McGill University Health CentreMay 2018
NCT03566485Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerP1/P2terminated12Vanderbilt-Ingram Cancer CenterJul 2018
NCT02366143IMpower150A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)P3completed1,202Hoffmann-La RocheMar 2015
NCT03059667Immunotherapy as Second-line in Patient With Small Cell Lung CancerP2completed73Intergroupe Francophone de Cancerologie ThoraciqueMar 2017
NCT02982694Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal CancerP2terminated46Vall d'Hebron Institute of OncologyNov 2017
NCT03206047Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerP1/P2completed12National Cancer Institute (NCI)Nov 2017
NCT04422210ES-SCLCA Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).P1terminated2Hoffmann-La RocheSep 2020
NCT03922477A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaP1terminated13Hoffmann-La RocheOct 2019
NCT03041311G1T28Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLCP2completed107G1 Therapeutics, Inc.Jun 2017
NCT03115801A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary CancersP2terminated6Weill Medical College of Cornell UniversityNov 2016
NCT02631577A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaP1/P2completed38Hoffmann-La RocheDec 2015
NCT02792192BCGSafety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) ParticipantsP1/P2terminated24Hoffmann-La RocheJun 2016
NCT03178851Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced MelanomaP1completed155Hoffmann-La RocheJun 2017
NCT03786419A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural MesotheliomaP2withdrawn0Health Pharma Professional ResearchAug 2020
NCT02323191A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid TumorsP1completed221Hoffmann-La RocheJan 2015
NCT03101280A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerP1completed29Hoffmann-La RocheApr 2017
NCT02458638A Study of Atezolizumab in Advanced Solid TumorsP2completed474Hoffmann-La RocheJul 2015
NCT03394885AdORNAtezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian CancerP1/P2completed18Duke UniversityJun 2018
NCT03050060Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerP2terminated21University of WashingtonJun 2017
NCT03616691Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLCP2unknown46Samsung Medical CenterAug 2018
NCT03264066A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid TumorsP2completed87Hoffmann-La RocheNov 2017
NCT02303951NEO-VCNeoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCP2terminated47University Hospital TuebingenJan 2015
NCT02596971CHOPA Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2completed91Hoffmann-La RocheDec 2015
NCT03647956Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase InhibitorsP2unknown40The University of Hong KongOct 2018
NCT03154827AMLSafety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)P1/P2terminated1BioLineRx, Ltd.Jan 2018
NCT01656642A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic MelanomaP1completed67Genentech, Inc.Aug 2012
NCT01633970A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsP1completed240Genentech, Inc.Jul 2012
NCT02924883KATE2A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based TherapyP2completed202Hoffmann-La RocheSep 2016
NCT02013219NSCLCA Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)P1completed52Hoffmann-La RocheApr 2014
NCT02220842MPDL3280AA Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaP1completed96Hoffmann-La RocheDec 2014
NCT02650713CEAA Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid TumorsP1completed228Hoffmann-La RocheJan 2016
NCT03455556Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung CancerP1terminated1Mayo ClinicAug 2018
NCT03465891Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular LymphomaP2terminated2Memorial Sloan Kettering Cancer CenterMar 2018
NCT02350673IVA Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid TumorsP1completed70Hoffmann-La RocheJun 2015
NCT02892318AMLA Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)P1completed40Hoffmann-La RocheOct 2016
NCT03438318Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung CancerP1completed29Regeneron PharmaceuticalsMar 2018
NCT02174172A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid TumorsP1completed158Hoffmann-La RocheAug 2014
NCT02410512A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid TumorsP1completed610Genentech, Inc.Apr 2015
NCT02605915Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerP1completed98Hoffmann-La RocheDec 2015
NCT03267940CISStudy of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder AdenocarcinomaP1terminated85Halozyme TherapeuticsOct 2017
NCT02304393RO7009789A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid TumorsP1completed140Hoffmann-La RocheDec 2014
NCT01988896Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid TumorsP1completed153Hoffmann-La RocheDec 2013
NCT03979066NEOiPANCStudy Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal AdenocarcinomaP2terminated1Gulam ManjiNov 2019
NCT02729896FLA Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2completed36Hoffmann-La RocheNov 2016
NCT02471846A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid TumorsP1completed158Genentech, Inc.Jul 2015
NCT03023423DARZALEXA Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung CancerP1/P2completed100Janssen Research & Development, LLCDec 2016
NCT03369964A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaP1withdrawn0Hoffmann-La RocheMar 2018
NCT02814669ATZSafety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway InhibitorP1completed45Hoffmann-La RocheSep 2016
NCT03087864PERFECTPDL-1 Targeting in Resectable Oesophageal CancerP2completed40Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Jun 2017
NCT02876224Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other TumorsP1completed51Hoffmann-La RocheSep 2016
NCT02508870A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic SyndromesP1completed46Hoffmann-La RocheSep 2015
NCT02541604A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid TumorsP1/P2terminated87Hoffmann-La RocheNov 2015
NCT02848651B-F1RSTA Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung CancerP2completed153Genentech, Inc.Sep 2016
NCT02784483Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic MyelomaP1terminated2Yale UniversityFeb 2017
NCT03330886A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentinacompleted13Hoffmann-La RocheFeb 2018
NCT03292172A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast CancerP1terminated36Hoffmann-La RocheNov 2017
NCT02609984Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)P2terminated89Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Apr 2015
NCT03399643AnnounceA Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)terminated22Hoffmann-La RocheDec 2017
NCT02031458BIRCHA Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerP2completed667Hoffmann-La RocheJan 2014
NCT02008227OAKA Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing TherapyP3completed1,225Hoffmann-La RocheMar 2014
NCT01984242IMmotion150A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell CarcinomaP2completed305Hoffmann-La RocheJan 2014
NCT02788279A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)P3completed363Hoffmann-La RocheJul 2016
NCT03228368TCRThe Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patientsunknown10First Affiliated Hospital of Zhejiang UniversityMar 2017
NCT03120676Study of Atezolizumab in Relapsed or Refractory Hodgkin LymphomaP2terminated3Memorial Sloan Kettering Cancer CenterApr 2017
NCT02302807A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]P3completed931Hoffmann-La RocheJan 2015
NCT01375842A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid TumorsP1completed661Genentech, Inc.Jun 2011
NCT01903993A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"P2completed287Hoffmann-La RocheAug 2013
NCT03208712Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based ChemotherapyEarly P1terminated1University of Michigan Rogel Cancer CenterNov 2017
NCT03029832A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based TherapyP2terminated5Genentech, Inc.Apr 2017
NCT01688206RO5520985A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsP1completed132Hoffmann-La RocheOct 2012
NCT02919449Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With AtezolizumabP1terminated2Vyriad, Inc.Aug 2017
NCT01846416PD-L1A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]P2completed138Genentech, Inc.May 2013
NCT02409355NSCLCA Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)P3terminated8Hoffmann-La RocheMay 2015
NCT02298153A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaP1terminated29Incyte CorporationJan 2015
NCT02543645A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerP1terminated18Celldex TherapeuticsOct 2015
NCT02589717An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapyapproved for marketing0Genentech, Inc.Nov 2015

Atezolizumab clinical trials: frequently asked questions

How many Atezolizumab clinical trials are there?
746 Atezolizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 162 are actively recruiting participants. 232 are marked completed.
Are Atezolizumab clinical trials recruiting in 2026?
Yes — 162 Atezolizumab trials are actively recruiting in 2026, with 1934 U.S. sites across 51 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Atezolizumab being studied for?
Atezolizumab is being studied for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Breast Cancer, Urothelial Carcinoma, Non-small Cell Lung Cancer and 966 more. The trials are grouped by indication on this page.
What phase is Atezolizumab in?
Atezolizumab clinical trials span 7 Phase 4, 106 Phase 3, 323 Phase 2, 138 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Atezolizumab clinical trials?
The lead sponsor across the most Atezolizumab trials is Hoffmann-La Roche, with 316 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Atezolizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: